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Metabolic networks provide a vital framework for understanding the cellular metabolism in 
both physiological and pathophysiological states, which will ultimately facilitate network analysis-
based drug discovery.  In this thesis, we aim to employ a metabolic network analysis approach to 
study cancer metabolism (a pathophysiological state) and the metabolism of the bacterial pathogen, S. 
aureus (a physiological state), in order to understand, predict, and ultimately target cell metabolism 
for drug discovery.   
Cancer cells have distinct metabolism that highly depend on glycolysis instead of 
mitochondrial oxidative phosphorylation alone, even in the presence of oxygen, also called aerobic 
glycolysis or the Warburg effect, which may offer novel therapeutic opportunities. However, the 
origin of the Warburg effect is only partially understood. To understand the origin of cancer 
metabolism, our theoretical collaborator, Prof. Alexei Vazquez, developed a reduced flux balance 
model of human cell metabolism incorporating the macromolecular crowding (MC) constraint and 
the maximum glucose uptake constraint.  The simulations successfully captured the main 
characteristics of cancer metabolism (aerobic glycolysis), indicating that MC constraint may be a 
potential origin of the Warburg effect. Notably, when we experimentally tested the model with 
mammalian cells from low to high growth rates as a proxy of MC alteration, we find that, consistent 
with the model, faster growing cells indeed have increased aerobic glycolysis.   
Moreover, the metabolic network analysis approach has also been shown to be capable of 
predicting the drug targets against pathogen metabolism when completely reconstructed metabolic 
networks are available. We deduced common antibiotic targets in Escherichia coli and 
Staphylococcus aureus by identifying shared tissue-specific or uniformly essential metabolic 
reactions in their metabolic networks. We then predicted through virtual screening dozens of potential 
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inhibitors for several enzymes of these reactions and demonstrated experimentally that a subset of 
these inhibited both enzyme activities in vitro and bacterial cell viability.  
Our results indicate that the metabolic network analysis approach is able to facilitate the 
understanding of cellular metabolism by identifying potential constraints and predicting as well as 
ultimately targeting the metabolism of the organisms whose complete metabolic networks are 
available through the seamless integration of virtual screening with experimental validation.  
 
 
 
  vi 
TABLE OF CONTENTS 
PREFACE….. ...................................................................................................................................... IX 
1.0 INTRODUCTION......................................................................................................... 1 
1.1 METABOLIC NETWORK ANALYSIS .................................................................... 2 
1.1.1 Metabolic networks ........................................................................................ 2 
1.1.2 Flux balance analysis ..................................................................................... 4 
1.1.3 Molecular crowding ....................................................................................... 7 
1.2 CANCER METABOLISM .......................................................................................... 9 
1.2.1 The Warburg effect...................................................................................... 10 
1.2.2 Possible origins of the Warburg effect ....................................................... 14 
1.2.3 Potential therapeutic significances of the Warburg effect ....................... 16 
1.3 S. AUREAS ANTIBIOTICS RESISTANCE ............................................................ 18 
1.3.1 Possible mechanisms of antibiotics resistance. .......................................... 19 
1.3.2 Current approaches to search for novel anti-Staphylococcus agents. .... 21 
1.4 THESIS OUTLINE ..................................................................................................... 23 
2.0 MOLECULAR CROWDING REPRESENTS AN IMPORTANT BOUND IN 
RAPIDLY DIVIDING E. COLI CELLS ........................................................................................... 27 
3.0 MOLECULAR CROWDING POTENTIALLY CONTRIBUTES TO THE 
WARBURG EFFECT ........................................................................................................................ 32 
3.1 INTRODUCTION....................................................................................................... 32 
3.2 RESULTS .................................................................................................................... 33 
  vii 
3.2.1 Reduced flux balance model of cell metabolism........................................ 33 
3.2.2 MC potentially contributes to aerobic glycolysis in human fibroblasts 
with serial oncogenic changes and stepwise increase in growth rates.................... 39 
3.2.3 MC potentially contributes to aerobic glycolysis in human fibroblasts 
different growth rates due to passage numbers ....................................................... 43 
3.3 DISCUSSION .............................................................................................................. 47 
3.4 MATERIALS AND METHODS ............................................................................... 50 
3.5 ACKNOWLEGMENT ............................................................................................... 54 
4.0 COMPARATIVE GENOME-SCALE METABOLIC NETWORK ANALYSIS 
OF MULTIPLE STAPHYLOCOCCUS AUREUS GENOMES IDENTIFY NOVEL ANTI-
MICROBIAL DRUG TARGETS ...................................................................................................... 55 
4.1 INTRODUCTION....................................................................................................... 55 
4.2 RESULTS .................................................................................................................... 56 
4.2.1 Analysis of metabolic reconstruction of S. aureus. ................................... 56 
4.2.2 Identification of single unconditionally essential enzymes and synthetic-
lethal pairs. .................................................................................................................. 58 
4.2.3 Analysis of the components of minimal medium for S. aureus. ............... 63 
4.3 DISCUSSION .............................................................................................................. 66 
4.4 MATERIALS AND METHODS ............................................................................... 68 
4.5 ACKNOWLEDGEMENT .......................................................................................... 75 
5.0 FASII AS A VALID ANTIMICROBIAL TARGET AGAINST S. AUREUS 
METABOLIC NETWORKS ............................................................................................................. 76 
5.1 INTRODUCTION....................................................................................................... 76 
5.2 RESULTS .................................................................................................................... 78 
5.2.1 Identification of antimicrobial targets by the analysis of bacterial 
metabolic networks ..................................................................................................... 78 
5.2.2 Virtual screening of small-molecule compounds against enzymes of 
bacterial fatty acid biosynthesis ................................................................................. 81 
  viii 
5.2.3 Testing the effect of predicted inhibitors by in vitro enzyme assays ....... 87 
5.2.4 Testing the effect of predicted inhibitors by in vivo cell-based 
experiments .................................................................................................................. 89 
5.3 DISCUSSION .............................................................................................................. 92 
5.4 MATERIALS AND METHODS ............................................................................... 94 
5.4.1 Identification of essential metabolic reactions in E. coli .......................... 94 
5.4.2 Computational chemistry protocols for hit identification ........................ 96 
5.4.3 In vitro enzyme assays and in vivo toxicity assays .................................... 98 
5.5 ACKNOWLEDGEMENT ........................................................................................ 103 
6.0 IDENTIFICATION OF NOVEL BACTERIAL HISTIDINE BIOSYNTHESIS 
INHIBITORS USING DOCKING, ENSEMBLE RESCORING AND WHOLE CELL ASSAYS104 
6.1 INTRODUCTION..................................................................................................... 104 
6.2 RESULTS .................................................................................................................. 105 
6.2.1 The histidine biosynthesis pathway in S. aureus ..................................... 105 
6.2.2 Identification of inhibitor scaffolds through computational chemistry 107 
6.2.3 Biological validation of potential inhibitors of the histidine pathway .. 116 
6.3 CONCLUSIONS ....................................................................................................... 121 
6.4 MATERIALS AND METHODS ............................................................................. 122 
6.5 ACKNOWLEDGEMENT ........................................................................................ 124 
7.0 CONCLUSIONS ....................................................................................................... 125 
BIBLIOGRAPHY ............................................................................................................................. 132 
  ix 
PREFACE 
My Ph.D. is a journey that I wouldn’t have been able to complete without the support of many 
people.  
First, I would like to express my appreciation and gratitude to my Ph.D. mentor, Dr. Zoltan N. 
Oltvai for his encouragement, guidance, and financial support throughout my thesis work. I would 
also like to thank Professors Marie DeFrances, Robert Bowser, Alexander Doemling, Xiaoming Yin 
and Bennett Van Houten for their service on my dissertation committee. Their suggestions, comments 
and continuous supports have been a critical part in achieving my goals.  
I would like to thank all the previous and present members in the Oltvai Lab, Yi Zhou, Basak 
Isin, Krin Kay, and Qasim Beg, without whom my work could not have been accomplished. In 
recognition of their scientific and intellectual contributions to this research, special thanks go out to: 
Yao Shen, Singe Henriksen, Guillerma Estiu and Dr. Olaf Wiest in University of Notre Dame; Dr. 
Alexei Vazquez in The Cancer Institute of New Jersey; Vinayak Kapatral in Integrated Genomics 
Inc.; and Dr. Deok-Sun Lee, Dr. Yong-Yeoh Anh and Dr. Albert-László Barabási in Northeastern 
University. I particularly appreciate Yi and her family for all the enjoyable scientific and non-
scientific discussions as well as great time together. 
Finally, and most importantly, I extend my thanks to all members in my family, especially my 
father Guomeng Liu, my mother Yunzhen Liang, my brother Xingming Liu, my lovely daughter Iris 
Cao and my husband Liangliang Cao. I could have not succeeded without their unconditional love 
and support. Thank you all! 
  1 
1.0  INTRODUCTION 
Cell metabolism, including both catabolism and anabolism, is the foundation of life, 
allowing cells to reproduce and divide, and to maintain cell structures and functions. Cell 
metabolism in physiological or pathophysiological states has been studied extensively using 
reductionist methodologies, but the understanding of cell metabolism as a complete 
interconnected system by such approaches remains incomplete. To overcome these limitations 
more recently developed network-based approaches - integrating genomic, transcriptomic, 
proteomic and metabolomic data - offer a new framework for understanding physiological or 
pathophysiological metabolisms, which in turn may ultimately contribute to the development of 
novel therapeutic approaches. This thesis focuses on employing a systems biology approach to 
better understand cancer metabolism (a pathophysiological state) and the metabolism of the 
bacterium, S. aureus (a physiological state), and to demonstrate that the derived insights can 
contribute to drug discovery.   
The following introduction describes the basics of the systems-level analysis of metabolic 
networks, the biology of cancer metabolism, and the antibiotic resistance mechanisms of S. 
aureus. This background information represents the main elements required to understand the 
significance of this thesis. 
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1.1 METABOLIC NETWORK ANALYSIS 
1.1.1 Metabolic networks 
Cell metabolism, the integrated interconversion of thousands of metabolites through enzyme-
catalyzed biochemical reactions, can be reduced to a complex network of interconnected 
molecules and reactions that function to generate mass, energy, information transfer and cell-fate 
specification. While reductionist approaches remain critically important to develop an 
understanding of the individual functions of genes and proteins, inevitably most cellular 
components exert their function through a network of metabolic and genetic interactions 
(Barabasi and Oltvai 2004; Kroemer and Pouyssegur 2008; Brezina 2010; Tyson and Novak 
2010). Recently, genome-driven in silico modeling and analysis of metabolic networks have 
been recognized as a promising approach for characterizing complex cellular systems and for 
deriving novel strategies for biomedical and biotechnological applications in the context of 
systems biology and biotechnology (Stelling, Klamt et al. 2002; Bugrim, Nikolskaya et al. 2004; 
Feist and Palsson 2008; Mo and Palsson 2009; Boran and Iyengar 2010). 
Metabolic network is a reduced representation of cellular metabolism at a highly abstract 
level, where each node represents a metabolite that is connected to others by links, each of which 
represents a metabolic reaction catalyzed by a gene-encoded metabolic enzyme (Barabasi and 
Oltvai 2004). With the availability of full-genome sequences since the mid-1990s (Fleischmann, 
Adams et al. 1995), organism-specific metabolic networks can be reconstructed to delineate all 
the genetic products and enzymatic reactions that determine the physiological and biochemical 
processes of a cell (Feist, Herrgard et al. 2009; Thiele and Palsson 2010). In brief, as depicted in 
Figure 1.1, the metabolic network reconstruction process is initiated by acquiring the genetic 
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content from the annotated whole genome sequence of a specific organism and/or strain. The 
available literature and metabolic pathway databases, such as KEGG (Kanehisa and Goto 2000), 
BRENDA (Schomburg, Chang et al. 2004), MetaCyc (Caspi, Foerster et al. 2006), are then 
utilized to facilitate the identification of enzymes and the metabolic reactions they catalyze 
together with the biochemical stoichiometry, cofactors and substrates information. Once the 
gene-protein-reaction association is established for each gene, the metabolic network can be 
reconstructed by integrating all the metabolic reactions (links) and metabolites (nodes). There 
have been multiple automated reconstruction tools available to aid the reconstruction process 
(Feist, Herrgard et al. 2009). However, extensive manual curation and different computational 
tools are needed to transform the draft reconstruction to a high quality metabolic network 
(Pitkanen, Rousu et al. 2010; Thiele and Palsson 2010).  
 
Figure 1.1  Metabolic network reconstruction 
The metabolic network reconstruction of a given organism starts from its annotated genome where a parts 
list (genes) can be obtained. With the use of published literature and available data bases, the association 
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of the genome-encoded metabolic enzyme and its corresponding catalyzed metabolic reaction can be 
established. Finally, a metabolic network can be reconstructed to contain all the gene-enzyme-metabolic 
reaction associations. 
 
Currently, such genome-scale models have been reconstructed for more than 30 microbes 
(Durot, Bourguignon et al. 2009), and for the generic mouse (Sheikh, Forster et al. 2005; 
Selvarasu, Wong et al. 2009; Selvarasu, Karimi et al. 2010), cattle (Seo and Lewin 2009) and 
human genomes (Duarte, Becker et al. 2007; Ma, Sorokin et al. 2007). These reconstructed 
metabolic networks provide valuable insights into the cellular metabolism and behaviors under 
various conditions.   
1.1.2 Flux balance analysis 
The predictive powers of metabolic network analyses are realized through mathematical 
computational modeling tools (reviewed in (Maertens and Vanrolleghem 2010)). One of the 
most extensively used network analysis tools is flux balance analysis (FBA), which is based on 
appropriate constraints to derive the steady-state metabolic capabilities of the system without the 
need for accurate kinetic data (Raman and Chandra 2009).   
The main underlying principle of FBA is that under any given environmental condition, 
the organism will reach a steady-state that satisfies all the physiochemical constraints of the cell, 
such as the stoichiometric balance of mass, and energy (Kauffman, Prakash et al. 2003). Figure 
1.2 briefly illustrates the steps of FBA (Schilling and Palsson 1998). Once the metabolic network 
has been reconstructed, the first step of FBA is to define the system boundary that includes all 
the internal metabolic reactions but not exchange processes across the system (Fig 1.2a, b). Once 
all the internal reactions and exchange mechanisms are identified, a mass balance equation, that 
is, an equilibrium of in-flux and out-flux is derived for each metabolite in the system (Fig 1.2c). 
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The set of coupled ordinary differential equations are then represented in a matrix format, where 
“S” is the stoichiometric matrix and “V” is the flux matrix (Fig 1.2d). Without any constraint, the 
solution for the metabolic fluxes is underdetermined (Fig 1.2e), that is, an infinitely large 
solution “space” is present. When additional constraints, e.g., the maximum uptake rate of a 
given substrate is applied, the totality of solutions that satisfy the constraints form an allowable 
solution space (Fig 1.2f) and a flux cone corresponding to the metabolic capacity under the 
specified constraints can be calculated (Schilling, Edwards et al. 2000). In turn, given a 
metabolic optimization objective, such as the maximal biomass production rate, FBA can 
identify the optimal set of the internal flux distribution through linear programming, which is a 
mathematical method for optimization of a linear objective function (Fig 1.2g). 
Due to its simple fundamentals, FBA does not require kinetic data and can be computed 
very quickly. Since its initial development about 25 years ago (Fell 1986), FBA has proved to be 
a robust and diverse tool to predict the physiologically meaningful steady state to achieve a given 
metabolic objective, e.g., ATP production rate or growth rate (Raman and Chandra 2009). It also 
proved successful in predicting metabolic and cellular phenotypes with different perturbations, 
such as different growth conditions or various genetic manipulations in E. coli and other 
organisms (Ishii, Nakahigashi et al. 2007; Selvarasu, Wong et al. 2009). For example, the most 
well studied E. coli metabolic network has been extensively exploited for characterizing its 
cellular metabolism (Edwards, Ibarra et al. 2001; Covert and Palsson 2002; Fong, Marciniak et 
al. 2003) and its behavior under different perturbations and growth conditions (Fong, Marciniak 
et al. 2003; Ishii, Nakahigashi et al. 2007; Holm, Blank et al. 2010; Jozefczuk, Klie et al. 2010). 
In addition, the in silico models can also be used to infer the transcriptional and translational 
regulation and functional modules (Covert and Palsson 2002; Ravasz, Somera et al. 2002; 
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Stelling, Klamt et al. 2002; Herrgard, Lee et al. 2006).  Last, but not least, FBA provides the 
ability to predict the pathways or core reactions of an organisms’ metabolism with obvious 
implications for metabolic engineering (Almaas, Oltvai et al. 2005; Deutscher, Meilijson et al. 
2006; Resendis-Antonio, Reed et al. 2007; Motter, Gulbahce et al. 2008; Ohlsen, Dandekar et al. 
2008). Taken together, metabolic network analysis by FBA is a powerful modeling approach to 
investigate cellular metabolism, including the identification of potential enzyme targets from a 
systems biology perspective.  
 
Figure 1.2  Flux balance analysis 
a) A given metabolic network; b) the system boundary that includes all the internal metabolic reactions 
but not exchange processes across the system is defined; c) An equilibrium of in-flux and out-flux is 
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derived for each metabolite in the system; d) The set of coupled ordinary differential equations are then 
represented in a matrix format, where “S” is the stoichiometric matrix and “V” is the flux matrix; e) 
Without any constraint, the solution for the metabolic fluxes is underdetermined; f) With additional 
constraints, e.g., the maximum uptake rate of a specified substrate, all the solutions that satisfy the 
constraints form an allowable solution space; g) Given an optimization objective, such as the maximal 
biomass production rate, FBA can identify the optimal solution of flux distribution within the allowable 
solution space. Reproduced with permission from (Orth, 2010; Schilling, 1998). 
 
However, traditional FBA without additional constraints or biological knowledge may not 
be enough to characterize the effect of mutations or shifts in the steady states (Segre, Vitkup et 
al. 2002).  Indeed, during the last several years, additional constraints or alternative objective 
functions have been gradually incorporated into FBA to enrich its predictive capabilities and 
accuracy. For example, transcriptional and translational regulatory constraints have been 
considered through Boolean logic in the FBA model that captures the dynamic shifts of gene 
regulation over time (Covert and Palsson 2002; Mahadevan, Edwards et al. 2002). Besides 
regulatory constraints, the incorporation of additional thermodynamic constraints (i.e. energy 
balance) (Beard, Liang et al. 2002) and physicochemical constraints (Beg, Vazquez et al. 2007) 
also holds the potential to improve the modeling of metabolic behaviors that cannot be 
interpreted by traditional FBA. Of note, each method has its own advantages and limitations. 
Therefore, optimal FBA methods and objective functions should be carefully selected for 
investigation to achieve respective research aims.  
1.1.3 Molecular crowding 
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Figure 1.3  Molecular crowding 
 a) Representation of the approximate numbers, shapes and density of packing of macromolecules inside 
an Escherichia coli cell. Small molecules are not shown. Reproduced from with permission (Hoppert and 
Mayer 1999); b) Examples of excluded volume. In this figure, the spheres represent three different 
species of roughly spherical globular protein. The volume excluded by the black sphere to the red sphere 
is a spherical volume bounded by the dashed red line. The volume excluded by the black sphere to the 
blue sphere is a spherical volume bounded by the dashed blue line. Reproduced with permission from 
(Minton 2006). 
 
Molecular crowding (MC) is an important characteristic of all cells’ interior (Fulton 1982; Ellis 
2001) (Fig 1.3a). The term MC means that the high concentration of intracellular 
macromolecules, such as DNA, RNA, polysaccharides and protein complexes, leads to a 
significant portion of cell volume physically occupied and thus, unavailable to other molecules 
(Ellis 2001; Acerenza and Graña 2006). Thus, the effect of MC is also known as the excluded 
volume effect (Fig 1.3b).  
How crowded is the cell cytoplasm? In general, the volume fraction physically occupied 
by macromolecules ranges from 5% to 40% of the total volume (up to 400g/L) (Ellis and Minton 
2003). For example, Zimmerman and coworkers estimated that the total concentration of protein 
and RNA inside an E. coli cell is in the range of 300-400g/L (Zimmerman and Trach 1991). The 
cytoplasm of a eukaryotic cell is also crowded. For example, red blood cells contain around 
350g/L hemoglobin alone (Ellis 2001).  
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Due to the fundamental influence of thermodynamic activities on biochemical reactions, 
such crowded intracellular environments have profound effects on many aspects of cellular 
information processing steps. For example, molecular crowding can stabilize folded DNA, RNA 
and protein structures and conformations (Hancock 2004; Miyoshi and Sugimoto 2008; Kilburn, 
Roh et al. 2010); It can also result in the alteration of equilibrium and rate constants of 
biochemical reactions by up to several orders of magnitude (Minton 2001; Hu, Jiang et al. 2007; 
Zhou, Rivas et al. 2008); in addition, MC is very important to determine the diffusion/ mobility 
of metabolites and macromolecules. Therefore, cell signaling and communication as well as 
regulation could be also impacted by MC (Minton 1993; Bray 1998; Garcia-Perez, Lopez-
Beltran et al. 1999; Goins 2007). Recently, there have been some attempts to study the effect of 
MC on the glycogenolysis enzymes (Chebotareva 2007).  
Previous studies from our lab suggested that MC is a physiologically relevant constraint for 
determining the substrate uptake order of E. coli under various growth medium compositions 
(Beg, Vazquez et al. 2007), and essential for constraining the cellular metabolism especially in 
fast growing E. coli  and S. cerevisiae cells (Vazquez, Beg et al. 2008; Vazquez, de Menezes et 
al. 2008). It is therefore likely that it also has a role in constraining the function of mammalian 
cellular metabolisms with potential contribution to cancer cell metabolism. 
1.2 CANCER METABOLISM 
Cancer is the second leading cause of death in the United States, resulting in one of every four 
deaths (Jemal, Siegel et al. 2007). More than 1 million people are diagnosed with cancer each 
year (Jemal, Siegel et al. 2007). However, not all types of cancer respond to current cancer 
  10 
therapies, such as chemotherapy and radiation therapy. Moreover, many cancer patients develop 
drug resistance or suffer severe toxicity, limiting the effect of available chemotherapy and 
radiation therapy. Thus, the identification of additional novel effective cancer therapeutic 
approaches is urgently needed.  
Cancer is a highly heterogeneous disease, both morphologically and genetically, with 
multiple genetic and regulatory abnormalities in the cell (Hanahan and Weinberg 2000). A major 
challenge in the pursuit of effective cancer therapy is the characterization of those common 
features that distinguish cancer cells from their normal counterparts, and how these differences 
can be exploited therapeutically to improve the specificity and effectiveness of cancer treatment. 
The hallmarks of cancer include growth signal independence, limitless replication potential, 
sustained angiogenesis, resistance to apoptosis, and tissue invasion and metastasis (Hanahan and 
Weinberg 2000), pathways of which some are already targeted by current cancer therapeutics. 
However, the molecular pathways underlying these cellular pathways are multifaceted and often 
redundant. Therefore, the alternative approach—targeting cancer metabolism, which is distinct 
from that of normal cells, represents a potentially major new therapeutic option. 
1.2.1 The Warburg effect 
Cellular energy metabolism, especially glucose metabolism, is one of the main processes that 
differentiate cancer cells from normal cells. Glycolysis is a catabolic process that converts 1 
glucose to 2 pyruvates and also yields 2 ATPs. In normal cells, pyruvate is oxidized to CO2 and 
H2O generating 36 ATPs in the mitochondrial oxidative phosphorylation pathway when oxygen 
is abundant. Alternatively, in the absence of oxygen, pyruvate is catalyzed to lactic acid (or 
lactate) in the anaerobic glycolysis pathway (Fig 1.4a). As early as the mid 1920s, Otto Warburg 
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made the seminal discovery that rapidly proliferating ascites tumor cells utilize glycolysis at a 
much higher rate than normal resting cells, resulting in enhanced lactate secretion, even in the 
presence of oxygen. This phenomenon in mammalian cells is referred to aerobic glycolysis or the 
Warburg effect (Fig 1.4b) (Warburg 1956). Indeed, such distinct glucose metabolism has been 
found in most types of cancers (Kim, Gardner et al. 2005; Hsu and Sabatini 2008; Ortega AD 
2009; Zhivotovsky and Orrenius 2009). Since glycolysis is far less efficient for ATP production 
than mitochondrial oxidative phosphorylation, cancer cells maintain high glycolytic fluxes, and 
such phenomenon has been clinically exploited to image cancer using the glucose analog 2-(18F)-
fluoro-2-deoxy-D-glucose (FDG) by positron emission tomography (PET) (Kroemer and 
Pouyssegur 2008).  
 
Figure 1.4  Glucose metabolism in normal and cancer cells. 
a) In normal cells of differentiated tissue, glucose is converted to pyruvate, which is oxidized to CO2 and 
H2O generating 36 ATPs in the mitochondrial oxidative phosphorylation pathway when oxygen is 
abundant. In the absence of oxygen, pyruvate is catalyzed to lactic acid (or lactate) in the anaerobic 
glycolysis pathway, generating 2 ATP per glucose. b) In cancer cells and other proliferative tissues, 
glucose is converted to pyruvate, most of which is catalyzed to lactic acid even in the presence of oxygen, 
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a phenomenon called Warburg effect. Modified with permission from (Vander Heiden, Cantley et al. 
2009). 
 
 
Irrespective of the initiating mechanism, the molecular mechanisms underlying the 
Warburg effect are increasingly understood. Aerobic glycolysis is always associated with the up-
regulation of glycolytic enzymes, such as glucose transporters (mainly GLUT-1), hexokinase-2 
(HK-2), pyruvate kinase M2 (PK-M2) and lactate dehydrogenase A (LDH-A) (Fig 1.5) 
(Reviewed in (Gatenby and Gillies 2007; Hsu and Sabatini 2008; Locasale and Cantley 2010)). 
The increased glucose utilization through upregulated glycolytic enzymes generates metabolic 
intermediates such as glucose 6-phosphate, which is then used, e.g., for nucleic acid synthesis 
through pentose phosphate pathway to support the cells’ fast proliferation. The abundant 
production of pyruvate is shunted from the TCA cycle in mitochondria to lactate production 
pathway through the up-regulation of pyruvate dehydrogenase kinase (PDK) and lactate 
dehydrogenase A (LDH-A).  Part of pyruvate may enter a truncated tricarboxylic acid (TCA) 
cycle, the result of which stimulates lipid synthesis to sustain the cell membrane formation 
during division by exporting acetyl-CoA from the mitochondrial matrix to the cytoplasm (Fig 
1.5) (Kroemer and Pouyssegur 2008; Frezza and Gottlieb 2009; Mayevsky 2009; Vander Heiden, 
Cantley et al. 2009; Kaelin and Thompson 2010). 
Although inefficient for ATP production per glucose molecule, such distinct glucose 
metabolism has been found to convey proliferative advantages for tumor growth. First, cells with 
aerobic glycolysis can be more resistant to hypoxic or anoxic environments, which would 
otherwise be lethal for normal resting cells (Mazure, Dayan et al. 2006; Pouyssegur, Dayan et al. 
2006). Second, aerobic glycolysis leads to accelerated lactate secretion, which can acidify the 
surrounding extracellular matrix and facilitate tumor metastasis and immune escape (Fischer, 
  13 
Hoffmann et al. 2007; Swietach, Vaughan-Jones et al. 2007). In addition, aerobic glycolysis 
provides biosynthetic precursor molecules needed for cellular biomass production pathways, 
including glycerol and citrate for lipids; ribose sugars for nucleotides; nonessential amino acids 
 
Figure 1.5  Metabolic reprogramming in cancer cells. 
Small arrows pointing up or down indicate cancer-associated upregulation/activation or 
downregulation/inhibition of enzymes, respectively. Alterations indicated in red can be caused by the 
activation of HIF-1. GLUT, glucose transporter; GSH, glutathione; HIF, hypoxia-inducible factor; IDO, 
indoleamine 2,3-dioxygenase; HK, hexokinase; OXPHOS, oxidative phosphorylation; LAT1, L-type 
amino acid transporter 1; LDHA, lactate dehydrogenase isoform A; MCT, monocarboxylate transporter; 
PDH, pyruvate dehydrogenase; PDK, pyruvate dehydrogenase kinase; PFK, phosphofructokinase; PI3K, 
phosphatidylinositol 3-kinase; PGM, phosphoglycerate mutase; PKM2, pyruvate kinase isoform M2; 
PPP, pentose phosphate pathway; SCO2, synthesis of cytochrome c oxidase 2; TLK, transketolase; 
VDAC, voltage-dependent anion channel. Reproduced with permission from (Kroemer and Pouyssegur 
2008). 
 
and NADPH (DeBerardinis, Lum et al. 2008; Vander Heiden, Cantley et al. 2009). Moreover, 
aerobic glycolysis may protect cells from reactive oxygen species and apoptosis as well as 
premature senescence (Brand 1997; Brand and Hermfisse 1997; Hsu and Sabatini 2008; Kondoh 
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2008). Taken together, the Warburg effect seems to provide growth advantages to proliferating 
cancer cells. 
1.2.2 Possible origins of the Warburg effect  
Even though the growth advantages of the Warburg effect for cancer cells, and the mode by 
which cells switch from full oxidative phosphorylation to partial aerobic glycolysis are becoming 
clearer, whether the aberrant glucose metabolism is the cause or the consequence of the 
oncogenic transformation in cancers is still debated.  
Originally, Warburg proposed that such aerobic glycolysis switch was due to permanent 
mitochondrial defects, preventing normal oxidative phosphorylation (Warburg 1956). While this 
may be true for some cancer cells, the generality of this hypothesis was challenged by the finding 
that some tumor cell lines maintain an intact capacity for oxidative metabolism (Guppy, 
Leedman et al. 2002; Rodriguez-Enriquez, Vital-Gonzalez et al. 2006). Gatenby and Gillies then 
proposed the hypoxia-induced metabolic reprogramming during early carcinogenesis within a 
hypoxic microenvironment, considering that partial oxygen pressure drops to very low values in 
the inner mass of a growing tumor (Helmlinger, Yuan et al. 1997; Gatenby and Gillies 2004). 
However, by now it is evident that the glycolytic switch is acquired very early in carcinogenesis, 
even before tumors encounter hypoxia (Vander Heiden, Cantley et al. 2009). For example, lung 
cancers and leukemic cells, which are surrounded by abundant oxygen, still metabolize glucose 
in part through the aerobic glycolysis pathway (Nolop, Rhodes et al. 1987; Gottschalk, Anderson 
et al. 2004), indicating that aerobic glycolysis cannot be solely attributed to hypoxia adaptation 
mediated through the key oxygen sensor, HIF-1. 
  15 
A third possible cause is thought to be a consequence of oncogenic alterations, such as 
mutations/deletions in p53, MYC, and/or AKT (Semenza 2009; Feng and Levine 2010; Locasale 
and Cantley 2010). For example, the activation of hypoxia-inducible factor (HIF), a transcription 
factor that is activated by hypoxic stress but also by oncogenic, metabolic, and oxidative stress, 
often leads to the overexpression of the glucose transporters and various glycolysis pathway 
enzymes or isozyme subtypes explaining the increased glucose uptake and altered utilization 
(Sutphin, Giaccia et al. 2007; Semenza 2009). p53, one of the most frequently mutated genes in 
cancers, is both a positive regulator of mitochondrial respiration and a negative regulator of 
glycolysis (Feng and Levine 2010). In agreement with these findings, it has recently been shown 
that germline mutation of metabolic enzymes of the TCA cycle (e.g., isocitrate dehydrogenase 
(IDH), succinate dehydrogenase (SDH) and fumarate hydratase (FH)) in themselves can also 
lead to the aberrant glucose metabolism (Favier, Briere et al. 2009; Kaelin 2009; Sudarshan, 
Sourbier et al. 2009; Ward, Patel et al. 2010). 
While the reasons listed above together can potentially explain the emergence of aerobic 
glycolysis in cancer cells, they cannot explain why proliferating primary lymphocytes also utilize 
similar aerobic glycolysis pathways (Wang, Marquardt et al. 1976). Indeed, proliferating 
lymphocytes are not alone. Human endothelial cells (Peters, Kamp et al. 2009), hepatocytes 
(Barbini, Rodriguez et al. 2007), vascular endothelial cells (Werle, Jahn et al. 2005), thymocytes 
(Brand 1997) and fibroblasts (Kittlick and Babin 1985) also exhibit a Warburg-like effect when 
they are proliferating rapidly in normoxic conditions. Taken together, these observations indicate 
that aerobic glycolysis is an inherent feature of all rapidly proliferating cells (Vander Heiden, 
Cantley et al. 2009). 
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1.2.3 Potential therapeutic significances of the Warburg effect  
As mentioned in Part 1.2.1, the distinctiveness of cancer cell metabolism has been successfully 
exploited for cancer diagnostics through the metabolic imaging technique, PET. With renewed 
research interest in the Warburg effect an emerging field aims to explore cancer cell metabolism 
for therapeutic purposes: for identifying metabolic tumor markers and for targeted therapies. 
There have been a number of glycolysis-related proteins investigated with regard to their 
potential as a prognostic tumor marker. For example, the over-expression of GLUT-1, the 
predominant glucose transporter in most tissues, is found to be correlated with 18F-FDG uptake 
and poor prognosis, thus acting as a potential marker of radioresistance and poor response to 
chemotherapy in various human malignancies (Brophy, Sheehan et al. 2009; Legan, Luzar et al. 
2009; Ayala, Rocha et al. 2010; Ohba, Fujii et al. 2010). Lactate dehydrogenase (LDH), the key 
enzyme converting pyruvate to lactate in the anaerobic glycolysis pathway, has also been shown 
to represent a marker of malignancy in gastric and lung cancers and tumors of other origins 
(Hann and Bombardieri 2000; Koukourakis, Giatromanolaki et al. 2003; Kimura, Yamaguchi et 
al. 2005; Kolev, Uetake et al. 2008). So called, oncometabolites (Ward, Patel et al. 2010), such 
as lactate or 2-hydroxyglutarate may also serve as serum markers for tumor diagnosis and 
monitoring therapeutic responses (Fischer, Hoffmann et al. 2007; Dang, White et al. 2010). 
Besides tumor diagnostic markers, the aberrant tumor cell metabolism is also attractive as 
cancer’s “Achilles’ heel” for targeted therapy (Kroemer and Pouyssegur 2008). Recently, 
Cuezva and coworkers have reviewed various small compounds targeting the metabolism of 
cancer cells with potential clinical utility (Table 1.1) (Cuezva, Ortega et al. 2009). In brief, there 
are two major directions explored for metabolic targeting. The first is to inhibit glycolysis, 
leading to ATP depletion and cell death. For example, the glucose analog, 2-deoxy-D-glucose (2-
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DG), can inhibit hexokinase, inhibit cell proliferation, and induce apoptosis in a variety of cancer 
cells in vitro; It can also sensitize the cancer cells in vivo and in vitro to radiation and 
chemotherapy treatments, and without affecting normal cells (Dwarakanath 2009; Farooque, 
Afrin et al. 2009). Similar to 2-DG, 3-bromopyruvate (3-BrPA) also targets hexokinase and 
abolishes the ATP production with potential antitumor activity and specificity (Buijs, Vossen et 
al. 2009; Ganapathy-Kanniappan, Vali et al. 2010; Qin, Xin et al. 2010).  
 
Table 1.1 Small compounds targeting the metabolism of the cancer cell with potential clinical utility 
 
GAPDH, glyceraldehyde 3-P-dehydrogenase; PK, pyruvate kinase; PDK1, pyruvate dehydrogenase kinase 1; G6PD, 
glucose-6-phosphate dehydrogenase; TK, transketolase; MOMP, mitochondrial outer membrane permeabilization; 
ACC, acetyl-CoA carboxylase; FAS, fatty acid synthase; CPT1, carnitine palmitoyl transferase 1; PPP, pentose 
phosphate pathway. Reproduced with permission (Cuezva, Ortega et al. 2009). 
 
The second major function of potential cancer therapeutic compounds is to shift 
glycolysis towards mitochondrial respiration or glucose oxidation, e.g., by inhibiting LDH 
activity through the use of oxamate or siRNA (Coe and Strunk 1970; Fantin, St-Pierre et al. 
2006). An intriguing and promising example is dichloroacetate (DCA), a clinically approved 
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drug for hereditary lactic acidosis disorders and a known inhibitor of pyruvate dehydrogenase 
kinase (PDK), which catalyzes the phosphorylation of pyruvate dehydrogenase (PDH) and 
therefore limits the amount of pyruvate entering the mitochondrial oxidative phosphorylation 
(Stacpoole 1989; Stacpoole, Henderson et al. 1998). It has been found recently that DCA can 
selectively kill cancer cells and established tumors by shifting metabolism from glycolysis to 
glucose oxidation and oxidative phosphorylation (Bonnet, Archer et al. 2007). DCA has also 
been shown to sensitize prostate cancer cells to irradiation (Cao, Yacoub et al. 2008). Currently, 
DCA is in phase I/II clinical trials (Cuezva, Ortega et al. 2009). 
Although the above examples offer hope for specifically killing cancer cells through 
metabolic targeting, the real-world situation is more complicated than expected. Cancer cells 
may switch to alternative energy sources and non-glycolytic pathways for tumor cell survival 
and growth (Buzzai, Bauer et al. 2005). For example, drug and radiation resistant cancer cells 
use fatty acid oxidation to support mitochondrial oxidative phosphorylation when glucose 
becomes limited (Harper, Antoniou et al. 2002). This indicates that tumor cell metabolism has 
intrinsic plasticity and flexibility to maintain its robustness against external perturbations.  This 
suggests that for the identification of the vulnerable points of cancer metabolism a systems-
oriented metabolic network analysis approach may prove helpful for drug target discovery. 
1.3 S. AUREAS ANTIBIOTICS RESISTANCE 
As we will describe in Chapter 3, the full metabolic network reconstruction of mammalian cells 
in a tissue and cell type-specific fashion is not yet possible. Therefore, we turn to prokaryotic 
cells in which full metabolic network reconstruction is now routine. Specifically, to provide a 
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proof-of-principle of the potential of a systems-oriented metabolic network analysis for drug 
discovery targeting cell metabolism, we focus on the bacterium, Staphylococcus aureus, because 
of its virulence, its adaptation ability to different environmental conditions (Lowy 1998), and 
because its mortality now surpasses that of human immunodeficiency virus/AIDS in the United 
States (Klevens, Morrison et al. 2007).  
S. aureus is a major hospital/community-acquired opportunistic pathogen, which can 
cause bacteremia, pneumonia, endocarditis, skin lesions, meningitis and other metastatic 
complications (Mongkolrattanothai, Aldag et al. 2009; Hulten, Kaplan et al. 2010; Wu, Wang et 
al. 2010). Although the use of existing antimicrobial agents, such as β-lactam antibiotics, sulfa 
drugs, tetracycline and clindamycin, has controlled some of these infections (Lowy 1998; David 
and Daum 2010; Herigon, Hersh et al. 2010; Hulten, Kaplan et al. 2010; Wu, Wang et al. 2010), 
the emergence of methicillin-resistant S. aureus (MRSA) and vancomycin-resistant S. aureus 
(VRSA) isolates underscores the need to identify new targets and molecules effective against 
multidrug-resistant strains of S. aureus. 
1.3.1 Possible mechanisms of antibiotics resistance.  
Resistant Staphylococcus aureus, especially methicillin-resistant Staphylococcus aureus 
(MRSA) and vancomycin-resistant Staphylococcus aureus (VRSA)—just as deadly as MRSA 
but more challenging to treat, have been one of the three classes of emerging antibiotic-resistant 
pathogens as major threats to public health (Lam and Wunderink 2006; Moran, Krishnadasan et 
al. 2006; Fischbach and Walsh 2009). The evolution of increasingly antibiotic resistant species 
results from a multitude of factors that include wide-spread and inappropriate use of antibiotics, 
increase of international travels, and the extensive use of antibiotics as growth enhancers in 
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animal feed (Butaye, Devriese et al. 2003; Adaleti, Nakipoglu et al. 2010; Bosso, Mauldin et al. 
2010; English and Gaur 2010; Martinez and Silley 2010).  
Although the antimicrobial resistance mechanisms of S. aureus have not been completely 
clarified, there are at least three major forms of it. First, S. aureus may acquire through e.g., 
lateral transfer genes encoding enzymes that destroy the antibacterial agent before it can exert its 
effect. For example, when S. aureus is exposed to β-lactam antibiotics, such as penicillin, an 
extracellular enzyme, β-lactamase, is frequently synthesized to hydrolyze the β-lactam ring 
leading to its inactivation (Tenover 2006). Secondly, susceptible S. aureus can also acquire 
resistance through stepwise chromosomal mutations to modify the target site, or to produce an 
alternative metabolic pathway to bypass the drug action. For example, in the critical regions of 
DNA gyrase, the enzyme that serves as the target for quinolones, amino acids changes can 
reduce the affinity of quinolone to its targets (Moudgal and Kaatz 2009; Martinez and Silley 
2010). In addition, bacteria can acquire resistance by mutation or transposon facilitated gene 
transfer from other organisms or strains to express efflux pumps that prevent the drug from 
reaching its intracellular targets (e.g., efflux of fluoroquinolones in S. aureus) (Martinezbeltran 
and Canton 1994; Lowy 2003; Moudgal and Kaatz 2009). Indeed, the fact that the efflux systems 
can mediate resistance to a variety of drug classes makes them very effective mechanisms of 
drug resistance.  
Indeed, antibiotic resistance genes from pathogens only comprise a tiny fraction of the 
antibiotics resistome, which is the collection of all the antibiotic resistance genes and their 
precursors in pathogenic and non-pathogenic bacteria (Wright 2007; Wright 2010). Genomic 
approaches have revealed that resistance genes are present in all bacteria, including bacterial 
pathogens (D'Costa, McGrann et al. 2006; Fajardo, Martinez-Martin et al. 2008). The intrinsic 
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resistome may be a potential source of antibiotic resistance, given the appropriate selection 
pressure (Wright 2007). Thus, as rapidly as new antibiotics are introduced, staphylococci can 
very often develop efficient mechanisms to neutralize them, inevitably leading to fewer effective 
bactericidal antibiotics to treat these often life-threatening infections. 
1.3.2 Current approaches to search for novel anti-Staphylococcus agents.  
As noted above, the emergence of MRSA and VRSA argues for the development of new 
antibiotics that act on novel targets through new mode of actions. Equally important is the quick 
and cost effective approach to find unique vulnerable targets in Staphylococcus aureus, including 
its resistant strains. 
One potential approach is to modify the existing antibiotics and scaffolds through 
synthetic tailoring to combat the mechanism of drug resistance. Indeed, most chemical scaffolds 
from which today’s antibiotics have been derived were discovered between the mid-1930s and 
the early 1960s (e.g., β-lactams, glycopeptides, tetracyclines) (Newman and Cragg 2009). Just 
four such scaffolds -cephalosporins, penicillins, quinolones, and macrolides- account for ~73% 
of the new antimicrobials developed between 1981 and 2005 (Newman and Cragg 2007). During 
synthetic tailoring, the core of the antibiotics is left intact while the chemical groups at its 
periphery are modified to improve the drug’s property to bypass the resistance mechanisms. In 
this sense, the analysis of the crystal structure of drug targets (e.g., modifications of β-lactams 
that attack the active site of its target) and synthesis of carbohydrate modified compounds 
(glycopeptides analogues with altered carbohydrates) are increasingly used to develop alternative 
agents (Tenover 2006). However, new antibacterial agents with different mechanisms of actions 
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are also needed, since it may be very difficult to outsmart organisms that have evolved for 
several billion years to be able to adapt to hostile environments. 
Since the introduction of penicillin in the 1940s, significant effort has been invested in 
whole-cell screening for natural products, in which antibacterial activities are identified before 
the targets or modes of action are determined. Most natural product antibiotics usually come 
from soil actinomycetes (Fischbach and Walsh 2009). Recently, more underexplored ecological 
niches, such as terrestrial and marine symbioses, and bacterial taxa have started to be searched 
for new antibacterial agents (Newman and Cragg 2007; Wang, Kodali et al. 2007).  For example, 
a deep-sea sediment sample yielded an actinomycete that produces a new antifolate scaffold, 
abyssomicins (Bister, Bischoff et al. 2004). Recently, a novel antibiotic, platensimycin, was also 
discovered from natural product screening to target the fatty acid biosynthesis pathways. More 
importantly, this promising antibiotic has displayed activity against various drug-resistant S. 
aureus strains (Wang, Soisson et al. 2006; Wang, Kodali et al. 2007). 
An additional approach is to search for synthetic antibiotics with novel targets by novel 
strategies. For example, the synthetic molecules, oxazolidinones, are of increasing importance in 
the treatment of Gram-positive pathogens, including MRSA (Fischbach and Walsh 2009). As 
bacterial genomics emerged in the late 1990s, genomics-based technologies and synthetic 
libraries in the discovery of synthetic antibiotics have been of great interest with the promise to 
accelerate the discovery of new antibiotics. However, they have not lived up to their promise for 
at least two reasons: First, access to the target through the bacterial cell wall/ membrane may be 
limited. Secondly, pre-existing efflux system may limit target accessibility (Payne, Gwynn et al. 
2007). Therefore, an unbiased whole-cell screen and novel strategies should be implemented for 
the success of synthetic antibiotics. 
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1.4 THESIS OUTLINE 
Compared to normal resting cells, cancer cells exhibit distinct metabolisms, in which 
glycolysis with lactic acid secretion is utilized concomitantly with mitochondrial oxidative 
phosphorylation even in the presence of oxygen, a phenomena known as the Warburg effect or 
aerobic glycolysis. The understanding of the Warburg effect may provide insights that can lead 
to the development of alternative therapeutic options against human cancers. However, the origin 
of the Warburg effect is not fully understood.  
In Chapter 2 of this thesis, we introduce one potential origin for the Warburg effect -, 
molecular crowding-, and provide background information of its relevance for the metabolism of 
fast growing E. coli cells. As cancer cells also proliferate rapidly and exhibit similar aerobic 
glycolysis phenotypes to fast growing E. coli cells, in Chapter 3 we aim to examine whether the 
MC is a relevant origin of cancer metabolism. Since the complete human metabolic network has 
not been fully reconstructed, we developed a reduced flux balance model of the human central 
metabolism that incorporates the molecular crowding (MC) constraint and the maximum glucose 
uptake constraint.  We found that the model successfully captured the main characteristics of 
cancer metabolism (aerobic glycolysis), indicating that MC constraint may contribute to the 
origin of the Warburg effect. Next, we experimentally tested the model’s predictions using 
mammalian cells from low to high growth rates as a proxy for MC alteration. We found that, 
consistent with the model, faster growing cells (i.e. cells with high MC) indeed have increased 
aerobic glycolysis, thus indicating MC as an important contributor to cancer metabolism. 
Living organisms are generally robust against various perturbations, such as mutations, 
toxins, environmental alterations, and even drugs, the fact which necessitates the exploitation of 
systems approaches to identify the fragile points of robust microbial systems. In turn, the 
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systems-oriented approach may prove helpful for drug discovery, targeting e.g., the Warburg 
effect in tumor cells for therapeutic utilization. However, the reliable identification of enzyme 
targets within metabolic networks requires a completely reconstructed, high quality human 
metabolic network to be cell type specific, which is not yet attainable. Therefore, to provide a 
proof-of-concept we investigate this potential instead on the single cell pathogen, Staphylococcus 
aureus, where the metabolic network of the strain N315 have previously been reconstructed 
(Becker and Palsson 2005; Heinemann, Kummel et al. 2005).  
As there are various S. aureus strains in terms of pathogenesis, antibiotic susceptibility, 
virulence and genome sequences, in Chapter 4, we first asked if it is sufficient to reconstruct the 
metabolic network on only one S. aureus strain to identify generic antimicrobial targets. We 
performed metabolic reconstructions and subsequent flux balance analyses of those 13 
multidrug-resistant and sensitive S. aureus strains, whose genome sequences were available. We 
identified 70 single enzymes and 54 pairs of enzymes whose corresponding metabolic reactions 
are predicted to be unconditionally essential for growth. Of these, 44 single enzymes and 10 
synthetic lethal enzyme pairs proved to be common to all 13 S. aureus strains, including many 
that had not been previously identified as being essential for growth by gene deletion 
experiments in S. aureus. We thus conclude that metabolic reconstruction and in silico analyses 
of multiple strains of the same bacterial species are needed for species-specific antibiotic target 
identification. 
Potential target identification is the very first step toward antibiotic drug discovery. To 
validate the essentiality and druggability of the identified potential targets, we studied the 
common targets of 13 S. aureus strains in fatty acid biosynthesis and histidine biosynthesis 
pathways as a proof-of-principle study in Chapter 5 and Chapter 6, respectively. 
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In Chapter 5, we focus on the predicted enzyme targets of the type-II bacterial fatty-acid 
biosynthesis (FAS II) pathway since most enzymes of this pathway are essential in the 13 S. 
aureus strains. We first identified a list of potential small molecule inhibitors through virtual 
screening targeting the individual enzyme targets in the FAS II pathways. We then showed 
experimentally that a subset of potential inhibitors could inhibit both enzyme activities in vitro 
and bacterial cell viability in vivo, which indicates the potential and accuracy of the systems 
oriented metabolic analysis in identifying drug targets.  
In Chapter 6, we have further extended the investigation to the histidine biosynthesis 
pathway where we predicted the potential inhibitors through virtual screening, which were then 
validated directly through whole-cell assays, avoiding the time-consuming and often difficult 
enzyme assays. Of 18 representative compounds tested on 3 S. aureus strains and 2 E. coli 
strains, we showed that 13 compounds are inhibitors of some or all of the S. aureus strains, while 
14 compounds are able to weakly inhibit growth in one or both E. coli strains. The high hit rate 
obtained from a fast virtual screen demonstrates the applicability of this novel strategy to the 
histidine biosynthesis pathway. 
In Chapter 7, we conclude the four parts of the thesis with a perspective on how each 
part contributes to the current understanding of cellular metabolism and possible therapeutic 
opportunities. 
 
The completion of this thesis has resulted in the following publications: 
1. Vazquez A., Liu J., Zhou Y., and Oltvai ZN. (2010) Catabolic efficiency of 
aerobic glycolysis: The Warburg effect revisited. BMC Systems Biology, 4(1):58. PMID: 
20459610 
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2. Henriksen ST., Liu J., Estiu G., Oltvai ZN. and Wiest O. (2010) Identification 
of novel bacterial histidine biosynthesis inhibitors using docking, ensemble rescoring and 
whole cell assays. Bioorg. & Med. Chem., 18(14):5148-56. PMID: 20573514 
 
3. Shen Y*, Liu J*, Estiu G, Isin B, Ahn YY, Lee DS, Barabási AL, Kapatral V, 
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networks. Proc Natl Acad Sci U S A. 107(3):1082-7. PMID: 20080587 (Shen Y. and Liu 
J. contributed equally to the paper.) 
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V. (2009) Comparative genome-scale metabolic reconstruction and flux balance analysis 
of multiple Staphylococcus aureus genomes identify novel antimicrobial drug targets. J. 
Bacteriol. 191(12):4015-24. PMID: 19376871 
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2.0  MOLECULAR CROWDING REPRESENTS AN IMPORTANT BOUND IN 
RAPIDLY DIVIDING E. COLI CELLS 
Understanding a cell’s metabolism at the system level and obtaining quantitative predictions for 
cellular metabolic activities require the identification and modeling of the physicochemical 
constraints that limit the cell’s metabolic capabilities at different growth conditions (Price, Reed 
et al. 2004; Vazquez, Beg et al. 2008). Molecular crowding (MC), also known as the excluded 
volume effect, is one such potential constraint in all cells’ interior, since the high concentration 
of intracellular macromolecules (DNA, RNA, polysaccharides and protein complexes) can exert 
profound influences on many cellular processes. These include diffusion, reaction equilibrium 
and reaction rates, protein folding, and protein-protein- and protein-DNA interactions (Ellis 
2001; Acerenza and Graña 2006; Zhou, Rivas et al. 2008), each of which can have an impact on 
the regulation of metabolic pathways. In this chapter, we will briefly summarize our previous 
results for developing an understanding the potential effects of MC on E. coli metabolism and 
explain why MC could be a potential metabolic constraint to the formation of the Warburg effect 
in cancer cells. 
To investigate the potential effect of MC on system-level cell metabolism, we 
incorporated the MC constraint to the flux balance analysis framework (FBAwMC) (Beg, 
Vazquez et al. 2007; Vazquez, Beg et al. 2008;). Briefly, as introduced in Chapter 1, in FBA a 
cell’s reconstructed metabolic network is mathematically represented by the stoichiometric 
matrix S with its element Smi indicating the stoichiometric coefficient of metabolite m in reaction 
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i. The FBA states that in the stationary state, the fluxes {Schilling, , 1998} of the metabolic 
reactions consuming and producing a metabolite should be in balance, 
                                                                                                             [1] 
where fi denotes the flux of reaction i. 
Due to the MC constraint, the volume occupied by one macromolecule will not be 
available to others, therefore there is only a limited solvent capacity for the allocation of 
metabolic enzymes. Thus, given that the enzyme molecules have a finite molar volume vi only a 
finite number of them fit in a given cell volume V. Indeed, if ni is the number of moles of the ith 
enzymes, then 
                                                                                                                   [2] 
where the inequality sign accounts for the volume of other cell components and the free volume 
necessary for cellular transport as well. Eq. 2 represents a constraint on the enzyme levels ni, 
potentially affecting their maximum attainable values and relative abundance. Dividing by cell 
mass M, we can reformulate this constraint in terms of the enzyme concentrations Ei = ni/M 
(moles per unit mass), resulting in 
                                                                                                               [3] 
where C=M/V≈0.34 g/ml is the cytoplasmic density of E. coli (Zimmerman and Trach 1991). As 
the reaction flux fi can be directly affected or determined by the enzyme concentration Ei, the 
MC constraint (Eq. 2), and the enzyme concentration constraint (Eq. 3), thus, can be considered 
as a metabolic flux constraint 
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                                                                                                                          [4] 
Where ai=Cvi/bi quantifies the contribution of reaction i to the overall crowding, thus referred as 
“crowding coefficient” (Beg, Vazquez et al. 2007). The parameter bi=fi/Ei is the coefficient of 
proportionality between reaction rate and enzyme concentration, thus determined by the reaction 
mechanism, kinetic parameters and metabolite concentrations. 
To understand the relevance of the metabolic flux constraint (Eq. 4) at physiological 
conditions we need to estimate the crowding coefficient ai from experimental data. At a first 
approximation we estimate bi from the enzyme’s turnover numbers in the BRENDA database 
(Schomburg, Chang et al. 2004) for about one hundred E. coli enzymes. The turnover numbers 
were found to vary over five orders of magnitude, from 10-2 to 102 l/s. As C=0.34 g/ml and the 
molar volume of proteins are proportional to their molar masses (v=0.73M) (Lee 1983), the 
crowding coefficient for these one hundred enzymes can be calculated, resulting in 0.014±0.009 
l/[mmol/g/h]. Because of the large enzyme turnover variations, the crowding coefficients are also 
distributed over a wide range, from 10-6 to 100 l/[mmol/g/h] (Vazquez, Beg et al. 2008). 
By superimposing this MC constraint as an additional metabolic flux constraint under 
conditions of aerobic growth in a glucose-limited medium, the application of FBAwMC on the 
E. coli MG1655 metabolic network is able to predict internal metabolic fluxes as a function of 
the growth rate. A subset of the FBAwMC-derived flux predictions in the central carbon 
metabolism are shown in Figure 2.1. At low growth rates, the model predicts (red line) higher 
fluxes in the TCA cycle and lower activities in the glycolysis pathway. In contrast, at high 
growth rates, the model predicts slightly decreased fluxes in the TCA cycles and increased fluxes 
in the glycolysis pathway. To be noted, in most cases the predicted fluxes (red line) are within 
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the experimentally determined range (black line), especially with high growth rate, indicating 
that MC constraint is most relevant in fast proliferating E. coli cells. These results indicate that 
even without knowing the precise value of the crowding coefficients, FBAwMC was able to 
capture the metabolic switch taking place from the TCA cycle to the glycolysis and acetate 
excretion pathway when shifting E. coli cells from slow to fast growth rate. Therefore, MC 
seems to represent an important, physiologically relevant bound to constrain the metabolism of 
fast growing E. coli cells. 
 
Figure 2.1: Predicted vs. measured metabolic fluxes in the E. coli central metabolism 
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Comparisons between the FBAwMC-predicted (red plots) and measured (black plots) fluxes as a 
function of growth/dilution rates for selected reactions in the central carbon metabolism of E. coli. The 
experimental flux measurements were performed at dilution rates 0.1, 0.25, 0.4, 0.55 and 0.72 h-1. 
Selected reactions of glycolysis (red boxes), the first reaction of the pentose phosphate pathway (zwf) 
(magenta box), the TCA cycle (blue boxes), acetate excretion pathway (green boxes) and the reactions 
catalyzed by ppc and aceE connecting the glycolytic- and TCA pathways (yellow boxes) are shown. 
Reproduced with permission from (Vazquez et al., 2008). 
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3.0  MOLECULAR CROWDING POTENTIALLY CONTRIBUTES TO THE 
WARBURG EFFECT 
3.1 INTRODUCTION 
The Warburg effect has been found in most, if not all, types of cancers (Kim, Gardner et 
al. 2005; Hsu and Sabatini 2008; Ortega AD 2009; Zhivotovsky and Orrenius 2009).  However, 
numerous studies have found that this distinct metabolic phenotype is not unique to cancer cells. 
For example, proliferating primary lymphocytes (Wang, Marquardt et al. 1976), human 
endothelial cells (Peters, Kamp et al. 2009), hepatocytes (Barbini, Rodriguez et al. 2007), smooth 
vascular muscle cells (Werle, Jahn et al. 2005), thymocytes (Brand 1997) and fibroblasts 
(Kittlick and Babin 1985) can also exhibit a Warburg-like effect when they are proliferating 
rapidly in normoxic conditions, indicating that there may be a direct correlation between aerobic 
glycolysis and rapid proliferation (Vander Heiden, Cantley et al. 2009).  
As of yet, a systems-level interpretation of why all rapidly proliferating mammalian cells 
exhibit aerobic glycolysis has not been provided. As we detailed in Chapter 2, our previous work 
strongly imply that MC represents an important bound for fast growing E. coli and S. cerevisiae 
cellular metabolism. 
Considering that cancer cells are also fast proliferating, the MC constraint is likely to 
affect cancer metabolism, as well. Therefore, we aim to assess the potential role of MC in cancer 
cell metabolism. To this end, we introduce a reduced flux balance model of ATP generation that 
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incorporates a glucose uptake capacity constraint and the MC constraint. The model indicates 
that the Warburg effect is a favorable catabolic state for rapidly proliferating mammalian cells 
with high glucose uptake capacity. We also experimentally examined human BJ fibroblast cell 
lines with serial oncogenic changes and stepwise increase in growth rates as a proxy for MC, as 
MC is only physiologically relevant in cells with high growth rates (Vazquez, Beg et al. 2008). 
We find that the fastest growing cell line exhibits the highest lactate excretion rate and the lowest 
mitochondrial respiration rate, which are consistent with the model predictions, thus inferring 
MC as a potential contributor to the Warburg effect.  
3.2 RESULTS 
3.2.1 Reduced flux balance model of cell metabolism 
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Figure 3. 1        Reduced model of cell metabolism.  
Schematic representation of ATP generation pathways via aerobic glycolysis (glycolysis + pyruvate 
reduction to lactate) and oxidative phosphorylation (glycolysis + mitochondrial respiration). The variable 
fG, denotes the glucose uptake rate, fL and fM, the components of the glucose uptake routed towards lactate 
excretion and respiration, respectively, and fATP the ATP production rate. Intermediate substrates of 
glucose catabolism are also used in a third process accounting for the production of precursor metabolites 
needed in anabolic processes (fP). The pathways considered in our model are shown in the gray-shaded 
area, while fP is treated as constant. Reproduced with permission from (Vazquez, Liu et al. 2010) 
 
Figure 3.1 depicts a schematic model of glycolysis and mitochondrial respiration, the 
main pathways for ATP generation in cells (Vazquez, Liu et al. 2010). The glucose uptake flux 
(fG) is partitioned into the flux of aerobic glycolysis (fL), to oxidative phosphorylation (fM), and to 
biomass synthesis pathways (fP) (e.g., intermediate metabolites of the pentose phosphate 
pathway and the TCA cycle (Vander Heiden, Cantley et al. 2009)). Aerobic glycolysis represents 
glycolysis, converting glucose into pyruvate, and then pyruvate reduction by lactate 
dehydrogenase (LDH) in the cytosol, resulting in 2 moles of the end product lactate and 2 moles 
of ATP per mole of glucose. ATP generation through oxidative phosphorylation is decomposed 
into the generation of pyruvate through glycolysis, followed by the oxidation of pyruvate in the 
TCA cycle and the respiratory chain in mitochondria, yielding 38 moles of ATP per mole of 
glucose. In this reduced model, we assume that fP has to be overall proportional with the 
available energy currencies (phosphate donors, mainly ATP) to enable cell growth. Thus, in the 
absence of a full scale kinetic model, in our modeling we do not take fP  into account and use fATP 
as a surrogate for the overall cell metabolic rate (Fig. 3.1). 
Summing up the ATP production rate from aerobic glycolysis and mitochondrial 
respiration, we can obtain 
(1) fATP = 2 fG + 36 fM = 2 fL + 38 fM , 
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Our aim is to determine the optimal flux distribution (fL, fM) that provides maximum ATP 
production rate under the cell's metabolic constraints. Of these, the first metabolic constraint is 
associated with the maximum glucose uptake rate (or glucose uptake capacity) 
(2) fL + fM = fG ≤ FG , 
where FG is the maximum glucose uptake rate.  
The second constraint, MC, quantified below, reflects on the high concentration of 
macromolecules within the cell’s cytoplasm (Ellis 2001; Minton 2006), resulting in a limited 
solvent capacity for the allocation of metabolic enzymes. Enzyme molecules have a finite 
volume and the total sum of their volumes cannot exceed the cell volume. In our case, this 
constraint applies to the volume occupied by glycolytic enzymes, LDH and mitochondria. 
Enzymes associated with other pathways occupy a fraction of the intracellular volume as well. 
Nevertheless, this fraction simply restricts the amount of the cytoplasmic space available to 
glycolytic enzymes, LDH and mitochondria. More precisely, if VG, VL and VM are the cell 
volume occupied by glycolytic enzymes, LDH and mitochondria, respectively, then 
(3)  VG + VL + VM ≤ VATP , 
where VATP is the total cell volume reserved for the allocation of components of the ATP 
producing pathways. The occupied volumes VG, VL and VM are proportional to the enzyme 
masses MG, ML and MM, with VG=vGMG, VL=vLML and VM=vMMM, where vG, vL and vM are the 
specific volumes of glycolytic enzymes, LDH and mitochondria, respectively. In turn, the 
glycolytic rate (fG), the lactate excretion rate (2fL) and the mitochondrial ATP production rate 
(36fM) are proportional to the mass of glycolytic enzymes, lactate dehydrogenase and 
mitochondria respectively, with fG=rGMG/V, 2fL=rLML/V and 36fM=rMMM/V, where rG is the 
glycolysis rate per unit of glycolytic enzyme mass, rL is the rate of lactate production per mass of 
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LDH, rM is the mitochondrial ATP production rate per unit of mitochondrial mass, and V is the 
cell volume. In these equations the product by the mass and the division by the cell volume takes 
into account that the rates r are commonly reported in the literature per unit of dry weight, while 
the pathway rates f are reported per unit of cell volume. Because of the interdependency of 
volume, mass and reaction rate, the volume constraint (3) can be translated to the metabolic 
constraint 
(4)  (aL + aG) fL + (aM + aG) fM ≤ φATP , 
where φATP = VATP/V is the total volume fraction of the cell cytoplasm occupied by 
glycolytic enzymes, LDH and mitochondria, and the crowding coefficients aG = vG/ rG, aL = 2 vL/ 
rL and aM = 36 vM/ rM quantify the occupied volume fractions per unit of glycolytic, lactate 
excretion and mitochondrial respiration rate, respectively. Using empirical data reported in the 
literature we have estimated the crowding coefficients. We obtain aG≈0.0027 (min/mM), 
aL≈0.00023 (min/mM) and aM ≈0.10 (min/mM), indicating that the mitochondria contributes 
about 5 and 50 times more to molecular crowding than glycolytic enzymes and lactate 
dehydrogenase, respectively. The unexpected consequences derived from this fact will be 
uncovered below. 
In our modeling we assume that VATP, rG, rL and rM are constant parameters that can be 
obtained from experimental estimates. Note though, that this is an approximation, as there may 
be regulatory mechanisms that under certain environmental or developmental conditions are 
capable of altering the amount of intracellular space allocated to ATP producing pathways and 
the activity of glycolytic enzymes, LDH and mitochondria. 
Taken together the relevant metabolic optimization problem is as follows: maximize the 
ATP production rate (1) under the metabolic capacity constraints (2) and (4). 
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The optimal solution is graphically illustrated in Figure 3.2a and b (lines). At low glucose 
uptake rates ATP is entirely produced by the oxidative phosphorylation pathway and there is no 
lactate production (and excretion). This trend continues up to a threshold glucose uptake rate, f1, 
when mitochondria occupy the entire cell volume fraction (VATP) available for ATP production 
pathways (Fig. 3.2a, blue dashed line, white background, glucose-limited regime).  
 
Figure 3.2.          Catabolic regimes within proliferating mammalian cells. 
a) Model-predicted (blue dashed line: mitochondrial OXPHOS flux; red solid line: lactate production 
flux) and measured (blue open square: mitochondrial OXPHOS; red open circle: lactate production 
flux in mouse LS cells (Sinclair 1974)) glycolysis and mitochondrial respiration fluxes as a function 
of the glucose uptake rate; gray dashed line: horizontal control line. 
b) Model-predicted (purple solid line: ATP production flux) and measured (purple open circle: ATP 
production flux in mouse LS cells (Sinclair 1974)) ATP production fluxes as a function of the 
glucose uptake rate; the two different metabolic regimes are indicated by the white and gray 
backgrounds, respectively. All fluxes are reported in units of f1, the glucose uptake rate threshold. 
Reproduced with permission from (Vazquez, Liu et al. 2010). 
 
Beyond this threshold value the concentration of mitochondria, and therefore the rate of ATP 
production through oxidative phosphorylation, cannot be increased further. However, additional 
glucose uptake may be diverted toward pathway(s) less efficient in terms of ATP yield per mole 
of glucose. Indeed, the optimal solution predicts a metabolic switch, in which glucose uptake 
rates larger than f1 leads to a linearly increasing lactate production (Fig. 3.2a, red solid line, gray 
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background, space-limited regime), and therefore a component of the ATP production is now 
derived from aerobic glycolysis. Furthermore, the increase in lactate production is accompanied 
by a slight, gradual reduction of the oxidative phosphorylation flux (Fig. 3.2a, blue dashed line, 
gray background). Therefore, due to the increased aerobic glycolysis rate ATP production can 
still be increased beyond f1 (Fig. 3.2b, purple line). However, because aerobic glycolysis has a 
lower yield than oxidative phosphorylation, the ATP production rate increases with a lower slope 
beyond f1 (Vazquez, Liu et al. 2010).  
To address the validity of these predictions we first utilized previously reported 
experimental data for mouse LS cells (Sinclair 1974) (Fig. 3.2a,b), the growth rate of which were 
manipulated by their growth in chemostat cultures at different dilution rates, a protocol that is 
known to substantially vary the cells’ glucose uptake rate. Surprisingly, the empirical lactate 
excretion plots follow the model predictions: at low glucose uptake rates there is no lactate 
excretion, but once a threshold is reached the lactate excretion rate increases linearly with the 
further increase in glucose uptake rate. Their oxidative phosphorylation (Fig. 3.2a, blue squares) 
and ATP production rate (Fig. 3.2b, diamonds) from the published experimental data (Sinclair 
1974) can also be calculated (Vazquez, Liu et al. 2010) and also exhibit a good agreement with 
the model predictions (lines). Not only the model fits for the LS cells, but also does it fit glucose 
uptake and lactate secretion data for hybridoma cells (Gambhir, Korke et al. 2003) and a mixture 
of cancer and normal cells (Zu and Guppy 2004), indicating that the MC constraint is potentially 
a contributor of aerobic glycolysis at high glucose uptake rate (Vazquez, Liu et al. 2010).  
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3.2.2 MC potentially contributes to aerobic glycolysis in human fibroblasts with serial 
oncogenic changes and stepwise increase in growth rates 
Based on the model predictions under the MC constraint, we hypothesized that the molecular 
crowding (MC) constraint may, at least partially, contribute to the Warburg effect when the 
glucose uptake rate is high.  To confirm and establish the role of MC in cancer metabolism, we 
used mammalian cells with stepwise oncogenic changes. 
To this end, first we examined human BJ fibroblast cells serially transduced with the 
catalytic domain of human telomerase (hTERT), SV40 large T (LT) and small T (ST) antigens, 
and an oncogenic allele of H-ras (H-RasV12) (Hahn, Counter et al. 1999). Similar to previous 
studies using these cells (Hahn, Counter et al. 1999), CL1-[hTERT], CL2-[hTERT+LT], CL3-
[hTERT+LT+ST], and CL4-[hTERT+LT+ST+H-Ras] cells displayed various growth rates, 
accompanied with increasing active Ras level and tumorigenic potential (Figure 3.3). 
 
Figure 3.3. H-Ras expression, colony formation and growth rate of normal and 
tumorigenic fibroblasts 
(a.) Growth curves of CL1, CL2, CL3 and CL4 cells. For each measurement, continuously cultured 
fibroblasts, which were cultured in DMEM supplemented with 10% FBS, 25mM glucose and 4mM 
glutamine in a 37 °C humidified CO2 incubator, were seeded at 2×104 cells in 12-well plates, and cell 
count data were determined by blinded counting of cells on a standard grid-patterned hemocytometer 
every 24h. 
(b.) Western blot of active H-Ras in CL1-4 cells. CL1-4 cell lysates (1mg) were subjected to active Ras 
pull-down assay (Thermo Scientific) and fifty percent of the eluted samples (25µl, active Ras) were 
separated by 15% Tris SDS-PAGE gel and immunostained with H-Ras antibody (Thermo Scientific). 
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(c.) Soft agar assay. 10,000 cells of each cell type were seeded on 0.35% Top Agar and colonies were 
stained with 0.005% crystal violet and counted. All experiments were performed in duplicates and the 
mean numbers are shown in the table. 
 
After confirming that CL1-4 did have different growth rates, we then characterized the 
metabolic features of these four cell lines. The glycolysis pathway utilizes the glucose that cells 
take up from the extracellular medium and converts it to pyruvate, which is then catalyzed by 
lactate dehydrogenase (LDH) to lactate, secreted to the extracellular medium resulting in the 
acidification. As it has been already shown by Ramanathan et al. that CL3 and CL4 have 
increased glucose uptake rates, compared to CL1 and CL2 (Ramanathan A 2005), we measured 
the lactate level in the extracellular medium and calculated the lactate production per total 
protein level of each cell line. It is evident that compared to the other cell types CL4 cells excrete 
a significantly higher levels of lactate than CL1 and CL2 cells at most time points tested (Fig. 
3.4a). Of note, starting from 96h CL3 cells also display significantly higher extracellular lactate 
levels, a finding that is likely related to their increased growth rate that is similar to that of CL4 
cells (Fig. 3.3a), and that has been shown to be independent of active H-Ras level.  
Correspondingly, the LDH enzyme activities of CL3 and CL4 are significantly higher 
than that of CL1 and CL2 cells at most time points (Fig. 3.4b). However, LDH protein 
expression levels and sizes are not significantly different among the four cell types (Fig. 3.4c and 
3.4d). These data confirm that lactate production increases with the rising glucose uptake rates in 
these cells (Ramanathan A 2005), and indicate that the increase in LDH activity is primarily 
achieved by posttranslational activation of the enzyme. We also compared the mitochondrial 
mass and membrane potential level of CL1-4 cells as a function of time at 48h, 72h, 96h and 
120h after seeding. As mitochondrial membrane potential is usually generated by the activities of 
respiratory chain complex, it can be used as a proxy for mitochondrial respiratory activity. The 
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mitochondrial membrane potential of CL1-4 cells was assessed by staining with JC-1, a dye that 
is able to monitor mitochondrial membrane potential (largely) independent of mitochondrial 
mass (Cossarizza, Baccaranicontri et al. 1993). The mitochondrial content of the cell was 
assessed using MitoTracker Green (MTG) staining (Agnello, Morici et al. 2008). 
 
 
Figure  3.4 Glycolytic characteristics of normal and tumorigenic fibroblasts 
(a.) Extracellular lactate levels normalized by the total protein concentration of CL1-4 cells;  
(b.) Relative LDH activity in 100µg protein lysates of CL1-4 cells expressed as the signal drop of NADH 
fluorescence at 340nm in the first 30s. Mean ± SD of a minimum of three independent experiments are 
shown. *: p<0.05, **: p<0.01, ***: p<0.001 compared to CL1 at the corresponding time point, in a 
Student’s t-test.  
(c.) Relative LDH protein levels of fibroblasts as assessed by ImageJ.  
(d.) LDH protein expression of fibroblasts. 50µg protein of each cell line lysates were subjected to 15% 
Tris SDS-PAGE gel and immunostained with LDH (Santa Cruz Biotech) and actin-specific monoclonal 
antibodies (Sigma).  
 
After normalizing all the data to the value of CL1 at 48h, it is apparent that CL4 cells have 
higher membrane potential than CL1 at 48h (Fig. 3.5a), followed by a progressive drop to values 
lower than CL1 afterwards. Interestingly, the mitochondrial mass/content in these fibroblasts 
displayed similar alterations over the time (Fig. 3.5b). These results demonstrate that 48 h after 
seeding CL4 cells display both a decreased mitochondrial content and activity, followed by 
similar but lesser trends in the other cell types. 
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Figure 3.5 mitochondrial characteristics of normal and tumorigenic fibroblasts 
(a.) Mitochondrial membrane potentials of the indicated cell types are shown, as determined by JC1 
staining and subsequent flow cytometry analyses;  
(b)  Mitochondrial content/ mass of the indicated cell types are shown, as determined by MitoTracker 
Green staining and subsequent flow cytometry analyses.  
 
As the model predictions were built on the flux of glycolysis and mitochondrial 
respiration, which is the rate of reactions or pathways, we next employed the Seahorse 
bioenergetic flux analyzer to indirectly measure the glycolysis flux (extracellular acidification 
rate, ECAR) and mitochondrial respiration flux (oxygen consumption rate) (Qian and Van 
Houten 2010). As shown in Figure 3.6, CL4 cells had displayed significantly higher glycolysis 
rate/ flux (Fig 3.6a) while lower mitochondrial respiration rate (Fig 3.6b) than slower growing 
CL1-3 cells, consistent with the results from previous glycolytic parameters and model 
predictions.  
 
Figure 3.6: The glycolysis (ECAR) and mitochondrial respiration (OCR) flux of CL1-4 
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a) The extracellular acidification rate (ECAR) per cell measured by the Seahorse flux analyzer 
in quadruplicates; 
b) The oxygen consumption rate (OCR) per cell measured by the Seahorse flux analyzer in 
quadruplicates. Star represents statistic significance in paired student’s t-tests. ***: p<0.001. 
3.2.3 MC potentially contributes to aerobic glycolysis in human fibroblasts different 
growth rates due to passage numbers 
Compared to CL1-3, CL4 has an additional oncogenic H-Ras, which is known to be able to alter 
energy metabolism, both glycolysis and oxidative phosphorylation, in multiple ways (Biaglow, 
Cerniglia et al. 1997; de Groof, Lindert et al. 2009; Yang, Wang et al. 2010). To eliminate the 
possible contribution from oncogenes other than the growth rate itself, next we elected to utilize 
CL4 early vs. late passage cells as another experimental system, since the growth rate of 
transformed cells are shown to increase gradually during prolonged culture in vitro (de Groof, 
Lindert et al. 2009). Indeed, CL4 late passage cells grew faster than CL4 early passage cells (Fig. 
3.7a) even though they have relatively similar levels of active H-Ras (Fig. 3.7b) and tumorigenic 
potentials as determined by colony formation on the soft agar (Fig. 3.7c). This indicates that 
additional genetic/ epigenetic changes on the cell line play a role in the observed growth rate 
difference, but they are not sufficient to alter the tumorigenecity of the cell line. 
 
Figure 3.7. Growth rate, H-Ras expression and colony formation of CL4 early and late 
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passage cells. 
(a.) Growth curves of CL4 early and late passage cells. For each measurement, continuously cultured 
fibroblasts, which were cultured in DMEM supplemented with 10% FBS, 25mM glucose and 4mM 
glutamine in a 37 °C humidified CO2 incubator, were seeded at 2×104 cells in 12-well plates, and 
cell count data were determined by blinded counting of cells on a standard grid-patterned 
hemocytometer every 24h. 
 (b.) Western blot of active H-Ras in CL4 early and late cells. CL4 early and late cell lysates (1mg) 
were subjected to active Ras pull-down assay (Thermo Scientific) and fifty percent of the eluted 
samples (25µl, active Ras) were separated by 15% Tris SDS-PAGE gel and immunostained with H-
Ras antibody (Thermo Scientific).  
(c.) Soft agar assay. 10,000 cells from each cell lines were resuspended in 2 ml of 0.35% top agar in 
complete DMEM growth medium and seeded in six-well plates previously filled with 2 ml of 0.7% 
basal agar in complete growth medium. After 2 weeks, 1ml 0.005% crystal violet was added to each 
well to stain the colonies for 2h and colonies in each well were counted. 
 
Similar to the first system, after normalized to total protein level, the faster growing CL4 late 
passage cells still took up glucose and secreted lactate significantly more than the slower CL4 
early cells at almost all time points examined (Fig. 3.8a and b). The LDH enzyme activities of  
 
Figure  3.8 Glycolytic characteristics of CL4 early and late cells 
(a.) Glucose uptake normalized by the total protein concentration of CL4 early and late cells at 
different time points; 
(b.) Extracellular lactate levels normalized by the total protein concentration of CL4 early and late 
cells;  
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(c.) Relative LDH activity in 100µg protein lysates of CL4 early and late cells expressed as the signal 
drop of NADH fluorescence at 340nm in the first 30s. Mean ± SD of a minimum of three 
independent experiments are shown. *: p<0.05, **: p<0.01, ***: p<0.001  
(d.) Relative LDH protein levels of CL4 cells. 50µg protein of each cell line lysates were subjected to 
15% Tris SDS-PAGE gel and immunostained with LDH (Santa Cruz Biotech) and actin-specific 
monoclonal antibodies (Sigma).  
 
CL4 late passage cells are significantly higher than that of CL4 early cells at most time points 
(Fig. 3.8c). Of note, at 120h CL4 early cells also display a significantly higher LDH activity, a 
finding that is likely related to their increased growth rate at 120h (Fig. 3.7a). However, LDH 
protein expression levels are not significantly different in the two cell lines (Fig. 3.8d). These 
data confirm that the increase in LDH activity is primarily achieved by posttranslational 
activation of the enzyme, and that faster cells tend to be more glycolytic.  
 
Figure 3.9 Mitochondrial characteristics of CL4 early and late cells 
(a.) Mitochondrial membrane potentials of CL4 early and late are shown, as determined by JC1 
staining and subsequent flow cytometry analyses;  
 (b.) Mitochondrial content/ mass of CL4 are shown, as determined by MitoTracker Green staining 
and subsequent flow cytometry analyses; 
(c.) Cell volume as estimated from forward scatter in the flow cytometry analyses; 
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(d.) Mito mass per cell volume as calculated from dividing mitochondrial mass in (b.) by cell volume 
(c.). Star represents statistic significance in paired student’s t-tests. *: p<0.05; **: p<0.01; ***: 
p<0.001. 
 
In terms of the mitochondrial mass and membrane potential level, CL4 late passage cells have 
higher membrane potential per cell than CL4 early cells initially at 48h and 72h (Fig. 3.9a), 
followed by a progressive drop to values lower than CL4 early cells after 96h. Interestingly, the 
mitochondrial mass/content of CL4 late cells proved lower than that of CL4 early cells all the 
time (Fig. 3.9b). The decreased mitochondrial respiration activity in CL4L cells is confirmed by 
this significantly lower oxygen consumption rate (Fig. 3.10b) and the diminished cell volume 
occupied by the mitochondria mass/ content (Fig. 3.9d). Of note, all the glycolytic parameters at 
different time points are normalized to the total protein level, while the glycolysis rate is 
quantified by the Seahorse flux analyzer normalized to total cell number. Thus, non-significant 
difference between CL4E and CL4L in the glycolysis rate (Fig. 3.10a), may be attributed to the 
smaller volume of CL4L (Fig. 3.9c); that is, given the same cell volume, CL4L will exhibit 
higher glycolysis rate per cell. Taken together, the observed alterations in glycolysis activities 
and mitochondrial parameters support the model predictions: an increase of lactate excretion rate 
and decline of mitochondrial respiration rate with an increasing growth rate, a proxy of MC 
levels. 
     
Figure 3.10  The glycolysis (ECAR) and mitochondrial respiration (OCR) rate of CL4 early 
and late cells 
  47 
a) The extracellular acidification rate (ECAR) per cell measured by the Seahorse flux analyzer in 
quadruplicates; 
b) The oxygen consumption rate (OCR) per cell measured by the Seahorse flux analyzer in 
quadruplicates. Star represents statistic significance in paired student’s t-tests. *: p<0.05; **: p<0.01; ***: 
p<0.001. 
3.3 DISCUSSION 
To provide a systematic view of why and how proliferation itself is associated with an 
increase of aerobic glycolysis and a decline of mitochondrial respiration, is fundamentally 
important to understand the origin of the Warburg effect and may suggest novel insights for 
cancer therapy. 
In our study, we first developed a reduced flux balance model of ATP production (Fig. 
3.1) and predicted the existence of two different metabolic regimes in mammalian cells, 
depending on whether the cell metabolic rate is limited by the glucose uptake or by the MC 
constraint. In conditions where glucose transport limits the cell’s metabolic activity the model 
predicts that the optimal solution is to produce ATP entirely via mitochondrial respiration; 
however, at high glucose uptake rates the optimal solution is characterized by an abrupt increase 
of the flux towards lactate production (and excretion) and a gradual decrease of mitochondrial 
respiration (Fig. 3.2). This second regime is determined by the existence of the MC constraint, a 
limited cytoplasmic solvent capacity for allocating the components of the ATP generating 
pathways. For glucose uptake rates exceeding the threshold level, f1, the cell cannot further 
increase the concentration of mitochondria and thus switch to aerobic glycolysis lacate 
production pathway in order to match the increased glucose uptake rate. The model predictions 
have been indirectly supported by the experimental data from mouse LS cells (Sinclair 1974), 
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hybridoma cells (Gambhir, Korke et al. 2003) and a mixture of cancer and normal cells (Zu and 
Guppy 2004). 
Based on this model prediction, we proposed that MC is a potential contributor to the 
Warburg effect. To provide additional experimental support to this hypothesis, we first used 
human foreskin fibroblasts with stepwise oncogenic transformation to mimic cells with 
increasing growth rates as an indirect measure of MC levels (Vazquez, Beg et al. 2008). We 
found that the fastest growing cell line exhibited increased lactate production, lactate 
dehydrogenase activity, and the glycolysis rate (ECAR), while it displayed a declined 
mitochondrial respiration activity (Fig. 3.3-7), consistent with what others have found using the 
same model system (Ramanathan A 2005). In addition, we showed that such metabolic 
alterations were not only due to the expression of the oncogenic Ras, since CL4E and CL4L, 
having the same active Ras level but different cell passage numbers, still followed a similar 
upregulation of glycolytic activities and downregulation of mitochondrial respiration rate as their 
proliferation capabilities differed (Fig. 3.8-10). The results are further supported from another 
similar experiments, where oncogenic Ras/E1A transformed low passage murine embryonic 
fibroblast (MEFs) (Ras-LP) also displayed higher mitochondrial respiration activity and lower 
lactate secretion compared to more rapidly dividing high passage MEFs (Ras-HP) (de Groof, 
Lindert et al. 2009). Yet, it is noteworthy, that the glycolytic rate of CL4L per cell is not different 
from that of CL4E cells, which disagrees with the model predictions and measured metabolic 
phenotypes, that faster growing cell have higher glycolytic rate. Indeed, the model assumes that 
the volume fractions occupied by ATP production pathway enzymes, that is, glycolytic enzymes 
and mitochondria, are constant. Given that each mitochondria alone hosts metabolic enzymes 
that function in the TCA cycle, heme biosynthesis, β-oxidation of fatty acids, steroidogenesis, 
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certain amino acids metabolisms and Fe/S cluster formations (Reichert and Neupert 2004), the 
total mass and thus occupied volume of glycolytic enzymes could be neglected, compared to 
mitochondria. In contrast to the modeling assumption, the mitochondrial mass and cell volume 
estimated from flow cytometry indicated that faster growing CL4L exhibited less mitochondria 
mass and smaller cell volume as well as lower volume fraction occupied by mitochondria (Fig. 
3.9), and that the assumed constant mitochondria volume fraction is one of the model’s 
limitations. Thus, cells may possess regulatory mechanisms to tune the volume fraction of 
mitochondria at different growth rates and whether such mechanisms are regulated by the MC 
remains to be investigated. 
This study, together with our previous efforts (Beg, Vazquez et al. 2007; Vazquez, Beg et 
al. 2008; Vazquez, de Menezes et al. 2008; Vazquez, Liu et al. 2010), indicates that MC is not 
only important for constraining the E. coli and S. cerevisiae metabolism, but also a potential 
contributor to the metabolism of rapidly proliferating mammalian cells, through controlling the 
optimal distribution of enzymes responsible for glycolysis or mitochondrial respiration. With the 
help of systems-oriented simulation of a reduced human cell metabolism model, here, we find 
that MC, as a biophysical constraint, could potentially contribute to aerobic glycolysis (the 
Warburg effect), for all rapidly proliferating cells. The identified biophysical constraint MC 
together with this systems-oriented approach may prove useful for future target identification for 
cancer therapy, once the tissue and cell type specific human metabolic network is fully 
reconstructed.  
These results may also have therapeutic indications on cancer therapy. It has been 
previously proposed that the Warburg effect may represent a unique property of cancer cell 
metabolism as a metabolic target (Chen, Lu et al. 2007; Gatenby and Gillies 2007; Vander 
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Heiden 2010). Pharmacological reduction of lactate production and excretion may indeed reduce 
the invasive potential of tumor cells or makes them more susceptible to apoptosis (Cao, Yacoub 
et al. 2008; Madhok, Yeluri et al. 2010). However, the metabolic state of tumor cells alone is not 
a unique target for cancer chemotherapy. The combination of the metabolic targeting with 
individual, tumor specific isozymes (Christofk, Vander Heiden et al. 2008; Christofk, Vander 
Heiden et al. 2008) or tumor-penetrating peptides (Feron 2010; Sugahara, Teesalu et al. 2010) 
may improve its specificity and efficacy.  
3.4 MATERIALS AND METHODS 
Cell culture and growth rate determination 
Genetically-manipulated derivatives of human BJ fibroblasts, transfected with the 
catalytic subunit of human telomerase (hTERT) (CL1), hTERT+ SV40 large T (LT) (CL2), 
hTERT+LT+ SV40 small T (ST)(CL3), and hTERT+LT+ST+ V12 mutant human Ras (Ras) 
(CL4) (Hahn, Counter et al. 1999) were used. The cells were maintained in DMEM 
supplemented with 25mM glucose, 4mM glutamine, 1mM pyruvate and 10% FBS at 37° in a 
CO2 incubator with 5% CO2 and 95% air. For assessing their growth rates cells were seeded at a 
density of 2 × 104 cells in 12-well plates and at every 24 h a subset were collected following 
trypsinization (in 0.25% trypsin, 0.53 mM EDTA). Cell numbers were determined by blinded 
counting of cells on a standard grid-patterned hemocytometer.  
 
Western blot 
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CL1-4 cells were harvested by trypsinization at 48h, 72h, 96h and 120h after seeding, and 
washed with PBS. The cell pellets were dissolved in 100µl RIPA lysis buffer supplemented with 
Halt complete protease inhibitor cocktail and phosphatase inhibitor cocktail (ThermoFisher) on 
ice for 1h. After centrifugation for 15min at 4°C, and the protein concentration of the 
supernatants were determined by Bradford assay (Bio-Rad). 50 µg of each sample was then 
applied to 15% Tris SDS-PAGE gel and, following electrophoresis, transferred to PVDF 
membranes at 6v for 16 hr at 4°C. The membranes were then immunostained using actin-specific 
monoclonal antibody (Sigma, 1:8000), LDH monoclonal antibody (Santa Cruz Biotech, 1:4000) 
and VDAC/porin monoclonal antibody (Abcam, 1:5000), respectively; All experiments were 
performed in triplicates. 
 
Ras activity measurements 
Ras activity was performed using active Ras pull-down and detection kit (Thermo 
Scientific), as instructed. Briefly, 1mg fresh lysates from CL1-4 were subjected to affinity 
precipitation of activated Ras with the GST-fused Ras-binding domain (RBD) of Raf1 through 
the glutathione agarose resin. Half of the eluted samples (25µl, active Ras) from CL1-4 lysates 
were separated with 15% Tris SDS-PAGE gel and immunoblotted with anti-Ras Ab. 
 
Soft agar assay 
Soft agar assays were performed as described (Stausbol-Gron, Havsteen et al. 1998). 
Briefly, 10,000 cells from each cell lines were resuspended in 2 ml of 0.35% top agar in 
complete DMEM growth medium and seeded in six-well plates previously filled with 2 ml of 
0.7% basal agar in complete growth medium. The assay was performed in duplicate. After 2 
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weeks, 1ml 0.005% crystal violet was added to each well to stain the colonies for 2h and 
colonies in each well were counted. 
 
LDH activity measurements 
LDH activity was determined by the decreasing absorbance of β-NADH at 340nm as 
described (Wu, Daugulis et al. 1992) with slight modifications. Sodium pyruvate and β-NADH 
were dissolved separately in 0.2M Tris-HCl, pH 7.4. The mixture solution of 2mM sodium 
pyruvate and 0.2mM β-NADH was prepared fresh before being used in the LDH activity assay. 
A total cell lysate sample (100µg) was pipetted into a 1.5ml disposable semi-micro cuvette (1cm 
light path), followed by the addition of 1ml pyruvate-NADH mixture solution. After mixing the 
cuvette was immediately placed in the spectrophotometer and the absorbance was recorded for 
30s at 340nm. The slope of the absorbance over this time period (-∆A/min) was proportional to 
the rate of NADH consumption, which represents the LDH activity. 
 
Measuring mitochondrial content and membrane potential 
Cells were trypsinized and washed with PBS in suspensions of 1 x 106 cells/ml at the 
indicated time points, followed by incubating them with 2µg/ml JC-1 or 100nM MitoTracker 
Green (Invitrogen) at 37 °C for 15min, respectively. After rinsing with PBS, cells were subjected 
to flow cytometry to read the fluorescence intensity at 590nm (red channel) and 520nm (green 
channel). All fluorescence intensities were normalized to that of CL1 fibroblasts at 48h. 
 
Measurement of cellular oxygen consumption and acidification rate:  
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All cell lines were cultured in one T175 and T75 flasks prior to time-course experiments 
when monolayer cells were trypsinized and suspended in the complete growth medium DMEM. 
After cell counting, 7.4X105 cells were seeded in each 145cm2 petri-dish (6 dishes, one for each 
day) for each cell line. The final volume was brought to 30ml in each dish. 24h after seeding, all 
petri-dish cultures were replenished with fresh complete DMEM. At each time point, each dish 
was trypsinized and counted for growth curve. Also, at 48h and 120h after seeding, cells were 
detached and counted for experiments using the Seahorse instrument platform, which allows the 
simultaneous measurement of oxygen consumption rate and extracellular acidification rate by the 
use of pO2 and pH probe in the formed microchambers (Qian and Van Houten 2010). The whole 
experiment was repeated once with the same cell lines (one passage older, only 2 dishes per cell 
line, 48h and 120h only). 48h and 120h after seeding, all 6 cell lines were seeded at 30,000 
viable cells per well in triplicates or quadruplicates into XF24 tissue culture plates in complete 
DMEM medium. Cell medium was changed after 20h to unbuffered DMEM (8.3g/L DMEM, 
25mM glucose, 4mM glutamine, 1mM pyruvate, 31.6mM NaCl, and 15mg Phenol Red, adjusted 
pH to 7.4 with NaOH) and kept in CO2-free incubator for 1h. Measurement of cellular oxygen 
consumption and extracellular acidification rate was performed during 4-min intervals. After the 
experiment, all the measurements were normalized to the total cell number.  
 
Statistical analyses  
Paired two-tail student’s t-tests were used to assess the significance between two groups. 
For more than two groups, one-way ANOVA was performed to determine the differences 
between groups. *: p<0.05; **: p<0.01; ***: p<0.001.  
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4.0  COMPARATIVE GENOME-SCALE METABOLIC NETWORK ANALYSIS OF 
MULTIPLE STAPHYLOCOCCUS AUREUS GENOMES IDENTIFY NOVEL ANTI-
MICROBIAL DRUG TARGETS 
4.1 INTRODUCTION 
As we described in Chapter 3, the full metabolic network reconstruction of mammalian cells in 
a tissue and cell type specific fashion is not yet possible. Therefore, we turn to prokaryotic cells 
in which full metabolic network reconstruction is now routine. Specifically, to provide a proof-
of-principle of the potential of a systems-oriented metabolic network analysis on drug discovery 
targeting cell metabolism, we focus on Staphylococcus aureus because of its virulence, and its 
adaptation ability to different environmental conditions (Lowy 1998), and because its mortality 
now surpasses that of human immunodeficiency virus/AIDS in the United States (Klevens, 
Morrison et al. 2007). In addition, the emergence of methicillin-resistant S. aureus (MRSA) and 
vancomycin-resistant S. aureus (VRSA) isolates, underscores the need to identify new targets 
and molecules effective against multidrug-resistant strains of S. aureus. 
In order to address the differences in the metabolic capabilities of various S. aureus 
strains and further refine a generic antimicrobial drug target identification scheme (Almaas, 
Oltvai et al. 2005) from a systems-biology perspective, we performed metabolic reconstructions 
on multidrug-resistant and sensitive strains of all 13 S. aureus, with available whole genome 
sequences. They include strain N315 (a MRSA strain), Mu50 (a VRSA strain), JH9 (a 
vancomycin-nonsusceptible MRSA strain), JH1 (a vancomycin-susceptible, hospital-acquired 
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MRSA strain), COL (a hospital-acquired MRSA strain), 252 (a hospital-acquired MRSA strain), 
USA 300 (a community-acquired MRSA strain), MW2 (a community-acquired MRSA strain), 
and RF122 (a bovine mastitis strain). This approach enabled us to identify the functional 
pathways, metabolic reactions, and transport reactions of several sequenced strains of S. aureus. 
The identified metabolic pathways and their individual reactions were systematically compared 
with those archived in the KEGG ligand database (Kanehisa and Goto 2000). After metabolic 
reconstruction, we also performed flux balance analysis (FBA) on such reconstructed metabolic 
networks to identify single enzymes and synthetic enzyme pairs that are unconditionally required 
for the growth (biomass production) of all S. aureus strains as potential anti-Staphylococcus 
targets. 
4.2 RESULTS 
4.2.1 Analysis of metabolic reconstruction of S. aureus.  
We initially studied the MRSA N315 strain as a model for reconstruction and FBA studies, and 
then studied the other 12 strains. From the ERGO genomic database, we identified 2,593 ORFs 
in the S. aureus N135 chromosome and 31 ORFs on its plasmid, of which 2,505 ORFs were 
assigned a functional role. A total of 906 ORFs were identified to have an enzymatic activity (i.e., 
they had EC numbers), and 668 ORFs had unique complete EC numbers (including two full EC 
numbers on the plasmid). We identified a list of 61 functions with incomplete or partial EC 
numbers. For all the complete and incomplete EC number annotations, the associated reactions 
were identified from the ERGO pathway collections and the KEGG pathway database. A total of 
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1,493 reactions were generated from the two databases, after reactions with substrates that were 
not likely to be metabolized by S. aureus and those that did not have a corresponding transport 
system were removed. 
We compared this genome-scale reconstruction with two previous reconstructions of S. 
aureus N315 (Becker and Palsson 2005; Heinemann, Kummel et al. 2005). We found that 75 
reactions in Becker and Palsson’s reconstruction did not have a corresponding ORF in the S. 
aureus N315 genome, and several reactions were catalyzed strictly by eukaryotic enzymes. In a 
similar study by Heinemann et al. (Heinemann, Kummel et al. 2005), only 774 reactions 
representing only 23% of the ORFs with 394 unique enzymes were considered. In contrast, we 
identified a total of 546 enzymes representing 1,497 reactions. The number of identified 
transport reactions in our study was 164 compared to 84 in the Becker and Palsson (Becker and 
Palsson 2005) and 59 in the Heinemann et al. (Heinemann, Kummel et al. 2005) studies. We also 
found that 51 of the 59 transport reactions had an associated ORF, and 47 of them (92%) were 
also found in our reconstruction. Using annotations based on protein similarities, comparative 
genomics, and pathways for all the strains, we obtained a comprehensive list of enzymes, 
reactions, and metabolites for all the S. aureus strains (Table 4.1). We found that over 90% of the 
enzymes, metabolic reactions, and metabolites were common to all strains, suggesting the 
presence of a common “core of metabolic reactions” among all the strains studied (Almaas, 
Oltvai et al. 2005).  
 
Table 4.1. Comparative statistics for enzymes and metabolites that were used for the 
metabolic reconstructions of 13 S. aureus strains 
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4.2.2 Identification of single unconditionally essential enzymes and synthetic-lethal pairs.  
In an effort to identify antibiotic drug targets, we performed in silico enzyme deletion 
studies for each S. aureus strain (Almaas, Oltvai et al. 2005; Becker and Palsson 2005; Thiele, 
Vo et al. 2005; Deutscher, Meilijson et al. 2006). With a metabolic reconstruction in hand, we 
built a flux balance-based model of S. aureus. The vulnerability of the reconstructed metabolic 
network models can be utilized to derive the candidates for antibiotic targets. In the case of S. 
aureus N315, of the 1,497 identified metabolic reactions, only 23% were active, i.e., carrying 
nonzero fluxes (Almaas, Oltvai et al. 2005). The FBA, as described in Materials and Methods, 
identified only 337 reactions that were active in the rich growth medium, in which all the 
included transport reactions can occur without limitation. Furthermore, to validate the identified 
potential antibiotic drug targets, we initially performed an in silico single enzyme deletion study 
for growth in (simulated) rich medium for each S. aureus strain. In various natural environments, 
in which uptake reactions are limited, more enzymes are essential than in the rich medium. In 
contrast, the unconditionally essential enzymes are at the intersection of the sets of such essential 
enzymes in all possible environments. We found that 70 enzymes proved essential for growth in 
one or more of the 13 S. aureus strains, while 44 of these were essential in all the strains (Table 
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4.2). Figure 4.1a shows the network structure of the common unconditionally essential enzymes. 
For example, two enzymes, EC 2.5.1.7 and EC 1.1.1.158, that are involved in the conversion of 
UDP-N-acetyl-D-glucosamine to UDP-N-acetylmuramate through UDP-N-acetyl-3-O-(1-
carboxyvinyl)-D-glucosamine are predicted to be unconditionally essential. Deletion 
(inactivation) of either of these enzymes leads to failure in generating the biomass component 
UDP-N-acetylmuramate, since these two consecutive reactions constitute the only pathway 
generating UDP-N-acetylmuramate. While there is no comprehensive list of experimentally 
confirmed essential genes for any strain of S. aureus, we used the list of available ORFs that 
were identified to be essential for S. aureus strains RN450 and RN4220 (Ji, Zhang et al. 2001; 
Forsyth, Haselbeck et al. 2002) to determine if our prediction matched any experimentally 
verified genes. 
Of the 44 common single essential enzymes that were identified from FBA, we found at 
least six enzymes, including transketolase (EC 2.2.1.1), hydroxyl-methylbilane synthase (EC 
2.5.1.61), methionine adenosyltransferase (EC 2.5.1.6), UDP-N-acetylglucosamine 1-
carboxyvinyltransferase (EC 2.5.1.7), protein N (pi)-phospho-histidine-sugar 
phosphortransferase (EC 2.7.1.69), and acetyl-CoA carboxylase (EC 6.4.1.2), to be 
experimentally verified in S. aureus (Forsyth, Haselbeck et al. 2002). In addition, orthologs for 
17 enzymes were found experimentally to be essential in other bacteria. Many enzymes were 
predicted to be dispensable for growth, i.e., biomass could be generated in the presence of 
alternate biosynthetic routes, along with their corresponding ORFs. We hypothesized that if pairs 
of enzymes independently play an imporant role in metabolism, then deleting both enzymes 
could lead to lethality (Lehar, Stockwell et al. 2008; Torella, Chait et al. 2010). Such pairs were 
identifiable by monitoring the biomass production reactions on inactivation of two enzymes 
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simultaneously in the FBA computations. We identified 54 synthetic lethal pairs of enzymes in 
all 13 strains whose deletions could completely abolish biomass generation. Interestingly, only 
10 of these 54 synthetic-lethal pairs were common to all 13 strains (Table 4.3).  
 
Table 4.2. Single essential enzymes in all strains of S. aureus 
 
Reproduced with permission from (Lee et al., 2009). 
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Figure 4.1. Single essential and synthetic-lethal enzymes of the S. aureus metabolic network 
and their strain dependence.  
(a) Sub-networks of 44 strain-independent single essential enzymes of multiple S. aureus strains. Two 
nodes (enzymes) are connected if their reactions involve common metabolites. The EC number and the 
associated genes are presented for each node. The node colors correspond to the metabolic pathways the 
enzymes belong to.  
(b) Subset of the amino sugar pathway involving two single essential enzymes, EC 2.5.1.7 and 
EC1.1.1.158. Three pairs of enzymes, EC 2.3.1.157-EC 5.1.3.14, EC 2.7.7.23-EC 5.1.3.14, and EC 
5.4.2.10-EC 5.1.3.14, are synthetic-lethal pairs in all strains. The enzymes in each pair individually do not 
affect growth (biomass production), but their simultaneous inactivation/deletion causes lethality.  
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(c) Distribution of the numbers of strains in which an enzyme is singly essential. Altogether, 70 enzymes 
were identified as singly essential in at least one strain. Of these, more than 60% are found in all the S. 
aureus strains.  
(d) Distribution of the numbers of strains in which the deletion of a pair of enzymes is synthetic lethal. A 
total of 54 synthetic-lethal pairs were identified in at least one strain. About 40% of them are found only 
in one strain, reflecting the strain specificity of synthetic-lethal pairs, with less than 20% being present in 
all the strains. Reproduced with permission from (Lee et al., 2009). 
 
 
Six lethal pairs belong to amino sugars/peptidoglycan pathways that can be grouped 
under the cell wall metabolic subsystem. Two lethal pairs belong to the amino acid subsystem, 
and a single pair of enzymes belongs to amino acid and 1-carbon metabolic pathways. Only one 
pair of enzymes is grouped in the nucleotide and carbohydrate subsystems. An example of a 
common lethal pair is shown in amino sugar metabolism (Fig. 4.1b). In S. aureus, there are two 
pathways that can generate UDP-N-acetylglucosamine, the precursor of UDP-N-acetylmuramate. 
One is from D-glucosamine-1P through N-acetyl-D-glucosamine-1P, and the other is from 
Nacetyl- D- mannosamine. The first pathway consists of three enzymatic reactions catalyzed by 
EC 5.4.2.10, EC 2.3.1.157, and EC 2.7.7.23, and the second has EC 5.1.3.14. Therefore, we 
found three synthetic-lethal pairs (EC 5.3.1.14-EC 5.4.2.10, EC 5.1.3.14-EC 2.3.1.157, and EC 
5.1.3.14-EC 2.7.7.23). The subset of the amino sugar biosynthetic pathway involving these 
enzymes is shown in Fig. 4.1b. The number of single essential enzymes varies by individual 
strain. As seen in Fig. 4.1c, more than 90% of the identified single essential enzymes are 
essential in nine strains. The strain dependence of the single essential enzymes is, however, 
stronger than that of the metabolic reconstructions, as 63% of the single essential enzymes are 
found in all the strains, while more than 90% of the metabolic reconstructions overlap. Synthetic-
lethal pairs exhibit even stronger strain dependence (Fig. 4.1d); less than 20% are found in all the 
strains, and 40% are found in only one specific strain.  
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Table 4.3. Common synthetic-lethal pairs of enzymes required for growth identified in all 
13 S. aureus strains 
 
4.2.3 Analysis of the components of minimal medium for S. aureus. 
The minimal medium for the growth of the laboratory strain S. aureus NCTC 8385, 
requiring a combination of salts, carbon source, amino acids, and vitamins, was deduced by trial 
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and error in the early 1970s (Rudin, Sjostrom et al. 1974). However, with the availability of 
complete genome sequences, annotations, pathway analyses, and metabolic reconstructions, one 
can rationally design an optimum growth medium (Bhattacharyya, Stilwagen et al. 2002; Becker 
and Palsson 2005). We compared the published minimal-medium components (Rudin, Sjostrom 
et al. 1974) with the reconstructions and calculated that six components could be synthesized by 
S. aureus, and therefore, these components are not required for growth of S. aureus (Table 4.4). 
Specifically, for several salt components of the medium, a dedicated transport system(s) has been 
identified. For amino acids, such as L-arginine, L-glutamic acid, L-valine, L-threonine, and L-
phenylalanine, both biosynthetic pathways and transport systems are present in all genomes. We 
also identified the ORFs coding for synthesizing and transporting enzymes for cofactors, such as 
biotin and pantothenate. Interestingly, the ORF for pantothenate uptake (Na/pantothenate 
symporter) is not found in any of the S. aureus genomes (Table 4.4). We conclude that S. aureus 
can synthesize biotin and does not require its exogenous addition to the medium. 
To experimentally confirm the minimal-medium prediction, we compared the growth of 
three different S. aureus strains. These included 2 of the 13 reconstructed S. aureus strains 
(Mu50 and USA300), as well as a patient S. aureus isolate. We tested the growth abilities of 
these strains in rich LB medium (control), in the standard minimal medium (AAM+) (Rudin, 
Sjostrom et al. 1974), and in minimal medium (AAM-) predicted by our study. The growth 
patterns of all three strains were the highest in LB medium compared to growth in either minimal 
medium and followed a typical sigmoid growth curve (Fig. 4.2). However, the growth rates in 
the predicted minimal growth medium (AAM-) without the addition of seven compounds were 
similar to those in the standard minimal medium (AAM+). These results thus support the 
minimal-medium predictions, and hence, the validity of our metabolic-pathway reconstructions.  
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Table 4.4. Analysis of minimal growth medium for S. aureus
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Figure 4.2. Experimental validation of S.aureus growth in metabolic-reconstruction-based 
minimal medium.  
Shown are the growth curves of S. aureus Mu50 (a), S. aureus USA300 (b), and an S. aureus patient 
isolate (c). AAM– is a modified minimal medium derived from metabolic reconstruction; AAM+ is a 
published minimal medium (Rudin, Sjostrom et al. 1974). Reproduced with permission from (Lee et al., 
2009). 
4.3 DISCUSSION 
The availability of whole-genome sequences not only provides the possibility of identifying gene 
variability and pathogenic features, but is also valuable for identifying in silico metabolic 
networks and their modeling. Although several virulence and pathogenic genes in S. aureus have 
been identified, they tend not to be feasible drug target candidates, as they are usually strain or 
species specific or prophage borne. On the other hand, metabolic enzymes tend to be common to 
all strains and offer broad-spectrum target candidates irrespective of the bacteria or their host 
specificities. 
In this study, we performed metabolic-network reconstructions of fully sequenced S. 
aureus strains via protein similarity calculation, automated annotation, and manual curation. 
Compared to the previous reconstructions made for a single strain of S. aureus (N315), our 
reconstructions contain a larger data set of both biochemical reactions and transport compounds. 
Moreover, based on the functional annotation of several S. aureus strains, we completed strain-
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dependent metabolic reconstructions, which help us to understand the wide range of virulence 
and drug resistance among the S. aureus strains. As the first step, we carried out FBA on the 
metabolic reconstructions and derived unconditionally essential single enzymes and pairs of 
enzymes in each strain.  
The variation of the reconstructed metabolic networks among the strains does not appear 
to be great, i.e., over 90% of the metabolic enzymes and reactions are similar in the 13 strains. 
This was expected, owing to the clonality of the S. aureus genomes, with more than 80% overall 
DNA sequence similarity (Baba, Bae et al. 2008; Feng, Chen et al. 2008). However, in order to 
describe the metabolic diversity of various drug-resistant phenotypes of S. aureus, we performed 
the FBA for these metabolic networks. In particular, we identified unconditionally essential 
metabolic enzymes by in silico enzyme deletion studies, which in turn represent potential 
antimicrobial drug targets. These essential enzymes partly overlap among all the strains to about 
60% for single essentiality and about 20% for synthetic lethality, suggesting strong strain 
specificity of the functional states of the metabolic networks. We therefore conclude that 
development of antimicrobial drugs should take into consideration the strain dependency of the 
vulnerability of metabolic networks in S. aureus. We presented a list of the single essential and 
synthetic-lethal enzymes for each drug-resistant S. aureus strain. Previously published 
experimental results show that more than half of the single essential enzymes were identified 
experimentally as being essential in various bacteria, including S. aureus.  
Two interesting findings of this study are the identification of new single essential 
enzymes and paired synthetic-lethal enzymes as antibiotic targets common to all strains of S. 
aureus. A surprising finding is that a majority (six pairs) of synthetic-lethal pairs of enzymes are 
in the amino sugar biosynthesis pathways, which are involved in cell wall metabolism. Three 
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lethal enzyme pairs were identified in amino acid metabolic pathways. Among the single 
essential enzymes, eight were identified as playing roles in fatty acid biosynthesis.  
It should be noted that the metabolic reconstructions performed in this work are not 
complete. First, incorrect ORF calling led to inevitable errors in the reconstructions for several 
reasons (Feist, Herrgard et al. 2009). Second, in contrast to well-studied model prokaryotic 
organisms, such as E. coli and B. subtilis, there are limited biochemical and physiological data 
for S. aureus, which hinders testing and improving the metabolic networks reconstructed in this 
study, in spite of the accessibility of literature-based curation (Feist, Herrgard et al. 2009). For 
instance, protein complexes and isoenzymes in the metabolic network of S. aureus have not been 
identified as extensively as in E. coli (Feist and Palsson 2008). Given this limitation, we assumed 
that each of the genes associated with a reaction was needed to catalyze the reaction, and this 
might have created false positives in our essentiality predictions. Moreover, the biomass 
components of S. aureus have not yet been fully described, forcing us to use those of the related 
gram-positive bacterium B. subtilis or those derived from literature searches. Future biochemical 
experiments on S. aureus will improve and confirm the results obtained in this study. It would 
also be informative to perform experimental gene deletion studies to test our findings. 
4.4 MATERIALS AND METHODS 
Metabolic reconstruction of multidrug-resistant S. aureus strains.   
In this study, we carried out the metabolic reconstruction of multiple S. aureus genomes 
using the ERGO bioinformatics suite (Overbeek, Larsen et al. 2003) and the KEGG 
ligand/reaction database as of 2007 (http://www.genome.jp/ligand) (Kanehisa and Goto 2000). 
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Initially, we focused on the MRSA strain N315 as a model organism for metabolic reconstruction 
and FBA studies. Its whole-genome sequence (NC_002745) and the sequence for plasmid pN315 
(NC_003140) were obtained from NCBI (GenBank) and downloaded into ERGO, a genome 
informatics platform that is developed and maintained by Integrated Genomics, Inc. Similar 
processes were performed on several other sequenced genomes, including S. aureus Mu50 
(NC_002758), S. aureus MW2 (NC_003923), S. aureus subsp. aureus COL (NC_002951), S. 
aureus EMRSA-16 strain 252 (NC_002952), S. aureus methicillin-sensitive strain 476 
(NC_002953), S. aureus subsp. aureus JH1 (NC_009632), S. aureus subsp. aureus JH9 
(NC_009487), S. aureus RF122 (NC_007622), S. aureus subsp. aureus COL (NC_002951), S. 
aureus subsp. aureus USA300 (NC_007793), S. aureus subsp. aureus USA300_ TCH1516 
(NC_010079), and S. aureus subsp. aureus Newman (NC_009641).  
In general, the whole-genome DNA sequences, along with associated open reading 
frames (ORFs)/protein sequences, were integrated into the ERGO genome database. Automated 
and manual annotations of the ORFs were carried out as described previously (Kapatral, 
Anderson et al. 2002). Briefly, automatic ORF calling was performed using a combination of 
programs, including GLIMMER and Critica. The protein similarities were computed by BLAST 
"all against all," with over 3.5 million protein sequences present in the non-redundant database 
from over 1,362 genomes. This was followed by functional assignments, relationship 
computation, pathway analyses, and automated metabolic reconstruction (metabolic and 
nonmetabolic subsystems). These automated annotations are largely based on the existence of 
ortholog and protein family clusters. Manual annotation included a review of every gene in the 
genome. Once the functional annotations were assigned, we performed additional manual 
pathway curations of the functions in order to identify their roles in appropriate metabolic 
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subsystems. The automatically assigned functions were validated using both proprietary and 
publicly available tools to make new functional assignments. During manual annotation, we also 
considered and reconciled motif/domain database results (for example, from COGS, Pfam, and 
INTERPRO) to make functional assignments. Missing steps in pathways were identified, and 
genes that could fulfill these functions were sought in order to determine if the pathways should 
be included in the organism's metabolic catalog. This process resulted in the identification of 
functions for un-annotated or erroneously annotated proteins. Metabolic/cellular reconstructions 
were finally derived by interconnecting the entire set of pathways identified in a given strain. 
These pathways in ERGO were grouped into metabolic and non-metabolic systems that were 
interconnected into a metabolic network between subsystems, such as amino acids, 
carbohydrates, lipids, secondary metabolism, and sulfur and phosphorus metabolism. The non-
metabolic pathways contained lists of genes/functions that represented subsystems, such as 
protein secretion, virulence, secretion, and phages. All 13 S. aureus genomes were 
simultaneously annotated and analyzed. Gap-filling reactions were not performed because the 
ORFs corresponding to the missing enzymes were not present. Unlike in the work of Becker and 
Palsson , where the gap-filling reactions were performed, the aim of this study was to identify the 
genes that could be experimentally tested for essentiality. In cases of missing steps within a given 
pathway, we searched for orthologs or published biochemical activities (for example, for the 
histidine biosynthesis pathway). ORFs with enzymes as functions with complete or incomplete 
Enzyme Commission (EC) numbers were identified from the functional categories of the ERGO 
genome analysis suite. The associated biochemical reactions for each of the enzymes were 
selected in the KEGG reaction database. The biochemical reactions with substrates that did not 
have an identified transport or uptake system and those that were not supported by experimental 
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studies of S. aureus were considered "unlikely reactions" and were not included in the FBA. 
Individual transport reactions were added from the ERGO pathway collection. Universal 
(SwissProt) names were used for enzymes to avoid nomenclature conflict for the FBA studies. 
All the reactions and their corresponding KEGG identifiers (reaction IDs and compound IDs) 
were used in the FBA computations.  
 
FBA of S. aureus metabolic networks.  
The metabolic networks were constructed individually for all 13 S. aureus strains, and the 
reaction data from each of the species were used for FBA computations. The total numbers of 
enzymes of all the species ranged from 522 to 547. The biochemical reactions varied from 1,444 
to 1,497, with total metabolites ranging from 1,399 to 1,437. The metabolic reactions were 
classified into three categories: cellular (reactions in the cytoplasm), transport (reactions 
involving both the intra- and extracellular metabolites), and exchange (reactions involving either 
uptake or excretion of the extracellular metabolites). The stoichiometries of these metabolic 
reactions were adapted from the KEGG ligand database and the ERGO bioinformatics suite, 
yielding the stoichiometry matrix S, with its element Sij indicating the stoichiometric coefficient 
of the metabolite i in the reaction j. The FBA states that in the stationary state, the fluxes {vj} of 
the metabolic reactions are those that maximize vbiomass subject to:  
 
 
 (1) 
where vbiomass indicates the flux of the reaction that produces biomass, acting as a drain of those 
biomass compounds. The biomass-generating reaction is given by in which mi is 
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each of the biomass compounds and ci is the coefficient. Currently, there are two predicted 
biomass compositions proposed for S. aureus strain N315 (Becker and Palsson 2005; Heinemann, 
Kummel et al. 2005): one is based on and similar to that of a related gram-positive bacterium, 
Bacillus subtilis (Becker and Palsson 2005), with 58 biomass compounds, and the second was 
established from an extensive literature search on S. aureus resulting in 50 biomass compounds 
(Heinemann, Kummel et al. 2005). For each set of biomass components, we first checked 
whether each of the biomass compounds, mi, was synthesized in our metabolic-network 
reconstructions by performing the FBA assuming the biomass-generating reaction to be mi
biomass for each mi. If this reaction had a nonzero flux, we considered the biomass compound to 
be synthesized in the given strain of S. aureus. For the biomass composition from (Becker and 
Palsson 2005), we found that for nine S. aureus strains (TCH1516, USA300, Mu3, JH9, JH1, 
RF122, Mu50, MRSA252, and N315), 47 of the 58 biomass components could be synthesized, 
that is, the flux of the modified biomass-generating reaction for each of these compounds was 
nonzero. In contrast, the other 11 components could not be synthesized, suggesting absence of 
the biosynthetic pathways to generate them or absence of the uptake transporters for them. Three 
S. aureus strains, Newman, COL, and MW2, could synthesize only 44 biomass components, 
whereas 43 components could be synthesized by the methicillin-sensitive strain 476. For the 
biomass composition of (Heinemann, Kummel et al. 2005), each of the 13 strains synthesized 41 
compounds of the proposed 51. For the missing components, one could assume that unknown 
gene products catalyzed the corresponding biosynthetic pathways and therefore add them to the 
metabolic network. Those added pathways would be likely to be essential for the growth of S. 
aureus. However, we elected to retain only the biomass components synthesized in the current 
form of the metabolic networks of S. aureus strains to obtain definitely and unconditionally 
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essential enzymes. These computational studies predicted the synthesis of 47 and 41 biomass 
compounds, respectively, with 25 common compounds (see Dataset 1 in the supplemental 
material). We considered both biomass compositions from Becker and Palsson and Heinemann in 
our study for comparison. Therefore, we used two metabolic-reconstruction versions for each S. 
aureus strain. The two versions were identical except for the biomass generation reaction 
involving biomass compounds from either Becker and Palsson or Heinemann et al. this study, we 
present the results obtained from the metabolic reconstructions with the biomass composition 
based on the studies of Becker and Palsson. The results using the biomass composition from 
Heinemann et al. can be found in the supplemental material (Lee, Burd et al. 2009). For the FBA 
computations, we used ideally rich medium in which all the uptake reactions could occur without 
limitation on their fluxes, since we aimed to identify unconditionally essential enzymes, which 
we define below. The FBA is a linear programming problem and was carried out using the GNU 
Linear Programming Kit.  
Identification of single unconditionally essential and synthetic-lethal enzymes of S. 
aureus strains.  
In the FBA scheme, an enzyme is considered to be essential (Almaas, Oltvai et al. 
2005) if an additional constraint,  
 2) 
for all reactions j catalyzed by the selected enzyme lead to no growth (vbiomass = 0). If 
inactivation of an enzyme leads to no growth in an ideally rich environment (medium) in 
which all the uptake reactions are allowed to have unlimited fluxes, it would also lead to no 
growth in any other environment. Therefore, the unconditionally essential enzymes, i.e., 3) 
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essential under all growth conditions, can be obtained from the FBA equation 1 combined 
with equation 2 and setting all upper limits of uptake reactions as follows:  
 
for all uptake reactions j. Similarly, an unconditionally synthetic-lethal pair of enzymes can be 
identified by monitoring the biomass generation reaction while blocking the reactions catalyzed 
by the considered pair of enzymes in an ideally rich environment. That is, the removal of two 
enzymes, E1 and E2, is considered to be unconditionally lethal if the removal of just one of them 
is not lethal and the FBA (equation 1) in the ideally rich environment (equation 3) leads to no 
growth (vbiomass = 0) (Deutscher, Meilijson et al. 2006) under the following constraints:  
 4) 
for all uptake reactions j catalyzed by the enzyme E1 or E2.  
Design and analysis of growth media.  
Using the complete metabolic analysis of all the strains of S. aureus and the reference 
minimal medium, we derived a medium that supports growth on a minimal medium, using 
metabolic-reconstruction methods, as described for Xylella fastidiosa (Bhattacharyya, Stilwagen 
et al. 2002). The compounds from the published minimal medium (AAM+) for S. aureus (Rudin, 
Sjostrom et al. 1974) were verified with the metabolic reconstruction of S. aureus genomes. A 
modified synthetic minimum medium was predicted that did not contain L-arginine, L-glutamic 
acid, L-valine, L-threonine, L-phenlyalanine, and biotin (AAM–). The AAM+ and AAM– media 
were calibrated to pH 7.4 to prevent salt precipitation, and LB was prepared using standard-grade 
chemicals. Three strains, including two MRSA strains (S. aureus Mu50 and USA300) and a 
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methicillin-sensitive patient isolate (from the University of Pittsburg Medical Center), were 
tested for growth in the minimal media under identical medium and growth conditions. These 
strains were inoculated into a sterile glass tube containing 3 ml LB and were grown at 37°C at 
200 rpm for 16 h. For each strain, 900 µl of the overnight culture was pipetted into three separate 
1.5-ml microcentrifuge tubes, centrifuged, and washed with LB, AAM+, or AAM– medium, 
respectively. The individual pellets were then resuspended in 200 µl of LB, AAM+, or AAM– 
medium, and 10 µl of each suspension was then inoculated into 2 ml of the corresponding 
medium for culture in a 24-well plate with uninoculated LB, AAM+, or AAM– medium as a 
control. The cultures were placed on a shaker rotating at 225 rpm at 37°C. Each experiment was 
done in triplicate and was repeated three times, and the growth was measured for 25 h at 600 nm 
using a microplate reader. 
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5.0  FASII AS A VALID ANTIMICROBIAL TARGET AGAINST S. AUREUS 
METABOLIC NETWORKS 
5.1 INTRODUCTION 
Antibiotic drug resistance significantly eroded the effectiveness of currently available 
antimicrobial drugs towards disease-causing bacteria (Fischbach and Walsh 2009). As a 
consequence, today the yearly mortality rate in the United States due to multi-drug resistant S. 
aureus infections is higher than due to AIDS (Klevens, Morrison et al. 2007). Therefore, the 
emergence of superbugs, methicillin-resistant S. aureus (MRSA) and vancomycin-resistant S. 
aureus (VRSA) isolates, underscores the need to identify new targets and molecules effective 
against multidrug-resistant strains of S. aureus. 
The challenge to find “druggable” targets (Russ and Lampel 2005) that will have an 
effect in the complex interaction network of a living organism has only been partially met by 
genomics and functional genomics approaches (Orth, Batalov et al. 2004). For example, 
systematic gene deletion studies have been widely used to identify essential genes whose protein 
product could serve as potential antibiotic targets in a given bacterium. This approach yields only 
growth-condition specific results, as a molecular target that is found to be essential in one 
specific environment may not be essential in others. Our previous study (Lee, Burd et al. 2009) 
utilized comparative systematic analysis on the reconstructed metabolic networks of 13 S. aureus 
strains to predict a list of single essential enzymes and synthetic lethal pairs as essential under all 
conditions and thus representing potential targets for antimicrobial drug discovery. Here, to 
  77 
provide a proof-of-principle demonstration that the predicted single essential enzymes or 
synthetic lethal pairs through metabolic network analysis can yield potential “druggable” targets, 
we focus on the initiation step and elongation cycle of the fatty acid biosynthesis pathway (FAS 
II) from the predicted list as a case study. We elected to focus on this pathway because the FASII 
elongation cycle is catalyzed by enzymes fundamentally different from their eukaryotic 
counterpart (Campbell and Cronan 2001), several antimicrobials have already successfully 
targeted its enzymes in various bacteria (Heath, White et al. 2001; Wang, Kodali et al. 2007; 
Abbanat, Morrow et al. 2008; Chan and Vogel 2010), and because many of its enzymes were 
shown to be essential in E. coli under select growth conditions (Gerdes, Scholle et al. 2003; 
Kang, Durfee et al. 2004; Baba, Ara et al. 2006).   
In conjuction with computer-aided virtual screening of small-molecule chemical libraries 
against the enzymes’ active sites, we discovered forty potential inhibitors of FabD, FabH, 
FabB/F, FabI, and FabA/Z, of which a small subset inhibited both enzyme activities in-vitro and 
bacterial cell viability in vivo. Therefore, the systems-analysis of metabolic networks identified 
FAS II as a valid anti-Staphylococcus target, representing an effective approach for antimicrobial 
target identification. 
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5.2 RESULTS 
5.2.1 Identification of antimicrobial targets by the analysis of bacterial metabolic 
networks  
Our previous study (Lee, Burd et al. 2009) performed comparative systematic analyses on 
the reconstructed metabolic networks of 13 S. aureus strains to predict a list of single essential 
enzymes and synthetic lethal pairs under all growth conditions. To identify generic targets 
against both Gram-positive (S. aureus) and Gram-negative (E. coli) bacteria, we performed a 
similar Flux Balance Analysis (FBA) to identify the essential metabolic reactions of E. coli 
MG1655 using a recent metabolic network reconstruction of this Gram-negative model organism 
(Feist, Henry et al. 2007). This analysis predicted 38 metabolic reactions as having nonzero flux 
under all growth conditions and being indispensable for the synthesis of the full set of biomass 
components in this bacterium. In the absence of isozymes or compensatory (non-specific) 
enzymatic activities, the enzymes catalyzing these reactions are expected to be essential under all 
conditions and thus represent potential targets for antimicrobial drug discovery (Almaas, Oltvai 
et al. 2005; Lee, Burd et al. 2009). A high fraction of the enzymes catalyzing the 38 predicted 
indispensable reactions were found to be essential in three previous genome-scale gene deletion 
studies (Gerdes, Scholle et al. 2003; Kang, Durfee et al. 2004; Baba, Ara et al. 2006). Seven of 
these indispensable reactions are shared among E. coli MG1655 and 13 S. aureus strains (Lee, 
Burd et al. 2009), with five of them being experimentally validated as essential in at least one of 
the E. coli gene deletion studies (Table 5.1). These reactions are not distributed randomly within 
the metabolism but cluster into distinct metabolic pathways that are known to play key roles in 
bacterial cell wall-, amino acid-, and porphyrin biosyntheses. 
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Table 5.1     Enzymes catalyzing essential metabolic reactions conserved between E. coli 
and     S. aureus strains may represent novel antibiotic targets.  
 Gerdes Baba Kang 
aminosugars metabolism 
murB       
amino acid biosynthesis 
aroA       
aroC       
porphyrin metabolism 
hemB       
hemD       
methionine metabolism 
metK       
mtn       
 
fatty acid biosynthesis 
fabD       
fabH       
fabF       
fabG       
accA       
accD       
 
Top: the list of enzymes of shared unconditional essential metabolic reactions of E. coli MG1655 
and 13 S. aureus strains predicted from FBA analysis. Bottom: enzymes of fatty acid biosynthesis that are 
unconditionally essential in both bacteria in the absence of exogenous unsaturated fatty acids. Predicted 
enzyme targets with uniform agreement with E. coli viability studies (red color), with one or two 
mismatch (blue color), or in disagreement with all 3 E. coli viability studies (green color). Background 
color of orange (grey) indicates the enzyme-encoding gene is identified as essential (non-essential) in the 
indicated E. coli deletion phenotype study (Gerdes, Scholle et al. 2003; Kang, Durfee et al. 2004; Baba, 
Ara et al. 2006). 
 
Some reactions are indispensable only in one type of bacterium. For example, most 
enzymes of the type II bacterial fatty acid biosynthesis (FAS II) pathways (Zhang and Rock 
2008) are predicted as unconditionally essential in 13 S. aureus species (Lee, Burd et al. 2009), 
but not in E. coli MG1655 that has several transporters that enable it to take up fatty acids 
directly from the environment (Feist, Henry et al. 2007). Yet, in standard (fatty acid-free) growth 
media the inactivation of most FAS II enzymes renders E. coli cells inviable (Table 5.1). This 
can be countered by the addition of unsaturated fatty acids to the growth media (Harder, 
Ladenson et al. 1974; Campbell and Cronan 2001). In a recent intraperitoneal infection model 
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with gram positive S. agalactiae inactivation of FAS II enzymes also proved ineffective 
(Brinster, Lamberet et al. 2009), suggesting that pharmaceutical inhibition of FAS II enzymes 
may not be a feasible strategy for the treatment of systemic bacterial infections. However, these 
enzymes may be suitable targets for the eradication of cutaneous antibiotic-resistant bacterial 
colonizations or for treating cutaneous infections caused by e.g., methicillin-resistant S. aureus 
(MRSA) (Jones, Sura et al. 2003; Kazakova, Hageman et al. 2005). 
 
Figure 5.1  FAS II pathway and Small molecule inhibitors against FAS II enzymes  
 
a. FAS II pathway and structures of select, existing antimicrobials (blue) and the newly identified small 
molecule inhibitors (red) against their target enzymes. The structures used for the virtual screenings are 
  81 
also shown. E. coli viability data for FAS II pathway enzymes from three independent gene deletion 
studies are indicated: uniformly essential (red), dispensable (black) or conflicting deletion phenotype 
(blue) enzymes are shown. 
b. The active site of E. coli FabD (PDB#2g2z, in red) superimposed on human mitochondrial MCAT 
(PDB#2c2n, in blue) with two docked ligands, FDi2 (cyan) and FDi14 (yellow); c-g. Interactions of 
selected inhibitors in the active sites of their respective targets: c. FDi2 in E. coli FabD after 8ns MD; d. 
FDi10 docked to S. aureus FabD homology model built from E. coli FabD; e. ECi8 docked to S. aureus 
FabF; f. ECi16 docked to E. coli FabI; and g. ECi23 in a homlogy model of E. coli FabZ after 8ns MD. 
Reproduced from (Shen and Liu et al., 2010). 
5.2.2 Virtual screening of small-molecule compounds against enzymes of bacterial fatty 
acid biosynthesis 
Enzymes of the FAS II pathway with uniformly lethal deletion phenotype in E. coli are 
considered as potential high-confidence targets, while those with at least one mismatch in the E. 
coli deletion phenotype data, or having isozymes, were considered lower-confidence targets 
(Table 5.1). Previous analyses demonstrated that the essential metabolic enzymes of E. coli, and 
particularly those in the metabolic core, tend to be conserved among bacteria on the amino acid 
sequence level (Gerdes, 2003; Almaas, 2005). Therefore, we next examined the amino-acid level 
conservation of those enzymes of bacterial fatty acid biosynthesis that have at least one 
experimentally-determined crystal structure among the fifteen most common human bacterial 
pathogens found in hospital patient populations at the University of Pittsburgh Medical Center. 
Of these enzymes, we first focused on the Malonyl-CoA-acyl carrier protein transacylase 
(MCAT, FabD, EC 2.3.1.39) which catalyzes the first committed step in the initiation step of the 
fatty-acid biosynthesis pathway (Fig. 5.1a). 
Structural conservation of an enzyme target among prokaryotes, and especially the 
conservation of its active site, is one prerequisite for broad-spectrum antibiotic development. A 
second prerequisite is that either no human ortholog exist for that enzyme, or that it is 
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sufficiently different from its bacterial counterparts, in order to minimize potential drug toxicity. 
In humans, the elongation cycle enzymes are fundamentally different from their bacterial 
counterparts (Campbell and Cronan 2001; Maier, Leibundgut et al. 2008). However, FabD exists 
in a cytosolic and mitochondrial form, the former playing the major role for fatty acid 
biosynthesis in human cells (Campbell and Cronan 2001; Heath and Rock 2004; Maier, 
Leibundgut et al. 2008). For human mitochondrial FabD, a crystal structure is also available 
(PDB ID 2c2n). Hence, we first performed a quantitative sequence homology search between E. 
coli FabD and the fifteen most common hospital isolates from the University of Pittsburgh 
Medical Center. We found that the bacterial enzymes’ active sites show high amino acid 
sequence conservation (Fig. 5.2a), while the human mitochondrial enzyme has some critically 
different residues. Additionally, human mitochondrial FabD active site showed the largest 
evolutionary distance compared to all examined bacterial species (Fig. 5.2b). Figure 5.2c 
displays the E. coli FabD structure (right panel) and its active site (left panel), including catalytic 
and substrate binding residues and bound substrate of the enzyme (malonate). 
On a structural level, overall secondary structure of human FabDs showed similarity to its 
bacterial counterparts (see main text). However, a detailed structural comparison of the E. coli 
and human mitochondrial and cytosolic FabD active sites reveal sufficient differences between 
the human and prokaryotic enzymes to suggest that bacterial FabD may indeed serve as a useful 
molecular target for novel antibiotics.  
Subsequently, we have identified 15 potential inhibitors (FDi1-15) of bacterial FabDs 
(Serre, Verbree et al. 1995; Keatinge-Clay, Shelat et al. 2003; Oefner, Schulz et al. 2006; Li, 
Huang et al. 2007). Briefly, the ZINC lead library (Irwin and Shoichet 2005) containing ~106 
small molecules pre-filtered for drug-like properties was docked either to the crystal structures of 
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E. coli FabD or to a FabD homology model derived for S. aureus N315 using successively more 
accurate scoring functions, followed by manual inspection of poses and rescoring by MM-PBSA 
calculations from an ensemble of molecular dynamics (MD) simulations (see Supporting 
Information for details) (Thompson, Humblet et al. 2008). Figure 5.1b shows two representative 
potential inhibitors, FDi2 and FDi14, bound to the active site of E. coli FabD. They exemplify 
the pharmacophore that is further confirmed by other docked structures and the putative binding 
mode of the natural substrate (Oefner, Schulz et al. 2006). The close-up of FDi2 in the active site 
of E. coli FabD illustrates the relevant interactions (Fig. 5.1c). The carboxylate acts as a 
phosphate isostere and interacts with the catalytic Arg117, Leu93 and Gln11, respectively. A polar 
linker to a thiophene ring enables stacking against His91 and occupation of a hydrophobic pocket 
by a benzene moiety.  Similar interactions are found for FDi10 in the active site of S. aureus 
FabD (Fig. 5.1d).  
A particular strength of the approach used here is that it has an inherently systems-wide 
view rather than targeting a single enzyme, as is done in traditional drug design. If an enzyme is 
essential by itself (e.g., FabD) its specific inhibitors should be able to kill bacteria. Similarly, 
isozyme pairs, such as FabB and FabF in E. coli, are also promising targets if both of them are 
targeted simultaneously. For example, FAS II inhibitors thiolactomycin, cerulenin or 
platensimycin are known to simultaneously inhibit both FabB and FabF (Fig. 5.1a) and have 
broad-spectrum antibacterial activity (Wang, Soisson et al. 2006).  
We therefore screened all remaining enzymes of the FAS II pathway (FabH, FabB/F, 
FabG, FabA/Z, and FabI) (Fig. 5.1a) using ligand bound crystal structures or homology models. 
This yielded 26 small molecules that can potentially inhibit the FAS II elongation cycle enzymes 
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(ECi1-26). As several of the enzymes are functionally redundant in some organisms and the 
product of one step is the substrate of the next, the binding sites share many similarities. As a 
Figure 5.2. 
Comparison of 
FabD sequence 
and structure 
between human 
mitochondrial and 
the 16 most 
common bacterial 
pathogens (among 
hospital isolates).  
a. Sequence 
similarities of the 
FabD active sites. The 
residues lining the 
active site of FabD of 
human mitochondria 
and the bacterial 
species show some 
distinct features. The 
residues are labeled 
with their 
corresponding residue 
numbers in E. coli 
FabD. The middle 
panel shows the 
conservation score for 
each residue. Stars 
indicate full 
conservation among 
all species. The 
bottom panel shows 
the most common 
residues in the active 
sites.  
b. Evolutionary 
distance of FabDs. 
The phylogenetic tree shows the evolutionary relationships among pathogenic bacteria with existing FabD 
sequence and human mito-chondrial FabD. The numbers on the tree branches indicate the average 
distance measured in sequence identity.  
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c. The structure of E. coli FabD. The right panel shows the ribbon diagram of E. coli FabD, while the left 
panel is a closer look at its active site. Catalytic and substrate binding residues are displayed and labeled. 
A bound substrate of the enzyme (malonate) is shown in green. PDB IDs that are used for the figure are 
1mla, 2g2y, 2g2z.  Reproduced from (Shen and Liu et al., 2010). 
 
result, similar common binding moieties, such as a phosphate isostere, a hydrogen binding polar 
group, and a nonpolar ring system in similar position emerge from the screens. This suggests the 
possibility of inhibiting several targets simultaneously. This concept of poly-pharmacology has 
been successfully applied in a number of cases before (Lehár, Stockwell et al. 2008) and is part 
of the inherent design in our case. 
Representative results from these studies are shown in Figures 5.1e-g. ECi8 is predicted 
to inhibit both FabB and FabF (Fig. 5.1e), shares the binding characteristics of known inhibitors 
(Wang, Soisson et al. 2006; Wang, Kodali et al. 2007), and has a good shape complementary to 
the active sites of both enzymes. In agreement with the hypothesis outlined above, cross-docking 
shows that ECi8 also has good poses and scores for binding to FabI and FabG, the adjacent 
enzymes in the elongation cycle. 
The NADPH and NADH dependent reductases FabG and FabI have similar active sites 
and several inhibitors exist for the latter, including triclosan (Fig. 5.1a). The most promising 
inhibitor identified by virtual screening, ECi16, shows similar interactions as triclosan: the 
fluorophenyl ring π-stacks with the oxidized nicotinamide while the oxygen atoms of the 
sulfamide group participate in hydrogen bond interactions with the conserved active site tyrosine 
(Y156 in E. coli FabI) and the 2’hydroxyl of NAD+ (Fig. 5.1f).  
The active sites of the dehydratases FabA and FabZ are formed along the dimer interface, 
with the critical His70 and Asp84 (FabA)/Glu63(FabZ) contributed by different monomers. The 
virtual screening identifies the interaction with Asp84/Glu63 as the most relevant for inhibitor 
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binding. Figure 18g depicts this interaction in the binding of ECi23 in the FabZ active site, where 
the inhibitor is also stabilized by π-stacking with Tyr86. A complete list of the identified potential 
FabD and elongation cycle inhibitors are presented in Table 5.2. 
Table 5.2.   Structures of compounds showing activity in in vitro experiments 
S
O
NH
N O
COO-
 
FDi2  
ZINC0072513 
2g2y  
GScore: -6.09 
MMPBSA: -41.56 
FDi4  
ZINC00152793 
2g2y 
GScore: -9.94 
MMPBSA: -42.61 
FDi7  
ZINC00200929 
2g2y 
GScore: -8.18 
MMPBSA: -52.72 
 
FDi8  
ZINC00284275 
2g2y 
GScore: -12.27 
MMPBSA: -33.51 
 
FDi10  
ZINC02968391 
2g2y 
GScore: -10.5 
MMPBSA: -34.22 
 
FDi11  
ZINC03350762 
2g2y 
GScore: -7.28 
MMPBSA: -40.94 
 
 
FDi12  
ZINC03660299 
2g2y 
GScore: -8.54 
MMPBSA: -31.81 
FDi14  
ZINC04819675 
2g2y 
GScore: -7.94 
MMPBSA: -18.89 
 
FDi15  
ZINC06702282 
2g2y 
GScore: -7.35 
MMPBSA: -31.07 
 
ECi8  
ZINC02214825 
2gfv 
GScore: -11.67 
MMPBSA: -32.52 
ECi10  
ZINC06697642 
1q7b 
GScore  -9.10 
MMPBSA  -25.67 
 
ECi11  
ZINC04618181 
1hnj 
GScore: -10.52 
MMPBSA: -34.24 
 
ECi12  
ZINC00621461 
1hnj 
GScore: -11.36 
MMPBSA: -31.84 
 
 
ECi13  
ZINC04716354 
1mka 
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ECi14  
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ZINC00433116 
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ECi21  
ZINC04928462 
2gfx 
GScore: -11.03 
MMPBSA: -37.35 
 
ECi23  
ZINC01281455 
Homolog built on 1z6b 
GScore  -15.07 
MMPBSA  -42.84 
 
 
ECi26  
ZINC01317935 
1hnj 
GScore: -8.38 
MMPBSA: -40.79 
 
Table 5.2 includes the numbering of the compounds used in the study, their corresponding ZINC 
numbers, the PDB # of the crystal structures used to screen against in the computational studies, Gscore 
(kcal/mol) from docking using Glide XP and MMPBSA score (kcal/mol)from MMPBSA calculation 
based on 8ns molecular dynamics simulation using Amber9. Reproduced from (Shen and Liu et al., 
2010). 
5.2.3 Testing the effect of predicted inhibitors by in vitro enzyme assays 
To experimentally validate the inhibitory effect of the 41 compounds selected from the 
106 library members on bacterial fatty acid enzymes, we set up two separate published enzyme 
screening assays, one for testing FabD activity (Molnos, Gardiner et al. 2003) and the other for 
testing the inhibition of the elongation cycle (Kodali, Galgoci et al. 2006). For the FabD 
screening assay, we cloned the E. coli FabD, and its protein substrate, AcpP, into a prokaryotic 
expression vector, induced their expression, and purified them to homogeneity. We then tested 
the purified FabD’s activity in the absence or presence of 400µg/ml of the predicted inhibitors 
(see Table 5.3). Five inhibitors completely block the enzymatic activity of FabD (yellow 
shading) and generate negatively changing fluorescence signals (NADH), while the three weak 
inhibitors (orange shading) can significantly decrease the rate of fluorescence signals catalyzed 
by the purified FabD’s activity compared to that in the presence of DMSO or the absence of 
inhibitors (see Table 5.3). Since the established FabD enzyme assay (Molnos, Gardiner et al. 
2003) was based on the FabD-KDH coupled reactions, we also performed KDH counter-
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screening assay to eliminate the possible inhibition of potential inhibitors against KDH. FDi11, 
12, 14, and 15 did not show any inhibition against KDH compared to DMSO control, while 
FDi2, 7, 8, 10 can partially inhibit the KDH activity. 
Table 5.3 Summary of the in vitro enzyme assays of FabD inhibitors. 
  FabD assay KDH 
assay Slopes 1 2 3 
Control 40.856 34.51 40.1925 - 
DMSO 30.972667 31.410333 35.731 - 
FDi1 32.251 29.645 30.805 N/A 
FDi2 -13.557 -10.892 -17.063 ± 
FDi3 23.044 26.97 23.515 N/A 
FDi5 25.257 26.247 21.728 N/A 
FDi6 23.515 26.285 22.732 N/A 
FDi7 -575.525 -401.568 -623.088 ± 
FDi8 -4.537 -8.743 -7.943 ± 
FDi9 22.597 25.545 24.113 N/A 
FDi10 1.492 2.375 1.615 ± 
FDi11 2.292 -8.643 -17.61 - 
FDi12 18.667 15.572 19.612 - 
FDi13 23.272 31.678 22.952 N/A 
FDi14 21.112 24.532 19.297 - 
FDi15 16.681 18.493 14.22 - 
Strong inhibitors (yellow shading) and weak inhibitors (orange shading) are shown. +++: strong 
inhibition;  ±: partial inhibition; -: no inhibition in KDH counter screening. 
 
 
However, the partial inhibition of fluorescence signals catalyzed by KDH enzyme in the 
presence of FDi 2, 7, 8 and 10 could also be attributed to the direct destruction of NADH by the 
inhibitors. The strong negative slope suggests this possibility for the case of FDi7. Therefore, of 
the 15 predicted inhibitors, we found that five of them (FDi2, 7, 8, 10, and 11) strongly- and 
three of them (FDi12, 14 and 15) weakly inhibited FabD activity . 
We also tested the effect of the 26 small molecules that are predicted to block the activity 
of various elongation cycle enzymes using an established, fractionated cytoplasmic protein 
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extract-based elongation cycle assay (Kodali, Galgoci et al. 2006) with slight modifications (see 
Materials and Methods). ECi8, 21, 23, 26 have shown strong- and ECi10, 11, 12, 13, 14, 16 
weak inhibitions toward the FAS II elongation cycle enzymes (Table 5.4). Of the 41 potential 
inhibitors identified in the virtual screening protocol, eight were highly- and nine were weakly 
active. For each enzyme of the FAS II elongation cycle we could identify at least one validated 
inhibitor. This exceptionally high hit rate of >40% is remarkable considering the simple physical 
models used in the scoring functions and is significantly higher than what is typically obtained in 
virtual screening. This indicates that MM-PBSA rescoring is at least for the present systems able 
to describe side chain flexibility and hydrophobic effects and thus represents a significant 
improvement for virtual screening (Thompson, Humblet et al. 2008). It is expected that explicit 
treatment of entropy could further improve the hit rate, albeit at significant computational cost.  
5.2.4 Testing the effect of predicted inhibitors by in vivo cell-based experiments 
Next, we examined the effect of these compounds on bacterial cell viability by 
performing disc inhibition assays against two E. coli strains (MG1655 and a random patient 
isolate) and three S. aureus strains (S. aureus Mu50, USA300, and a strain isolated from a 
patient) using standard procedures (Woods and Washington 1995). As it was reported that serum 
is a rich source of unsaturated fatty acids excluding the use of FAS II inhibitors for the treatment 
of systemic infections (Brinster, Lamberet et al. 2009) we performed the experiments both on 
LB-agar and LB-agar plus 10% FCS plates at 10µg/µl (Fig. 5.3). 
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Figure 5.3     The inhibitory effects of small molecules against an S. aureus patient strain 
Representative disc inhibition assay results at 10µg/µl (except ECi11) on a. LB agar plate, and b. LB agar 
plate plus 10% human serum (B) together with positive (Ampicillin (Amp), 1µg/µl) and negative, solvent 
(DMSO)  controls are shown. Reproduced from (Shen and Liu et al., 2010). 
 
 
When using standard LB-agar plates (Fig. 5.3a, and blue shaded columns in Table 5.4) 
among the identified FabD and elongation cycle enzyme inhibitors FDi8, 11, 12 and 15 did not 
show any inhibitory effect in this whole cell assay. In contrast, FDi2, 7, 10, 14 and ECi8, 23 
were found to be active against all five strains tested, although their zone of inhibition was 
different both quantitatively and qualitatively for different strains (Fig. 5.3). ECi16 only 
displayed minor inhibitory effect on E. coli patient and MG1655 strains, while the remaining 
inhibitors, including ECi11, were without effect (Fig. 5.3). Of note, even though S. aureus Mu50 
and USA300 strains are methicillin and vancomycin resistant opportunistic pathogens, 
respectively, in the Mu50 strain FDi10 and ECi8 and 23 displayed a clear zone of inhibition that 
was even stronger than the one caused by ampicillin (Fig. 5.3a). In the presence of unsaturated 
fatty acids (Fig. 5.3b, and pink- shaded columns in Table 5.4) FDi2 and ECi16 completely lost 
their inhibitory function, while FDi7, 14 and ECi23 displayed partial inhibitory activities.  
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 FabD (FD) Elongation Cycle (EC) Controls 
 i2 i7 i10 i14 i8 i11 i16 i23 Amp DMSO 
S. aureus Mu50 + - + - ++ + + - ++ + - - - - - - ± + - - 
S. aureus patient + - + ± ++ ++ + ± +++ +++ - - - - + + +++ +++ - - 
S. aureus USA300 + - ++ - ++ ++ + ± +++ +++ - - - - + - +++ +++ - - 
E. coli MG1655 + - + - + - + ± + + - - + ND + + +++ +++ - - 
E. coli patient + - + - + - + ± + ± - - + - + - +++ +++ - - 
Mammalian cell toxicity Triclosan Cerulenin 
MTT activity - ± ± ± +++ ± ± +++ ± +++ 
Trypan blue excl. - + + + +++ + + +++ +++ +++ 
 
Table 5.4     Summary of bacterial disc inhibition and human fibroblast toxicity assay 
results 
+: weak inhibition; ++: weak inhibition plus zone of partial inhibition; +++: strong inhibition; ±: partial 
inhibition; -: no inhibition. The blue shading indicates the inhibition effect on S. aureus and E. coli strains 
growing on the LB agar plate, while the pink shading displays the inhibition effects on the LB plus 10% 
human serum agar plate. Reproduced from (Shen and Liu et al., 2010). 
 
In contrast, FDi10 and ECi8 retained most of their activity. These findings are consistent with 
the notion that the presence of unsaturated fatty acids can indeed bypass the need for FAS II 
enzymes (Brinster, Lamberet et al. 2009), and suggest that some of the identified inhibitors may 
also possess off-target growth inhibitory effects. 
To further test if the identified inhibitors react with their targets’ human orthologs and/ or 
cause toxicity in human cells through off-target effects, we employed MTT cell viability assay 
and trypan blue exclusion assay to examine the effect of potential inhibitors on mammalian cells. 
Normal human BJ foreskin fibroblast cells immortalized by hTERT (Hahn, Counter et al. 1999) 
were utilized for this purpose. After treating the cells with 400µg/ml of each inhibitor we found 
that FDi2 displayed comparable MTT activity and live cell numbers with the DMSO solvent 
control, indicating that it has no toxicity or inhibitory effect on cell viability (Table 5.4). In 
contrast, similar to the effect of cerulenin and triclosan, ECi8 and 23 completely blocked MTT 
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activity and killed the fibroblast cells. The other inhibitors, including FDi10, FDi14 and EC16, 
showed partial inhibition on mammalian cells and could potentially be further optimized for 
antibacterial selectivity. Of note, these experimental results are in agreement with the docking 
predictions for the bacterial selectivity (or lack of) of FabD inhibitors FDi2 and FDi14 (Fig. 
5.1b). 
5.3 DISCUSSION 
Here, from a list of predicted essential enzymes shared among 13 S. aureus strains (Lee, Burd et 
al. 2009) with consistently lethal deletion phenotype in E. coli, we focused on the enzymes of the 
initiation step and elongation cycle of fatty acid biosynthesis (FAS II) as a case study. We 
discovered forty potential inhibitors of E. coli FabD, FabH, FabB/F, FabI, and FabA/Z through 
virtual screening of small-molecule chemical libraries against the enzymes’ active sites, of which 
a small subset both inhibited enzyme activities in-vitro and bacterial cell viability in vivo.  Thus, 
we provide a proof-of-principle demonstration that the predicted single essential enzymes or 
synthetic lethal pairs through metabolic network analysis can be potential “druggable” targets 
(Russ and Lampel 2005).  
The promise of genome projects, functional genomics studies, and network biology in 
providing new molecular targets for pharmaceutical intervention in different disease states are 
now becoming a reality (Schadt, Lamb et al. 2005; Yang, Deignan et al. 2009). This is 
particularly important in the area of infectious diseases where the dual problems of multidrug 
resistance and the scarcity of effective therapy for a large number of diseases are well 
recognized. Although genome-scale gene deletions have been used for antimicrobial drug target 
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identification, this experimental strategy is time consuming and provides only growth condition-
specific results. In some organisms that are hard to cultivate, such as Plasmodium falciparum or 
Mycobacterium tuberculosis, it is technically not feasible. With the large number of sequenced 
genomes of disease causing prokaryotes (bacteria) and eukaryotes (fungi, malaria, trypanosomes, 
etc.), the blueprint we demonstrate here starts from genomic information and combines the 
network biology-based molecular target identification with computational chemistry aided 
virtual screening as well as experimental validation (Figure 5.4), providing novel potential 
targets for antimicrobial drug discovery, thus representing an increasingly attractive alternative. 
This blueprint may be applicable for systematic drug target identification and subsequent lead 
candidate development in any cell type with high quality metabolic reconstruction. 
 
 
Figure 5.4     Blueprint for antimicrobial hit identification 
Genome-scale metabolic network reconstruction and subsequent flux balance analysis identifies those 
reactions that are required for biomass formation under all growth conditions (left panel). The enzymes 
catalyzing the essential reactions are docked against a small molecule library to identify their potential 
small molecule inhibitors (middle panel). The potential inhibitors are then tested experimentally (right 
panel). Reproduced from (Shen and Liu et al., 2010). 
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5.4 MATERIALS AND METHODS 
5.4.1 Identification of essential metabolic reactions in E. coli 
Flux Balance Analysis (FBA) to identify the essential metabolic reactions of E. coli 
MG1655 using its recent metabolic network reconstruction (Feist, Henry et al. 2007) was 
performed as previously described (Lee, Burd et al. 2009). In brief, the reconstructed metabolic 
network and biomass composition of E. coli MG1655 was obtained from its recent 
reconstruction, called iAF1260 (Feist, Henry et al. 2007), that contains 1260 enzymes, 2077 
reactions, and 1039 metabolites. This reconstruction introduces another compartment (periplasm) 
in addition to cytoplasm and extracellular space, and shows the exchange and transport reactions 
among these three compartments accordingly. The reconstructed metabolic network of E. coli 
MG1655 from (Feist, Henry et al. 2007) yields the stoichiometric matrix S with its element Sij 
indicating the stoichiometric coefficient of metabolite i in reaction j. The FBA states that in the 
stationary state, the fluxes {vj} of the metabolic reactions are those which maximize vbiomass 
subject to  
S · v = 0  
v j  ≥ 0              for all irreversible reactions j  
vj  ≤ vmax,j          for all uptake reactions j                     (1) 
where vbiomass indicates the flux of the reaction that produces biomass, acting as a drain of those 
biomass compounds. The biomass generating reaction is given by  
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in which mi is each of the biomass compounds and ci is the coefficient. In calculating the 
unconditionally essential enzymes, first we run the calculation using both biomass compositions 
(wild-type, core) obtained in (1), and then consider only the enzymes that appear to be essential 
in both conditions.  
For the FBA computations, we used ideally rich medium in which all the uptake reactions 
can occur without limitation on their fluxes, since we aim at identifying unconditionally essential 
enzymes, which we define below. The only exception was when the environment of the skin was 
considered. Here, due to the unique antimicrobial properties of the lipids on the skin surface 
(Drake, Brogden et al. 2008) the fatty acid transporters were turned off. 
The FBA is basically a linear programming problem and we performed the analysis using 
the GNU Linear Programming Kit (GLPK). In the framework of the FBA, an enzyme is 
considered to be essential (Feist, Henry et al. 2007; Lee, Burd et al. 2009) in a given 
environment if the constraint  
vj = 0          (2) 
for all reactions j catalyzed by an enzyme leads to zero flux of the biomass generating reaction,  
vbiomass = 0 
In the FBA scheme, the zero flux of the biomass generating reaction is interpreted as no growth 
of the organism. If such inactivation of an enzyme leads to no growth even in an ideally rich 
environment (medium) in which all the uptake reactions are allowed to occur without limitation, 
it would also lead to no growth in any other environment and therefore we identify 
i i
i
c m biomass→∑
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unconditionally essential - essential in all growth conditions - enzymes from the FBA (1) 
combined with (2) and setting all upper limits of uptake reactions to 
vmax,j = ∞            for all uptake reactions j     (3) 
5.4.2 Computational chemistry protocols for hit identification  
Docking & virtual screening 
The lead library of the ZINC database (Irwin and Shoichet 2005), containing 
approximately 106 commercially available small molecules pre-filtered for drug-like properties 
(Teague, Davis et al. 1999), was screened using Glide 4.5 (Friesner, Banks et al. 2004; Friesner, 
Murphy et al. 2006) The crystallographic structures for the enzymes involved in the different 
steps of the bacterial fatty acid pathway were downloaded from the Protein Database (See Table 
S2 for pdb codes of the crystal structures used for virtual screening, as well as the known 
inhibitors for each enzyme). Homology models for E coli FabZ were built where necessary using 
Prime (Zhu, Shirts et al. 2007) with the P. falciparum ortholog (pdb code1z6b) as template. 
Solvent molecules and ligands were removed and Macromodel (Macromodel 2007) atom types 
were assigned. Before the docking calculations, the protein and the ligands were preprocessed 
using the protein preparation and ligprep modules of the Schrodinger 2007 Suite. For the protein 
preparation, grid generation and docking procedures, default Glide settings were used.  
For each protein, the 105 top-ranked structures of the Glide high throughput virtual 
screening were re-docked at the single precision level, saving the 104 top scored molecules. The 
resulting set was further screened using the Glide extra precision scoring algorithm (Glide XP), 
retaining a database of 2,000 molecules. 50 compounds of this database were selected based on 
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structural diversity, poses and scores, significance of the interactions in the active site, and 
further cross-docked using GOLD (Verdonk, Cole et al. 2003). 15 compounds available 
commercially were selected for each protein for a more detailed evaluation of the free energy of 
binding by means of ensemble MM-PBSA calculations. 
 
Molecular dynamics (MD) simulations 
To include protein flexibility into the rescoring of the putative ligands, MD simulations 
were performed for 15 FabD-ligand complexes and 26 FASII enzyme-ligands complexes. The 
SANDER.MPI module in the AMBER 9.0 (Case, Darden et al. 2006) program package was used 
throughout the production simulations as well as for the minimization and equilibration 
protocols. Long-range interactions were handled using the Particle-Mesh-Ewald (PME) 
summation (Essman, Perera et al. 1995). The SHAKE algorithm (Ryckaert, Ciccotti et al. 1977; 
Macromodel 2007) was employed on all atoms covalently bound to a hydrogen atom, allowing 
for an integration time step of 2 fs. Langevin dynamics (Pastor, Brooks et al. 1988) was used to 
control the temperature (300K) using a collision frequency of 1.0 ps-1, with isotropic position 
scaling to maintain the pressure (1 atm). Initial atomic coordinates of each protein-ligand 
complex were taken from the pose derived from Glide XP docking.  The complex was solvated 
in a  periodic box of TIP3P (Jorgensen 1983) water molecules that extended 10Å from the 
protein, and  was neutralized by Na+ counterions using the  LEaP module (Schafmeister, Ross et 
al. 1995; Case, Darden et al. 2006). The ff99 (Cieplak, Caldwell et al. 2001) and GAFF (Wang, 
Wolf et al. 2004) force fields of AMBER 9 (Case, Darden et al. 2006) were used to model the 
systems. Partial charges of the compounds were assigned using the antechamber program in 
AMBER (RESP) (Bayly, Cieplak et al. 1993) (Fox and Kollman 1998) (Pearlman, Case et al. 
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1995), after geometry optimizations at the B3LYP/6-31G* level (Becke and Yarkony 1995).  For 
all MD simulations, 8ns trajectories were computed after minimization and equilibration protein-
compound systems. The trajectories were analyzed using the PTRAJ module of AMBER. 
 
Binding free energy calculations using Ensemble MM-PBSA 
The MM-PBSA approach represents the postprocessing method to evaluate free energies 
of binding, combining molecular mechanical energies with continuum solvent approaches 
(Wang, Morin et al. 2001; Gohlke and Case 2003). It has been demonstrated to significantly 
improve correlation with experimental binding constants (Guimaraes and Cardozo 2008; 
Thompson, Humblet et al. 2008). The PBSA module of Amber 9 has been used in all cases with 
default parameters. Snapshots of the protein, small molecule ligand and complex were extracted 
every 10ps from the last 4ns of each MD trajectory. The electrostatic contribution to the 
solvation free energy was calculated by solving the PB equation in MM-PBSA (Onufriev, 
Bashford et al. 2000). The hydrophobic interaction term was derived from the solvent-accessible-
surface-area-dependent term (Sitkoff, Sharp et al. 1994). The entropy term was neglected, 
assuming that it is similar when similar compounds bind to the same protein, and will not affect 
differences in binding energies. 
5.4.3 In vitro enzyme assays and in vivo toxicity assays 
Materials and reagents 
Malonyl–CoA, CoA, BSA, NADP, NADPH, KDH (porcine heart), α-ketoglutaric acid, 
TPP, Cerulenin, Triclosan, MTT, and IPTG were purchased from Sigma. EDTA, TCEP, and 
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DMSO were obtained from Fluka. DMEM, glutamine, sodium pyruvate, phenol red, pET-151 
vector and E. coli BL21 and Top10 competent cells were obtained from Invitrogen. The agarose 
gel-extraction kit and the plasmid DNA isolation kit were purchased from Qiagen. The FabD 
inhibitors and elongation cycle inhibitors were purchased from ChemBridge, ChemDiv, and 
Ryan Scientific. HisTrap FF columns were obtained from GE Healthcare. Bradford reagents and 
Coomassie blue were purchased from Bio-Rad. 
 
FabD enzyme assay and the screening of potential FabD inhibitors 
Purification of his-FabD and his-holo-ACP: 
E. coli fabD was amplified from the genomic DNA of E. coli MG1655 strain using PCR 
and cloned into the pET151-TOPO vector from Invitrogen. Plasmids, pDSNdeIacpPec and 
pDSNdeIacpSec, containing the coding sequence for E. coli AcpP and AcpS, respectively, were 
generous gifts from Dr. Roland Lange (Actelion Pharmaceuticals Ltd., Switzerland). pET-151-
fabD or pDSNdeacpPEc and pDSNdeIacpSEC were transfected or co-transfected into competent 
E. coli Top10 cells (Invitrogen). E. coli his-FabD and his-holo-ACP were overexpressed in E. 
coli BL21 cells induced with 0.5mM IPTG at 37 °C for 3 hours. Cells were then harvested by 
centrifugation and stored at -80°C. The bacterial cell pellet was resuspended in the lysis buffer 
and disrupted by sonication. After centrifugation, the supernatant was filtered and applied to 
AKTA system (GE Healthcare) using HisTrap FF column. The FabD-containing fractions were 
then pooled, concentrated and equilibrated in the enzyme assay buffer (50mM phosphate buffer, 
pH 6.8, 1mM EDTA, 1mM DTT). The protein concentration of his-FabD and his-holo-ACP was 
determined by Bradford assays. 
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Fluorometric coupled FabD enzyme assay:  
The FabD enzyme assay was performed as described previously (Molnos, Gardiner et al. 
2003) with minor modifications. Briefly, 46 μl 0.06nM his-FabD solution (50mM phosphate 
buffer, pH 6.8, 1mM EDTA, 1mM DTT and 0.1mg/ml BSA) was pre-incubated with 4 μl 10μg/ 
μl of the 15 different predicted FabD small molecule inhibitors or DMSO for 30min at 28 °C. 25 
μl ACP/KDH mix (240μM his-ACP, 8mM α-ketoglutaric acid, 1mM NAD, 60 mU/100 μl KDH 
and 0.8mM TPP) and 25μl Malonyl-CoA solution (100 μM Malonyl-CoA in 50mM phosphate 
buffer, pH 6.8, 1mM EDTA, 1mM DTT) were added to start the reaction. NADH-dependent 
fluorescence was immediately measured for a minimum of 5 min using a microtiter plate reader 
(Beckman Coulter DTX880) equipped with an excitation filter at 340nm (bandwidth 20 nm) and 
an emission filter at 465nm (bandwidth 35 nm). The fluorescence signal was set to an integration 
time of 1s (no lag time) and three flashes per well. The experiments were run at 28°C in 
triplicates. 
 
Fluorometric KDH counter screening assays: 
The KDH assay was performed as follows: 3.75mU KDH was diluted in 75μl 50mM 
phosphate buffer, pH 6.8, 1mM EDTA, 1mM DTT, 2.67mM a-ketoglutaric acid, 0.33mM NAD, 
0.267mM TPP and added to 4μl DMSO (controls) or 10μg/μl inhibitors dissolved in DMSO. A 
60μM CoA solution was prepared in 50mM phosphate buffer, pH 6.8, 1mM EDTA, 1mM DTT. 
All solutions and the microplate reader were pre-warmed at 28°C; 21 μl CoA solution was added 
to start the reactions that were measured immediately over 5 min in triplicates. 
 
Elongation cycle assay and the screening of potential inhibitors  
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We utilized an established elongation assay for type II fatty acid synthesis (Kodali, 
Galgoci et al. 2006) with slight modifications. Briefly, E. coli MG1655 was grown to a 
stationary phase in LB medium. The cultures were centrifuged and the pellets were washed and 
lysed in ice-cold buffer. The supernatant were then precipitated using ammonium sulfate. The 
45%-80% ammonium sulfate saturated protein fraction which contained all the FASII enzymes 
was dialyzed. Subsequently, 2-16μg cell lysate was first incubated with different concentrations 
of inhibitors at 37°C for 20 min in 50μl buffer containing 5mM EDTA, 1mM NADPH, 1mM 
NADH, 5mM β-mercaptoethanol, 150μM DTT, 16μM ACP (pretreated with 3mM ice-cold DTT 
for 20 min), 40μM acetyl-CoA, 4% DMSO, 100mM sodium phosphate (pH 7.0). Then, 120μM 
10μl malonyl-CoA was added into the 50μl solution to initiate the reaction. After 30 minutes 
reaction at 37°C, 60μl of each sample (plus 15μl 5X native sample buffer) were applied to a 16% 
polyacrylamide gel containing 0.5M Urea (to separate intermediate & final products) or 4M Urea 
(to separate different chain lengths of acyl-ACP products). After electrophoresis, the gels were 
stained with Coomassie Blue for visualization. Reactions with no inhibitor (only DMSO) were 
used as negative control. Known FASII elongation cycle inhibitors triclosan (167μg/ml) and 
thiolactomycin (167μg/ml) were used as positive controls. 
 
Bacterial disc inhibition assay 
The disc inhibition assay was performed as described previously (Woods and 
Washington 1995). Briefly, freshly grown E. coli (MG1655 strain and patient strain) and S. 
aureus (Mu50 strain, USA300 strain and patient strain) cultures (OD600=0.3) were evenly 
inoculated onto the surface of LB or LB plus 10% human serum agar plates. Sterile filter discs 
soaked with 10μl of 10mg/ml of the different inhibitors were then applied to the surface of the 
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inoculated plates and incubated for 16-20h at 37 °C. 1mg/ml Ampicillin and 10μl DMSO were 
utilized as positive and negative controls, respectively. 
 
MTT cell viability assay 
Cell viability was determined by 3-[4,5-dimethyl-triazolyl-2]2,5-diphenyl tetrazolium 
bromide (MTT) assay. The human BJ fibroblast cells expressing hTERT (CL1 cells) (Hahn, 
Counter et al. 1999) were seeded in 24-well plates at a density designed to reach 90% confluency 
at the time of assay. The next day, the culture medium was replenished with fresh medium with 
400μg/ml of the potential inhibitors. The same amount of DMSO was used as control. After 24 h 
of inhibitor treatment, MTT was added to a final concentration of 0.5 mg/ml, and the plate was 
incubated for 3 h at 37 °C. Cells having functional mitochondrial succinate dehydrogenase can 
convert MTT to formazan that generates a blue color when dissolved in dimethyl sulfoxide 
(DMSO). The absorbance was read at 540 nm using a plate reader (Beckman DTX880). 
 
Trypan blue exclusion assay 
CL1 cells were seeded at a density of 1×105 cells in 12-well plates and cultured in 
DMEM (25mM glucose, 4mM glutamine) containing 10% FBS at 37°C in an incubator with 5% 
CO2 and 95% air. The next day, the culture medium was replenished with fresh medium with 
400μg/ml of the inhibitors. The same amount of DMSO was used as control. After 24 h of 
inhibitor treatment, the cells were harvested by releasing them with 0.05% trypsin, 0.53mM 
EDTA, stained with trypan blue, and counted. Cell counting data were determined by blinded 
counting of both live (unstained) and dead (blue) cells on a standard grid-patterned 
hemocytometer. The mean number of cells and the standard deviation of the mean were 
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determined and data was then compared using a standard Student’s t test to determine 
statistically significant differences between cell populations. 
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6.0  IDENTIFICATION OF NOVEL BACTERIAL HISTIDINE BIOSYNTHESIS 
INHIBITORS USING DOCKING, ENSEMBLE RESCORING AND WHOLE CELL 
ASSAYS 
6.1 INTRODUCTION 
Although virtual screening has become an established tool for computer aided 
molecular design and frequently reproduces experimentally observed binding poses, there is 
usually no good correlation between docking scores and experimentally observed binding 
constants. Therefore, a significant number of compounds from virtual screens are usually 
selected for experimental confirmation by enzyme assays early in the hit discovery process. 
This requires significant effort in the acquisition and screening of the compounds and 
typically results in varying enrichment factors that depend on the scoring function and the 
enzyme studied. It would therefore be desirable to further refine the scoring to increase 
enrichment and possibly bypass the biochemical assay in favor of whole cell assays. To 
further refine the proposed blueprint in Chapter 5 and improve the accuracy of the virtual 
screening to the point where a whole cell assay is directly utilized to replace the often 
problematic enzyme assay, we select another one of the families of targets identified in these 
studies -- the histidine biosynthesis pathway, an unbranched pathway consisting of 10 
enzymatic reactions with no routes to bypass any of the enzymes (Fig. 6.1) (Alifano, Fani et 
al. 1996).   
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Here, we report the results of a study of inhibitors of the histidine biosynthesis 
pathway, where ensemble rescoring was used to select compounds that were then directly 
tested in whole-cell assays. To demonstrate this novel strategy to identify potential inhibitors 
of the histidine biosynthesis, we chose three enzymes from the pathway as targets for 
antibiotic hit identification based on the availability of crystal structures and established 
biochemical assays: Phosphoribosyl-AMP Cyclohydrolase (HisI) (D’Ordine, Klem et al. 
1999; Sivaraman, Myers et al. 2005), Imidazoleglycerol Phosphate Dehydratase (IGPD) 
(Glynn, Baker et al. 2005), and Histidinol Phosphate Aminotransferase (HisC) (Ames and 
Horecker 1956; Haruyama, Nakai et al. 2001; Sivaraman, Li et al. 2001; Fernandez, Vega et 
al. 2004; Marienhagen, Kennerknecht et al. 2005).  The efficacy of the identified hits will 
then be tested in whole-cell assays. This suggested that the computational predictions can be 
sufficiently accurate to be tested directly in in vivo disk inhibition assays, which would 
accelerate the process.  
6.2 RESULTS 
6.2.1 The histidine biosynthesis pathway in S. aureus 
The first step in the biosynthesis of histidine is catalyzed by the enzyme ATP 
phospho-ribosyltransferase (HisG) and results in the condensation of ATP and 5-
phosphoribosyl 1-pyrophosphate to form N’-5’-phosphoribosyl-ATP. The triphosphate 
group of the product is then hydrolyzed by the enzyme phophoribosyl-ATP 
pyrophosphohydrolase (HisE) to form N’-5’-phosphoribosyl-AMP, and subsequently the 
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purine ring is hydrolyzed by phosphoribosyl-AMP cyclohydrolase (HisI) to form N’-[(5’-
phosphoribosyl)-formimino]-5-aminoimidazole-4 carboxamide-ribonucleotide. In the fourth 
step of the pathway, the product is converted to N’-[(5’-phosphoribulosyl)-formimino]-5-
aminoimidazole-4 carboxamide-ribonucleotide via an Amadori rearrangement. This product 
is then cleaved into imidazole glycerol phosphate (IGP) and 5-aminoimidazole-4-
carboxamide 1-beta-D ribofuranosyl 5’-monophosphate (AICAR). The first of these is used 
in the further synthesis of histidine, while the latter is used in the de novo synthesis of 
purine. In the sixth step of the pathway IGP is dehydrated by imidazole glycerole phosphate 
dehydratase (IGPD). This gives the product imidazole acetol phosphate, which in the 
seventh step of the biosynthesis is transaminated by the enzyme histidinol phosphate 
aminotransferase (HisC) to give L-histidinol phosphate. This product is then converted into 
L-histidinol, which is oxidized to L-histidine in two steps via the L-histidinal intermediate 
by a single enzyme (HisD). 
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Figure 6.1  Histidine biosynthesis pathway. Reproduced with permission from 
(Henriksen, Liu et al., 2010). 
 
Based on our analyses of the metabolic network of thirteen S. aureus strains by flux 
balance analysis,(Lee, Burd et al. 2009)  inhibition of a single enzyme of the pathway is 
expected to stop the production of histidine, an essential biomass component.  
Evolutionarily, the pathway is highly conserved among different bacterial species, which 
makes the pathway a potential target for the treatment of bacterial infections other than 
caused by S. aureus. The histidine pathway has been extensively studied in the past, and 
these studies have contributed to the development of the operon theory of gene clustering 
and function.(Alifano, Fani et al. 1996) More recently, the histidine biosynthesis in plants 
has received a lot of attention due to its vital role for plant growth.(Stepansky and Leustek 
2006) Particularly the sixth enzyme of the pathway, IGPD, has been used as a target for the 
design of herbicides (Mori, Iwasaki et al. 1995; Cox, Hawkes et al. 1997; Ohta, Mori et al. 
1997; Gohda, Kimura et al. 1998; Schweitzer, Loida et al. 1999; Gohda, Mori et al. 2000; 
Schweitzer, Loida et al. 2002). 
6.2.2 Identification of inhibitor scaffolds through computational chemistry  
Phosphoribosyl-AMP Cyclohydrolase (HisI) (EC 3.5.4.19) catalyzes the third step 
of the histidine biosynthetic pathway, the hydrolysis of phosphoribosyl-AMP (Fig. 6.1). The 
crystal structure of HisI for S. aureus has not yet been determined, but the structure of HisI 
from Methanobacterium thermoautotrophicum (PDB ID: 1zps), which has a 51% homology 
to HisI from S. aureus, has been solved to a resolution of 1.70 Å.  We have built a homology 
model of the S. aureus MRSA252 enzyme and compared it to the structure of the M. 
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thermoautotrophicum enzyme to validate its use in the docking experiments. HisI is a 
homodimeric metalloenzyme dependent on both Zn2+ and Mg2+. Two pairs of metal ions are 
bound on the interface between the two subunits, and make up two active sites, each 
containing one zinc and one magnesium ion, respectively. EDTA inhibits the enzyme by 
chelation of Mg2+, and exogenous Zn2+ also reduces enzyme function, but no small molecule 
inhibitors of this enzyme have previously been reported.  
Application of the virtual screening procedure to the lead library from ZINC yielded 
12 small molecules that have good poses in both the docking and the subsequent MD 
simulations. Six of these molecules, shown in Table 6.1 together with their G-scores from 
Glide XP as well as predicted binding energies from MM-PBSA and MM-GBSA 
calculations, were selected based on their structural diversity. It should be noted that the 
absolute binding energies calculated by either method are not meaningful (Thompson, 
Humblet et al. 2008). Unfortunately, no known inhibitors are available for referencing the 
values and that the scores can only be used for a relative ranking of the compounds.  
Figure 6.2 shows two representative examples of the binding modes observed after 8 
ns MD simulation (for representations of other poses, see the Supporting Information). The 
HisI active site is solvent exposed and contains a zinc and a magnesium ion, which explains 
the high abundance of carboxylate derivatives among the docking hits. Inhibitor HisI2 is a 
typical case for the bidentate coordination of the zinc ion by the carboxylate group. This 
zinc coordination is always preferred over the coordination of the magnesium ion (only one 
of the selected docking poses, HisI10, showed the carboxylate group coordinating to both 
metal ions). The magnesium ion is surrounded by three aspartate residues from one side and 
a hydrophobic pocket consisting of the residues Ile25, Ile25’, Val27, Val27’, Leu37, Leu37’, 
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Val39, Val39’, Tyr41 and Tyr41’ from both subunits (shown as four blue colored β-sheets 
in Figure 6.2). Several docking poses place a hydrophobic group pointing into this pocket 
(HisI2, 3, 4, 6, and 8), and most of these allow a cation-π interaction with the magnesium 
ion and an aromatic moiety.  
Table 6.1: Selected Inhibitors for HisI 
ID Structure 
G-score 
kcal/mol 
MM-
PBSA 
kcal/mol 
MM-
GBSA 
kcal/mol 
HisI1 
 
-15.23 -55.73 -22.50 
HisI2 
 
-14.44 -60.15 -29.58 
HisI4 
 
 
-14.08 
 
 
-60.16 
 
 
-25.46 
HisI8 
 
-13.80 -22.33 -22.28 
HisI9 
 
-13.69 -35.48 -30.28 
HisI11 
 
-13.42 -45.83 -19.40 
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Figure 6.2     Active site of homology model of S. aureus with HisI2 (left) and HisI9 
(right) in the active site after 8ns MD. Reproduced with permission from (Henriksen, 
Liu et al., 2010). 
 
Imidazoleglycerol Phosphate Dehydratase IGPD (EC 4.2.1.19) catalyzes the 
dehydration of imidazoleglycerol phosphate to imidazoleacetol phosphate, which is the sixth 
step of histidine biosynthesis (Fig. 6.1). A crystal structure of the S. aureus N315 IGPD with 
a resolution of 2.01 Å (PDB ID: 2ae8) is available. However, many moieties close to the 
active site are not resolved, making this structure unsuitable for virtual screening 
approaches. We have therefore chosen the well characterized Aridopsis thaliana IGPD 
(PDB ID: 2f1d, 42% homology) to build a homology model of the S. aureus MRSA252 
IGPD. IGPD is a manganese dependent metalloenzyme consisting of 24 identical subunits. 
Each active site consists of three subunits and two manganese ions. Each manganese ion is 
coordinated by a glutamate and three histidine residues from two different subunits (Mn2+1: 
His47A, His169A, Glu173A, and His74B; Mn2+2: His170A, His73B, Glu77B, and 
His145B). The IGPD enzyme has been used as target for the development of herbicides, and 
several inhibitors of this enzyme are known from these efforts (Mori, Iwasaki et al. 1995; 
Cox, Hawkes et al. 1997; Ohta, Mori et al. 1997; Gohda, Kimura et al. 1998; Schweitzer, 
Loida et al. 1999; Gohda, Mori et al. 2000; Schweitzer, Loida et al. 2002). The known 
inhibitors resemble the natural substrate imidazole-glycerol phosphate (IGP). They typically 
contain a phosphonate group instead of the phosphate group present in IGP, a triazole group 
instead of imidazole, and a number of hydroxy groups.  
The selected potential IGPD inhibitors and their G-scores are listed in Table 6.2. It is 
evident that the MM-PBSA and MM-GBSA scores obtained for all inhibitors as well as for 
the known inhibitors (data not shown) are relatively unfavorable. This might be a 
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consequence of an underestimation of binding to the manganese ions, possibly due to the 
Mn2+ parameters employed for the MM-PBSA/GBSA calculations (see the Supporting 
Information for further details).  Structurally, there is a high abundance of carboxylate 
derivatives among the best docking hits. In the majority of these, the carboxylate group is 
placed between the two manganese ions coordinating both of them. The key interactions are 
exemplified by the structures of IGPD13, 14, 17, and 18 in the IGPD active site after 4ns of 
MD simulation shown in Figure 6.3.  
Most of the potential inhibitors interact with Asp69, either forming a salt bridge 
through an ammonium group like in the case of IGPD1, 2, and 5 or by hydrogen bond 
donating, either through a hydroxy group (IGPD6, 8, 10, 11, 12, 14, and 16) or a NH 
functionality (IGPD17 and 18), as shown in Figure 3 b-d. In accordance with the negatively 
charged substrate, the active site is highly positively charged with the presence of three 
arginines (Arg8 and Arg295, with an additional arginine residue Arg268 in the periphery of 
the active site) and Lys534. As a result, all selected potential inhibitors posses a negative 
charge, either as a carboxylate or a sulfonate. The sole exception, IGPD13, has an acidic 
phenol hydroxyl group that is likely deprotonated upon binding to the manganese, as shown 
in Figure 6.3a. Five of the selected poses interact with Lys534 (IGPD3, 5, 9, 10, and 18), 
and four interact with Glu12 (IGPD2, 6, 13, and 18). The rest of the active site pocket is 
filled out by aromatic groups stacking against the α-helix forming one wall of the active site 
(IGPD13, 17 and 18) or the β-sheet forming the other (IGPD14). As mentioned before, all 
known inhibitors of the IGPD enzyme are small, polar compounds. We have therefore 
chosen fewer hits containing large, hydrophobic groups and more relatively small, polar 
compounds for further evaluation than is actually representative of the abundance with 
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which they appear among the docking hits (e.g., IGPD2, 3, 5, and 6). We have also included 
two sulfonate derivatives (IGPD7 and 17) in the compound set to be evaluated 
experimentally, since a sulfonate group is a better bioisostere for the phosphonate group 
than the carboxylate group.  
Table 6.2: Selected Inhibitors of IGPD 
ID Structure 
G-score 
kcal/mol 
MM-
PBSA 
kcal/mol 
MM-
GBSA 
kcal/mol 
 
IGPD1 
  
 
 
-8.61 
 
 
-17.22 
 
 
-36.66 
IGPD6 
 
 
-8.05 12.28 -1.75 
IGPD10 
 
-7.78 -5.53 -24.67 
 
IGPD13 
 
-7.70 
 
-1.30 
 
 
-20.34 
 
IGPD14 
 
-7.68 
 
-0.30 
 
 
-20.53 
 
 
IGPD16 
 
-7.62 10.30 -13.25 
IGPD17 
 
-7.32 5.21 -12.98 
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Figure 6.3     Structures of potential inhibitors a) IGPD13, b) IGPD14, c) IGPD17, 
and d) IGPD18 bound to IGPD active site from 4 ns MD simulations. Reproduced with 
permission from (Henriksen, Liu et al., 2010). 
 
Histidinol Phosphate Aminotransferase (HisC). The seventh step of the histidine 
biosynthesis in eubacteria is the transamination between imidazoleacetol phosphate and 
glutamate to form L-histidinol phosphate (LHP) and α-ketoglutarate (Fig. 6.1), which is 
catalyzed by the enzyme HisC (EC 2.6.1.9). HisC uses the cofactor pyridoxal-5’-phosphate 
(PLP) to transfer the amino group from glutamate, forming pyridoxamine-5’-phosphate 
(PMP) that is subsequently transferred to the substrate. Except for the metal ions Cu2+ and 
Co2+ and hydroxyl amine, iodoacetate and semicarbazide, no HisC inhibitors are currently 
known. In our docking calculations, we have used the crystal structure of HisC complexed 
with PMP from E. coli (PDB ID: 1fg7, 29% homology), which has been solved to a 
resolution of 1.5 Å .(Sivaraman, Li et al. 2001) HisC from S. aureus MRSA252 has a high 
sequence similarity with its E. coli ortholog, making the latter a suitable model. One 
important difference is that the E. coli residue Tyr110 is substituted to a Phe in the S. aureus 
ortholog. Although the active enzyme functions as a homodimer, all relevant residues are 
contained in the monomer that was used in the docking calculations. In the crystal structure, 
the phosphate group of PMP forms a salt bridge with Arg222 and hydrogen bonds to 
Thr211, Ser213, and to the backbone amide groups of Ala84 and Asp85. The amino group 
forms a hydrogen bond to Lys214 and the hydroxy group hydrogen bonds to Tyr187 and 
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Asn157. Asp184 forms a salt bridge with the protonated pyridinium nitrogen and Tyr110 
interacts with the pyridinium ring via π-stacking. The substrate, LHP, is known to form 
hydrogen bonds to Tyr20 and Asn157 and salt bridges to Arg322 and Arg335 via its 
phosphate group. Furthermore, the LHP imidazole ring forms hydrogen bonds to the 
residues Tyr20, Asp85, and Tyr110 in the E. coli HisC.22 Based on the sequence alignment 
MRSA252 HisC cannot form the latter hydrogen bond. 
Table 6.3: Selected Inhibitors of HisC 
 
 
The docking hits for the HisC enzyme are shown in Table 6.3 and are again 
negatively charged or polar compounds for the same reasons as discussed for IGPD. The 
ID Structure 
G-score 
kcal/mol 
MM-
PBSA 
kcal/mol 
MM-
GBSA 
kcal/mol 
HisC5 
 
-15.02 -40.92 -49.55 
HisC9 
 
-14.50 -38.74 -43.95 
 
HisC11 
 
-14.25 -28.80 -35.94 
HisC14 
 
-13.84 -12.95 -35.13 
HisC16 
 
-13.70 -29.43 -37.33 
HisC19 
 
-13.53 -13.80 -26.48 
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affinity of carboxylate derivatives to the HisC enzyme can be ascribed to the phosphate 
binding site of the PMP cofactor (Arg222, Thr209, and Ser211) and to the residues Asn157 
and Arg335 which are part of the phosphate binding site of the substrate LHP. In all the 
docking hits that are carboxylate derivatives, the carboxylate functionality binds to either of 
the two phosphate binding sites. 
The two main binding modes where the carboxylate group occupies the PMP 
phosphate binding site and its pyridine ring interacting with the LHP binding site and where 
the carboxylate group binds to the LHP phosphate binding site are exemplified by the 
calculated docking poses of HisC5 and HisC9 and are shown in Figure 6.4a and b, 
respectively. Other structures that do not contain a carboxylate functionality have other polar 
groups that follow the same motifs and bind to at least one of the phosphate binding sites, as 
for example the azepine moiety of HisC14 shown in Figure 6.4c. Other key interactions 
include π-stacking with Tyr110 and hydrogen bonding or salt bridges with Lys214 and 
Asp184, respectively.  Overall, the calculated binding energies, shown in Table 12, are 
strongly favorable, but the lack of known inhibitors prevents the referencing to experimental 
data and allows only a relative ranking of the compounds.  
Several hits with good G-scores contain two carboxylate groups, which would seem 
favorable, since both phosphate binding sites then can interact with a carboxylate group. 
This is demonstrated in Figure 6.4d, which shows the docking pose of HisC19 where both 
carboxylate groups interact with the two phosphate binding sites of PMP and LHP. 
However, since the active site is buried deep within the enzyme, the cost of desolvation of 
these bis-anions is likely to decrease the binding of very polar ligands, as is indicated by the 
much lower binding energies calculated by MM-PBSA and MM-GBSA. We therefore 
  116 
selected only HisC19 as one example of this class of compounds for further experimental 
evaluation. Instead, we have chosen several structures where other polar groups are able to 
interact with the second phosphate binding site, e.g. the pyridine group of HisC5 and the 
amide group of HisC9 (Figure  6.4a, b, respectively). 
 
Figure 6.4     Structures of potential inhibitors  
a) HicC5, b) HisC9, c) HisC14, and d) HisC19, bound to HisC active site from 8 ns MD 
simulations. Reproduced with permission from (Henriksen, Liu et al., 2010). 
6.2.3 Biological validation of potential inhibitors of the histidine pathway 
A recent study of inhibitors of the FASII biosynthetic pathway (Shen, Liu et al. 
2010) demonstrated that 42% of the  inhibitors predicted to be good binders by the MM-
PBSA ensemble rescoring method were subsequently confirmed experimentally in enzyme- 
and whole cell assays. These results encouraged us to use a disk inhibition assay as a 
primary screen for the computationally predicted compounds. Although this approach can 
potentially yield both false positive results due to inhibition of targets other than the 
computational predicted ones and false negative results due to limited transport across the 
cell membrane, the simplicity of the assay and the fact that the results are more relevant for 
the ultimate goal of bacterial growth inhibition made this approach attractive.  
We therefore selected several representative structures with good calculated MM-
PBSA binding energies, structural features representative of the diversity of the larger 
dataset, and reasonable interactions to the active site of the respective enzymes to be tested 
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in disk inhibition assays. The goal of the selection was to identify the maximum number of 
active compounds with the minimum size of the total dataset. Of the potential HisI 
inhibitors, we selected HisI1, 2, 4, 8, 9, and 11 to be biologically tested. These compounds 
have been selected due to good calculated binding energies, and because they represent both 
of the two different binding modes discussed above. For IGPD, we have included the 
potential inhibitors IGPD1, 6, 10, 13, 14, 16, and 17. For HisC, we chose the potential 
inhibitors HisC9, 11, 14, 16, and 19 for biological evaluation. These 18 compounds were 
obtained commercially and tested in a standard bacterial growth assay(Woods and 
Washington 1995) in two MRSA strains (Mu50 and USA300) as well as a random patient 
isolate from the University of Pittsburgh Medical Center. As example of a gram-negative 
bacterium, we also tested the E. coli MG1655 strain and an E. coli random patient isolate. 1 
mg/ml Ampicillin and 10 µl DMSO were used as positive and negative controls, 
respectively. Figure 6.5 shows some representative plates for t E. coli and S. aureus strains 
and the results for active compounds are summarized in Table 6.4.  
 
Figure 6.5    Bacterial disc inhibition assays and human fibroblast toxicity assay.  
The inhibitory effect of selected small molecules against a./ E. coli MG1655 strain, b./ S. aureus 
Mu50 strain. Reproduced with permission from (Henriksen, Liu et al., 2010). 
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Table 6.4: Summary of results of growth inhibition and toxicity assays for 18 selected small 
molecules  
ID S. aureus 
patient 
strain 
S. aureus  
Mu50 
S. aureus 
USA300 
E. coli  
patient 
strain 
E. coli 
1655 
MTT 
activity 
Trypan 
blue 
HisI1 - ±/- - - + N.D. N.D. 
HisI2 + + + + + - - 
HisI4 + + - ± ± ± ± 
HisI8 - + ± - + N.D. N.D. 
HisI9 + +/± - - - N.D. N.D. 
HisI11 ± ± - ± + ± - 
IGPD1 +++ + +++ ± ± ± - 
IGPD6 + + + ± + ± + 
IGPD10 - - - - - N.D. N.D. 
IGPD13 ++ ++ ++ +/- + ± + 
IGPD14 - - - - - N.D. N.D. 
IGPD16 - + - + + N.D. N.D. 
IGPD17 - - - - ± N.D. N.D. 
HisC9 ± ± ± ± + N.D. N.D. 
HisC11 - - - - - N.D. N.D. 
HisC14 ± + +/± +/- + ± ± 
HisC16 + +/± - + ± N.D. N.D. 
HisC19 - - - - ± N.D. N.D. 
Amp +++ + + +++ + ± - 
DMSO - - - - - - - 
Summary of bacterial disk inhibition and human fibroblast toxicity assay results. +: weak 
inhibition; ++: weak inhibition plus zone of partial inhibition; +++: strong inhibition; ±: partial 
inhibition; -: no inhibition; N.D. not determined. Reproduced with permission from (Henriksen, 
Liu et al., 2010). 
 
Out of 18 tested compounds 10 compounds have different levels of activity against 
the S. aureus patient strain, 13 against S. aureus Mu50, and 7 against S. aureus USA300 as 
shown in Table 6.4. Especially encouraging is the fact that several of the compounds show 
significant activity towards the drug resistant strains of S. aureus, Mu50 and USA300 that 
show only weak susceptibility towards the well-established antibiotic ampicillin.  
It is interesting to note that of the six tested HisI ligands, HisI1 and HisI9 were 
predicted to bind in a different orientation than the rest. These two ligands show the least 
activity of the potential HisI inhibitors in the disc inhibition assay, which suggests that their 
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mode of binding is not favorable. The compound HisI8 seems to be the third least active 
compound, which is in accordance with a lower calculated binding energy for this ligand 
than for the rest. 
Out of the seven tested IGPD ligands, three show activity. This is the small polar 
compound IGPD6, the compound with a pyridinol group instead of a carboxylate group 
(IGPD13) and the carbazolyl derivative IGPD1. It is noteworthy that while IGPD1 shows 
strong inhibition of two S. aureus strains, the very similar compound IGPD14 shows no 
inhibitory effect at all. Glide does rank IGPD1 higher than IGPD14, but both poses are given 
high G-scores. However, MD and MM-PBSA/GBSA calculations are able to identify 
IGPD14 as a false positive. Two especially promising compounds are IGPD1 and IGPD13. 
The first shows strong inhibition against the S. aureus patient strain and the USA300 strain 
and it shows weak inhibition against the Mu50 strain. The second shows a clear zone of 
growth inhibition plus partial inhibition of the S. aureus strains Mu50 and USA300 
respectively, and a weak inhibition of growth in the patient strain.  
Three out of the five tested potential HisC ligands show an inhibitory effect. These 
three ligands all interact with one of the phosphate binding sites and with Tyr110, indicating 
the importance of these interactions for inhibitory activity on this enzyme. The positive 
results for HisC14 indicates that other groups than carboxylate can interact with the 
phosphate binding sites of this enzyme. The lack of activity of the dicarboxylate HisC19 
might be a consequence of too high a desolvation cost for binding of this very polar 
compound to the deeply buried HisC active site pocket. It might also be due to HisC19 being 
too polar to effectively penetrate the cell wall. 
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Activity against E. coli is generally much lower, which is possibly a result of both 
the selection of the compounds towards the S. aureus orthologs of the three enzymes studied 
as well as the different properties of the cell wall in gram negative bacteria, which could 
make it difficult for the mostly negatively charged inhibitors to pass the outer membrane. 
Nevertheless, 14 compounds were found to be weakly active or give partial inhibition for the 
E. coli 1655 strain.  
To check the computational prediction that the small molecules exert their effect 
through binding the the enzymes in the histidine biosynthesis pathway, we performed a 
complementation assay where the bacteria were grown on minimal medium agar plates, 
where the effect of the potential inhibitors is very similar to the LB plates. Upon addition to 
0.2mM L-histidine, five of ten inhibitors selected showed complete complementation of 
growth of the S. aureus, while the other five showed partial complementation in at least one 
of the strains tested. These results are consistent with the hypothesis that the small molecules 
indeed inhibit whole cell growth through interference with the histidine biosynthesis.    
Finally, we tested the toxicity of seven of the more active potential inhibitors in 
mammalian cells for off-target effects using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) cell viability and trypan blue exclusion assays. For this purpose, 
we used normal BJ foreskin fibroblast cells immortalized by hTERT, the catalytic subunit of 
human telomerase.(Hahn, Counter et al. 1999) The results of these studies are summarized 
in Table 4. Again, IGPD1 is the most promising compound for further development, since it 
has slightly lower human cell toxicity than the known antibiotic ampicillin. In comparison, 
the second best inhibitor, IGPD13, is significantly more cytotoxic (according to the trypan 
blue exclusion assay). Overall, the human cell toxicity of the selected compounds in these 
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assays is fairly limited; indicating that off-target activity of the selected compounds is 
relatively low. 
6.3 CONCLUSIONS 
The development of novel compounds with antibiotic activity is a pressing need in 
view of the rapidly expanding resistance of pathogens towards known antibiotics. In the 
ongoing race between drug development and new resistance, not only new compounds but 
more importantly, new methods for the discovery of new hits are needed. In the present 
study, the application of virtual screening and MM-PBSA ensemble rescoring to three 
enzymes in the histidine biosynthetic pathway, which was predicted to be essential for 
growth of S. aureus by systems-level approaches (Lee, Burd et al. 2009), yielded 49 
potential inhibitors. Based on structural diversity and physicochemical properties, 18 
compounds were selected for experimental tests in a whole cell growth inhibition assay. We 
found 13 and 14 compounds to be active in different strains of S. aureus and E. coli, 
respectively. Although the observed growth inhibitions are in many cases weak or only 
partial, two compounds (IGPD1 and IGPD13) show very promising activity comparable to 
the effects of the well-known antibiotic ampicillin. 
Several conclusions can be drawn from these studies. First, the scalable and fast 
computer-based methods of flux balance analysis and virtual screening used for target and 
hit identification, respectively, is an effective strategy for the early stages of antibiotic drug 
discovery. Secondly, refinement of the docking results by ensemble rescoring together with 
judicious compound selection leads at least in the examples present here and in our earlier 
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studies (Shen, Liu et al. 2010) to excellent hit rates and justifies the immediate use of cell-
based assays, which in many respects have a higher information content for drug discovery. 
Thirdly, at least two of the compounds disclosed here merit further development as 
inhibitors of the histidine biosynthesis pathway that is unconditionally essential for growth 
in S. aureus even though the possibility of transport of histidine or one of the relevant 
biosynthetic intermediates from external sources has to be, in analogy to studies of the 
FASII pathway,(Brinster, Lamberet et al. 2009) investigated in future studies.   
6.4 MATERIALS AND METHODS 
Computational methods Homology models of the S. aureus enzymes were built in 
Prime(2007) using comparative modeling using the template structures discussed in the text. 
The docking experiments were performed in Glide (Friesner, Banks et al. 2004; Friesner, 
Murphy et al. 2006), and using the “Lead” subset of the ZINC database (Irwin and Shoichet 
2005) of commercially available compounds. This subset was obtained from the complete 
dataset by applying filters(Teague, Davis et al. 1999) to have good drug potential, resulting 
in ~106 small molecules docked to the enzyme of interest using Glide’s high throughput 
mode. The highest scoring 100,000 hits were saved and docked to the enzyme again, this 
time using Glide’s standard precision mode. The highest scoring 10,000 hits were then 
saved, and docked to the enzyme using the extra precision mode. The highest scoring 2,000 
hits were saved, and by manual inspection we selected a small number of potential inhibitors 
representative of the chemical space covered by the best scored docking hits for ensemble 
rescoring. In this procedure, side chain flexibility is introduced through 8 ns MD 
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simulations, allowing the active site residues to move, and to test how these movements 
affect the binding mode of the ligand. Desolvation and hydrophobic effects are included 
through MM-PBSA/GBSA calculations of the binding energy on snapshots extracted from 
the last 4 ns of the MD run. These scores were then used to select compounds for 
experimental testing.  
 
Experimental protocols For the experiments two E. coli (MG1655 and a random 
patient isolate) and three S. aureus (MU50, USA300 and a random patient isolate) and one 
P. ariginosa (PA01) strains were used. The propagation of bacteria and their experimental 
manipulation were performed as previously described (Shen, Liu et al. 2010). In brief, sterile 
filter discs soaked with 10μl of 10mg/ml of the different inhibitors were applied to the 
surface of the evenly-inoculated LB plates, minimal medium agar plates, or minimal 
medium agar plates complemented by 0.2mM L-histidine and incubated for 16-20h at 37 °C. 
10μl 1mg/ml Ampicillin and DMSO were utilized as positive and negative controls, 
respectively. To test for potential human cell toxicity, human foreskin fibroblast cells were 
treated with 100 µg/ml of selected compounds or DMSO and their cell viabilities were 
determined by MTT (3-[4,5-dimethyl-triazolyl-2]2,5-diphenyl tetrazolium bromide) 
viability assay and  trypan blue exclusion assay, as previously described (Shen, Liu et al. 
2010).  
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7.0  CONCLUSIONS 
The main goal of our studies was to utilize a metabolic network analysis approach to understand 
and, ultimately pharmacologically target, cancer metabolism. I have shown that our approach, 
incorporating the additional biophysical constraint Molecular Crowding (MC) to metabolic 
modeling, was able to capture the main characteristics of the distinct cancer metabolism (Fig. 
3.1), indicating that MC can potentially contribute to the Warburg effect.  
Consistent with our theoretical work, I found experimentally that faster growing cells 
exhibit higher glycolytic activities than slower growing cells, even though they contain similar 
level of oncogenic Ras and tumorigenic potentials (Fig. 3.7-10). These results are consistent with 
what others have found using the same or similar model systems (Ramanathan A 2005; de Groof, 
Lindert et al. 2009). Not only in this fibroblast system, but also in primary lymphocytes (Wang, 
Marquardt et al. 1976) and thymocytes (Brand and Hermfisse 1997) it has been reported that 
glycolysis is tightly bound to proliferation. More interestingly, similar to S. cerevisiae (Tu, 
Kudlicki et al. 2005) the burst of glycolysis is coordinated in a cyclic fashion and coincides with 
the synthesis of cellular DNA in S phase in lymphocytes (Wang, Marquardt et al. 1976) possibly 
because the anaphase-promoting complex/cyclosome-Cdh1 (APC/C-Cdh1), a master regulator of 
G1-S transition inhibits glycolysis in proliferating lymphocytes by mediating the ubuquitinating 
two key metabolic enzymes for proteasomal degradation (Almeida et al. 2010, Colombo et al., 
2010, Najafov and Alessi, 2010). Moreover, it has been shown that the accumulation of 
mitochondrial membranes, mitochondrial DNA and several mitochondrial proteins of the 
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respiratory chain also happens in S phase (Martinez-Diez, Santamaria et al. 2006). Thus, I 
speculate that MC may happen in S phase of fast proliferating cells to promote glycolysis and 
decrease mitochondrial respiration in order to achieve high ATP production rate while avoiding 
oxidative stress (Brand 1997) probably due to proteasome regulation. To validate this possibility, 
future experiments that simultaneously measure cell mass, density and volume during the cell 
cycle of single mammalian cells (Bryan et al. 2010; Godin et al. 2010) will shed lights on the 
direct involvement of MC during cell cycles and in cell metabolism regulation. It is also 
interesting to study the effect of MC on the cell proliferation related pathways and proteins, as 
well as proteasome activities to better understand how MC is executed and interacted with those 
signaling pathways. 
All in all, this finding added a biophysical constraint, MC, to the previous proposed 
causes of the Warburg effect, that are  permanent mitochondrial defects (Warburg 1956), 
hypoxic adaptation during carcinogenesis (Helmlinger, Yuan et al. 1997; Gatenby and Gillies 
2004), and/or oncogenic alterations as well as metabolic enzyme mutations (Semenza 2009; 
Feng and Levine 2010; Locasale and Cantley 2010). Besides, this study helped explain why 
primary proliferating mammalian cells also utilize glycolysis pathway in the normoxic 
conditions. 
It has been proposed that the Warburg effect may represent a unique target for cancer 
therapy (Kroemer and Pouyssegur 2008). However, our work suggests that the Warburg effect 
itself may be not an effective target for cancer therapy. Yet, it cannot be ruled out that individual 
tumor specific isozymes (Christofk, Vander Heiden et al. 2008) or different essential enzymes or 
lethal pairs can be identified by comparing the metabolic networks of cancer cells with normal 
cells. The reliable identification of enzyme targets within metabolic networks requires the 
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completely reconstructed high quality human metabolic networks to be cell type specific, which 
is not yet attainable. Therefore, to provide a proof-of-concept we instead investigated this 
potential in the single cell pathogen, Staphylococcus aureus, where the metabolic network of the 
strain N315 has been reliably reconstructed (Becker and Palsson 2005; Heinemann, Kummel et 
al. 2005). 
Different S. aureus strains exhibit different pathogenesis, antibiotic susceptibility, 
virulence possibly due to their different genome sequences. In Chapter 4, we demonstrated that 
each of the examined 13 multidrug-resistant and sensitive S. aureus maintained a different set of 
unconditionally essential metabolic enzymes and synthetic lethal pairs. There are however 44 
single enzymes and 10 lethal pairs common to all 13 S. aureus strains (Fig. 4.2). Therefore, to 
identify targets specific for S. aureus, metabolic reconstructions and in silico analyses of 
multiple strains of the same bacterial species are needed. In addition, we demonstrated that 
enzymes of the Fatty Acid Synthesis pathway (Chapter 5) and Histidine synthesis pathway 
(Chapter 6), which were among the predicted common single essential enzymes, were indeed 
essential and druggable, since we have been able to identify small inhibitors against them that  
kill S. aureus but not mammalian cells. Drug validation processes are always time-consuming 
and involve complicated in vitro enzyme assays. In Chapter 6, I have shown that whole-cell 
assays can be directly utilized for validation after identifying potential small inhibitors through 
virtual screening. Thus, the blueprint we presented in Chapter 5, together with the fast 
experimental improvement in Chapter 6, provided a proof-of-principle demonstration that the 
metabolic network analysis approach can be an attractive alternative to identify potential 
“druggable” targets (Russ and Lampel 2005).  
  128 
This blueprint may be applicable for systematic drug target identification and subsequent 
lead candidate development in any cell type with high quality metabolic reconstruction, 
including cancer cells. More importantly, the notion of multiple metabolic networks comparison 
may be beneficial to identify generic targets against, e.g., different types of lung cancer or 
various species of Gram-positive or –negative bacteria, to simplify the treatment themes. By 
studying the metabolic networks with different drug resistant profiles, the predictions may help 
understand the mechanisms of drug resistance and further facilitate the route to target both drug 
sensitive and drug resistant metabolisms. When metabolic networks are available in a systematic 
fashion, the metabolic network analysis may be even capable to predict both the positive and 
negative effects of a given drug interruption at a specific metabolic state, thus defining the 
optimal metabolic state to maximize the positive effects while minimizing the side effects.  
From a more general perspective, a key aim of network medicine is to reconstitute the 
physiological network states of cells (e.g., from cancer cell metabolism to normal cell 
metabolism) in a systematic and computable fashion (Pawson and Linding 2008). In the case of 
microbial infections, however, this entails the drug therapy-induced alteration of network states 
that are deleterious to the infectious organism, including its ability to synthesize biomass 
constituents or virulence factors, or to the function of its key cellular constituents (e.g., the 
ribosome) (Fig. 7.1a). The blueprint we demonstrate here combines genomic information and 
network biology-based strain-specific molecular target identification (Fig. 7.1b, left panel) with 
computational ranking of ~106 small molecules to identify potential antimicrobial scaffolds 
against the identified target enzymes (Fig. 7.1b, right panel). In turn, these define the chemical 
subspace for organism- or strain-specific lead development using traditional or structure-based 
methods of medicinal chemistry. This strategy could easily be extended to other pathways found 
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to be essential for bacteria, such as those regulating the generation of reactive oxygen 
intermediates that can potentiate the activity of individual antibiotic compounds (Kohanski, 
Dwyer et al. 2007; Kohanski, Dwyer et al. 2008; Dwyer, Kohanski et al. 2009).  
 
 
Figure 7. 1 Approach to network-based therapy, including strain-specific - antiinfective 
therapy. 
a. For most diseases the aim of network medicine is to reestablish a physiological network state in a 
personalized fashion by affecting a ranked list of molecular targets, but for anti-microbial therapy the aim 
is just the opposite;  
b. For each pathogenic bacteria strain the list of essential enzymes in a given strain can be calculated (left 
panel). In turn, for each target enzyme an experimentally validated small molecule hit that inhibits a given 
strain/essential enzyme combination defines the chemical subspace for subsequent compound 
optimization (right panel). In principle, a similar approach can be devised for all human diseases for 
which a molecular target list has been calculated and verified.   Reproduced from (Shen and Liu et al. 
2010). 
 
 
While the work presented here provided encouraging results on the potential of systems-
level analysis of metabolic networks in understanding cancer metabolism and facilitating 
antimicrobial drug discovery, there is still a significant amount of work to be done to specifically 
target cancer metabolism. First, the detailed mechanisms of how MC exerts its impact on cell 
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metabolism remain elusive. As MC can promote the stability of protein, DNA and RNA 
structures (Miyoshi and Sugimoto 2008; Zhou, Rivas et al. 2008; Dong, Qin et al. 2010), it is 
likely that the expression as well as the conformation of glycolytic enzymes are improved to 
convey higher reaction activities. Another possibility is through cell volume regulation, as MC is 
proposed to be a cell volume sensor (Lajvardi, Summers et al. 1996; Burg 2000; Al-Habori 
2001), possibly due to its capability to increase the biochemical reaction activity of single 
macromolecules (Minton 2006; Zhou, Rivas et al. 2008). For example, cell swelling can increase 
glycogen synthesis and inhibit glycolysis (Peak, Alhabori et al. 1992; Haussinger and Schliess 
1995; Lajvardi, Summers et al. 1996); In addition, cell swelling and MC had also been shown to 
interfere with the transfer of reducing equivalents through the mitochondrial malate/aspartate 
shuttle (Hussinger, Lang et al. 1990) and stimulate flux through the pentose phosphate pathway 
and NADPH generation (Saha, Stoll et al. 1992). The elucidation of the acting mechanisms of 
MC on cell metabolism in details will require the direct manipulation of MC levels, e.g., through 
over-expression of exogenous proteins, or injection of a crowding agent such as various 
concentrations of dextran or nanoparticles (Van Horn WD et al. 2010). Since the proteasome 
predominantly catalyzes protein degradation and clearance of damaged or regulatory proteins, 
thus being essential to maintain the protein concentration and turnover in the cell (Chondrogianni 
and Gonos 2010), the proteasome activities under the effect of MC are well worth investigating 
to better conceptualize the role of MC in regulating cell metabolism and cell growth.  
Secondly, it has been reported that, in order to achieve high metabolic rates, cells 
maintain optimal MC (intracellular density) below or beyond which the overall metabolic rate 
would be diminished (Vazquez 2010). What the optimal density is for human normal and cancer 
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cells, respectively, and how MC is fine-tuned to achieve different metabolic states are interesting 
questions to be investigated.  
In addition, beside the MC constraint, other biophysical or chemical constraints may exist 
that further confine the metabolism of tumor cells. One speculation is that reducing equivalents 
in the form of NADPH may also pose an essential impact on the cell metabolism as 
NADPH/NADP+ ratio is critically important to protect from oxidative damage and for cell 
survival (Pollak N. et al. 2007). Therefore, the incorporation of additional physicochemical 
constraints to the existing cell metabolism model will be necessary to significantly improve the 
model in future.  
Lastly, once the reconstruction of human cell metabolic networks in a tissue and cell type 
specific fashion are attainable, minimal essential enzyme targets or pathways may be calculated 
through metabolic network analysis to restore the metabolic state from the diseased state. As 
suggested in Chapter 4, most of the identified single essential enzymes are common among 
different strains, while essential synthetic lethal pairs are more strain-specific. To overcome the 
possible high mutation rate in those predicted essential single enzymes, a combination therapy 
which targets two single essential enzymes or both single essential enzymes together with the 
synthetic lethal pairs may improve the efficacy of the treatment. In this respect, poly-
pharmacology, i.e., the inhibition of multiple targets with a single drug, may also be developed 
as tailored potent cancer therapy against cancer metabolism in different tissues or cell types. 
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